| {"_id": "trial_opt_adv_0002", "nctid": "NCT04083781", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors\n\nBrief Summary: This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B with inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use. Participants who usually only take medicine to treat bleeds (on-demand) will be placed in one of two groups. In one group, participants will get study medicine from the start of the study. In the other group, participants will continue with their normal medicine and get study medicine after 6 months. Which treatment the participant gets is decided by chance. Participants who usually take medicine to prevent bleeds (prophylaxis treatment) or who are already being treated with concizumab (study medicine) will receive the study medicine from the start of the study. Participants will get 1 injection with the study medicine every day under the skin. This participants will have to do themselves and can be done at home. The study doctor will hand out the medicine in the form of a pen-injector. The pen-injector will contain the study medicine. The study will last for about seven years. The length of time the participants will be in the study depends on when they agreed to take part or when the medicine is available for purchase in their country (31 December 2026 at the latest). The time between visits will be approximately 4 weeks for the first 6 to 12 months, depending on the group participants are in and approximately 8 weeks for the rest of the study. Participants will be asked to record information into an electronic diary during the study and may also be asked to wear an activity tracker.\n\nConditions: Haemophilia A With Inhibitors; Haemophilia B With Inhibitors\n\nInterventions: DRUG: Concizumab\n\nPhase: PHASE3\n\nEnrollment: 134.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: NONE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.\n* Male aged 12 years or older at the time of signing informed consent.\n* Congenital Haemophilia A or B of any severity with documented history of inhibitor (equal to or above 0.6 Bethesda Units (BU).\n* Patient has been prescribed, or in need of, treatment with bypassing agents in the last 24 weeks prior to screening (for patients not previously enrolled in NN7415-4310 (explorer 4)).\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to any constituent of the trial product or related products.\n* Known inherited or acquired coagulation disorder other than congenital haemophilia.\n* Ongoing or planned Immune Tolerance Induction treatment.\n* History of thromboembolic disease (includes arterial and venous thrombosis including myocardial infarction, pulm... (truncated)\n\nArms and Interventions: Arm 1: No prophylaxis (EXPERIMENTAL); Arm 2: Concizumab prophylaxis (EXPERIMENTAL); Arm 3: Concizumab prophylaxis (EXPERIMENTAL); Arm 4: Concizumab prophylaxis (EXPERIMENTAL)\n\nPrimary Outcome Measures: Rate of Treated Spontaneous and Traumatic Bleeding Episodes (Time: On demand (arm 1): From week 0 up until start of concizumab treatment (at least 24 weeks) Concizumab (arm 2): From week 0 up until the primary analysis cut-off (at least 32 weeks))\n\nSecondary Outcome Measures: Rate of Treated Spontaneous Bleeding Episodes (Time: On demand (arm 1): From week 0 up until start of concizumab treatment (at least 24 weeks) Extension concizumab (arm 1): From start of new concizumab dosing regimen (week 25) up until week 56 cut-off Concizumab (arm 2): From week 0 up until week 56 cut-off) | Rate of Treated Spontaneous and Traumatic Joint Bleeds (Time: On demand (arm 1): From week 0 up until start of concizumab treatment (at least 24 weeks) Extension concizumab (arm 1): From start of new concizumab dosing regimen (week 25) up until week 56 cut-off Concizumab (arm 2): From week 0 up until week 56 cut-off) | Rate of Treated Spontaneous and Traumatic Target Joint Bleeds (Time: On demand (arm 1): From week 0 up until start of concizumab treatment (at least 24 weeks) Extension concizumab (arm 1): From start of new concizumab dosing regimen (week 25) up until week 56 cut-off Concizumab (arm 2): From week 0 up until week 56 cut-off) | Change in 36-item Short Form Health Survey (SF-36v2) Bodily Pain (Time: Baseline (week 0), Week 24) | Change in SF36v2 Physical Functioning (Time: Baseline (week 0), Week 24) | Number of Thromboembolic Events (Time: On demand (arm 1 ): From week 0 until start of concizumab treatment (atleast 24 weeks) Concizumab (arms 2-4): From week 0 up until week 56 cut-off Extension Concizumab (arm 1): From start of new concizumab dosing regimen (week 25) up until week 56 cut-off) | Number of Thromboembolic Events (Time: From week 0 to end of trial (week 167)) | Number of Hypersensitivity Type Reactions (Time: On demand (arm 1 ): From week 0 until start of concizumab treatment (atleast 24 weeks) Concizumab (arms 2-4): From week 0 up until week 56 cut-off Extension Concizumab (arm 1): From start of new concizumab dosing regimen (week 25) up until week 56 cut-off) | Number of Hypersensitivity Type Reactions (Time: From week 0 to end of trial (week 167)) | Number of Injection Site Reactions (Time: On demand (arm 1 ): From week 0 until start of concizumab treatment (atleast 24 weeks) Concizumab (arms 2-4): From week 0 up until week 56 cut-off Extension Concizumab (arm 1): From start of new concizumab dosing regimen (week 25) up until week 56 cut-off) | Number of Injection Site Reactions (Time: From week 0 to end of trial (week 167)) | Number of Participants With Antibodies to Concizumab (Time: Concizumab (arms 2-4): From week 0 up until week 56 cut-off Extension Concizumab (arm 1): From start of new concizumab dosing regimen (week 25) up until week 56 cut-off) | Number of Participants With Antibodies to Concizumab (Time: From week 0 to end of trial (week 167)) | Pre-dose (Trough) Concizumab Plasma Concentration (Ctrough) (Time: Pre-dose (prior to concizumab administration at week 56)) | Pre-dose Thrombin Peak (Time: Pre-dose (prior to concizumab administration at week 56)) | Pre-dose Free Tissue Factor Pathway Inhibitor (TFPI) Concentration (Time: Pre-dose (prior to concizumab administration at week 56)) | Maximum Concizumab Plasma Concentration (Cmax) (Time: Week 24: Predose, 3 hours (h), 6h, 9h, 24h) | Area Under the Concizumab Plasma Concentration-time Curve (AUC) (Time: Week 24: Predose, 3 hours (h), 6h, 9h, 24h)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Replace the clinical efficacy primary endpoint (annualized bleeding rate) with laboratory-based co-primary endpoints using calibrated thrombin generation assay metrics (peak thrombin and endogenous thrombin potential) alongside anti\u2013TFPI target-engagement biomarkers. Power the study on these PD endpoints to enable a smaller sample size and move ABR to a key secondary endpoint in a hierarchical testing framework.\nB. Screen for and control interfering substances: exclude or stratify concomitants (e.g., high-dose biotin), predefine handling of hemolytic/lipemic samples, include covariate adjustments, and institute pre-analytic checks in protocol/central lab manuals.\nC. No optimization needed - the trial design is adequate\nD. Predefine a PK-guided dosing strategy: include more frequent early TDM (e.g., weeks 1\u20132\u20134\u20138), adherence monitoring, and protocolized dose adjustments. Power and specify PK variability analyses and exposure\u2013response modeling; include missed-dose mitigation in the SAP and IFU.\nE. Convert the parallel-group study to a two-period, two-sequence crossover (concizumab vs on-demand standard of care) with a 4\u20136 week washout to control for interpatient variability in bleeding propensity. Use within-subject comparisons as the primary analysis and calibrate each participant\u2019s period 2 outcomes to their period 1 baseline to reduce required sample size.\nF. Specify acceptance criteria in the protocol/SAP aligned to guidance (\u226420% CV). Conduct and document precision components (within-run, between-run, instrument-to-instrument, lot-to-lot) and predefine data handling for results near limits of quantitation.\nG. Pretrial root-cause analysis and remediation (e.g., calibrator matrix matching, parallelism, recovery, specificity checks); establish sample stability across storage/handling; re-validate accuracy and linearity; update SAP with validated assay parameters.\nH. Eliminate the randomized comparator and adopt a contemporaneous external control sourced from haemophilia inhibitor registries and claims databases. Employ propensity-score matching and synthetic control weighting so sites can enroll all participants to concizumab while benchmarking outcomes against the external control to accelerate accrual and increase effective power.\nI. Broaden eligibility to include haemophilia A and B patients without inhibitors and permit concomitant emicizumab use to better reflect real-world practice and accelerate enrollment, with subgroup analyses planned post hoc\nJ. Complete full fit-for-purpose bioanalytical validation before FPI: demonstrate sensitivity across clinically relevant drug levels with pretreatment steps, assess hook effect, matrix interferences (hemolysis, lipemia), drug and concomitant interference, positive control qualification, intra/inter-assay and lot-to-lot/instrument precision \u226420% CV, and sample stability; lock validated methods in the protocol.", "answer": "B, D, F, G, J"} |
| {"_id": "trial_opt_adv_0003", "nctid": "NCT04033445", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis\n\nBrief Summary: The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).\n\nConditions: Ulcerative Colitis\n\nInterventions: DRUG: Placebo; DRUG: Guselkumab\n\nPhase: PHASE2, PHASE3\n\nEnrollment: 1064.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: DOUBLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Documented diagnosis of ulcerative colitis (UC)\n* Moderately to severely active UC, defined by modified Mayo score\n* Demonstrated inadequate response or intolerance to medical therapies specified in the protocol\n* Screening laboratory test results within the parameters specified in the protocol\n\nExclusion Criteria:\n\n* Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, or Crohn's disease or clinical findings suggestive of Crohn's disease\n* UC limited to the rectum only or to less than (\\<) 20 centimeter (cm) of the colon\n* Presence of a stoma\n* Presence or history of a fistula\n* Receiving prohibited medications and/or treatment\n\nArms and Interventions: Induction Study 1: Guselkumab Dose 1 (EXPERIMENTAL); Induction Study 1: Guselkumab Dose 2 (EXPERIMENTAL); Induction Study 1: Placebo IV (PLACEBO_COMPARATOR); Induction Study 2: Guselkumab IV (EXPERIMENTAL); Induction Study 2: Placebo IV (PLACEBO_COMPARATOR); Maintenance Study: Maintenance Dose Regimen 1 (EXPERIMENTAL); Maintenance Study: Maintenance Dose Regimen 2 (EXPERIMENTAL); Maintenance Study: Placebo SC (PLACEBO_COMPARATOR)\n\nPrimary Outcome Measures: Induction Study 1: Percentage of Participants With Clinical Response at Week I-12 (Time: At Week I-12) | Induction Study 2: Percentage of Participants With Clinical Remission at Week I-12 (Time: At Week I-12) | Maintenance Study: Percentage of Participants With Clinical Remission at Week M-44 (Time: At Week M-44)\n\nSecondary Outcome Measures: Induction Study 1: Percentage of Participants With Clinical Remission at Week I-12 (Time: At Week I-12) | Induction Study 1: Percentage of Participants With Symptomatic Remission at Week I-12 (Time: At Week I-12) | Induction Study 1: Percentage of Participants With Endoscopic Healing at Week I-12 (Time: At Week I-12) | Induction Study 1: Percentage of Participants With Histologic-Endoscopic Mucosal Healing at Week I-12 (Time: At Week I-12) | Induction Study 1: Percentage of Participants With Endoscopic Normalization at Week I-12 (Time: At Week I-12) | Induction Study 2: Percentage of Participants With Symptomatic Remission at Week I-12 (Time: At Week I-12) | Induction Study 2: Percentage of Participants With Endoscopic Healing at Week I-12 (Time: At Week I-12) | Induction Study 2: Percentage of Participants With Clinical Response at Week I-12 (Time: At Week I-12) | Induction Study 2: Percentage of Participants With Symptomatic Remission at Week I-4 (Time: At Week I-4) | Induction Study 2: Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week I-12 (Time: At Week I-12) | Induction Study 2: Percentage of Participants With Histologic-Endoscopic Mucosal Healing at Week I-12 (Time: At Week I-12) | Induction Study 2: Percentage of Participants With Fatigue Response at Week I-12 (Time: At Week I-12) | Induction Study 2: Percentage of Participants With Symptomatic Remission at Week I-2 (Time: At Week I-2) | Induction Study 2: Percentage of Participants With Endoscopic Normalization at Week I-12 (Time: At Week I-12) | Maintenance Study: Percentage of Participants With Symptomatic Remission at Week M-44 (Time: At Week M-44) | Maintenance Study: Percentage of Participants With Endoscopic Healing at Week M-44 (Time: At Week M-44) | Maintenance Study: Percentage of Participants With Corticosteroid-free Clinical Remission at Week M-44 (Time: At Week M-44) | Maintenance Study: Percentage of Participants With Clinical Response at Week M-44 (Time: At Week M-44) | Maintenance Study: Percentage of Participants With Histologic-Endoscopic Mucosal Healing at Week M-44 (Time: At Week M-44) | Maintenance Study: Percentage of Participants With IBDQ Remission at Week M-44 (Time: At Week M-44) | Maintenance Study: Percentage of Participants With Fatigue Response at Week M-44 (Time: At Week M-44) | Maintenance Study: Percentage of Participants With Clinical Remission at Week 44 Among the Participants Who Had Achieved Clinical Remission at Maintenance Baseline (Time: At Week M-44) | Maintenance Study: Percentage of Participants With Endoscopic Normalization at Week M-44 (Time: At Week M-44)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Enhance IFU and labeling pre-trial to increase prominence of Important Information regarding pediatric exposure and device safety checks; include storage and safety statements in both IFU and carton; validate through HF testing that users comprehend and can act on these warnings.\nB. Plan iterative autoinjector and IFU refinements during the pivotal phase by introducing minor ergonomic modifications (e.g., plunger force, tactile click amplitude, window tint) across successive manufacturing lots and capturing user feedback in a nested usability substudy; manage these iterations via protocol amendments in lieu of formal bridging CMC or summative human factors validation.\nC. Designate a daily eDiary-based patient-reported composite (stool frequency and rectal bleeding) as the sole primary endpoint and remove centralized endoscopic/histologic assessments from the primary efficacy framework to reduce invasiveness and accelerate enrollment; retain site-read sigmoidoscopy only as an exploratory outcome for a subset of participants.\nD. Iterate device design and IFU prior to pivotal trial: remove cap ridges; add clear needle-end labeling; clarify and emphasize fill window color cue; add explicit end-of-injection cues (clicks and timing) in device and IFU; strengthen refrigeration handling instructions; conduct formative HF studies, then a passing summative HF validation on the to-be-marketed user interface. Include device performance and user-error endpoints in trial or bridging HF study to demonstrate safe use.\nE. Adopt a treat-to-target adaptive dosing strategy whereby guselkumab dosing frequency and dose are escalated or de-escalated every two weeks based on fecal calprotectin and CRP thresholds, with a matched sham-adjustment algorithm for placebo; include a protocolized systemic steroid rescue/taper pathway triggered by biomarker nonresponse to standardize concomitant medication use.\nF. Complete CMC validation for final formulation and device prior to pivotal trial or establish a predefined, FDA-aligned bridging plan. Conduct in vitro pyrogenicity/endotoxin risk assessments and, if applicable, rabbit pyrogen spiking studies or validated alternatives before trial. Ensure the clinical supply matches the intended commercial presentation to avoid post hoc bridging.\nG. Audit and align container/carton labels and prescribing information with CFR requirements and FDA guidance before trial start; include bold storage temperature, proper expiry format with non-zero day, 'Do not shake', 'No preservative' wording per 21 CFR 610.61(e), linear barcode, Medication Guide pharmacist statement, and consistent manufacturer name. Use these final materials in any usability/medication error assessments.\nH. No optimization needed - the trial design is adequate\nI. Embed concurrent noninferiority comparisons against two active biologic comparators (infliximab and ustekinumab) within the same protocol using a 1:1:1:1 randomization, while keeping a placebo arm as an internal benchmark; power each NI contrast at a 10% margin with multiplicity-controlled co-primary endpoints to enable head-to-head value claims in the Phase 3 portion.\nJ. Redesign IFU before trial: bold critical warnings; label figures (A, B, C\u2026) mapped to steps; correct anatomical injection-site depictions; add a post-injection 'lift pen' step illustration; revalidate with HF testing to acceptable error thresholds. Ensure the pivotal study uses the finalized IFU and captures real-world users.", "answer": "A, D, F, G, J"} |
| {"_id": "trial_opt_adv_0004", "nctid": "NCT03524092", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis\n\nBrief Summary: The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).\n\nConditions: Ulcerative Colitis\n\nInterventions: DRUG: Mirikizumab SC; DRUG: Mirikizumab IV; DRUG: Placebo SC\n\nPhase: PHASE3\n\nEnrollment: 1177.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: DOUBLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Have completed Study AMAN (NCT03518086), with at least 1 study drug administration and without early termination of study drug.\n* Are willing and able to complete the scheduled study assessments, including endoscopy and daily diary entry.\n* If female, must meet the contraception requirements.\n\nExclusion Criteria:\n\n* Participants diagnosed with Crohn's disease or inflammatory bowel disease-unclassified (indeterminate colitis) during the induction study AMAN (NCT03518086).\n* Participants with a bowel resection or other surgery for the treatment of UC during the previous induction study AMAN (NCT03518086), or are likely to require surgery for the treatment of UC during study AMBG.\n* Participants with evidence of colonic dysplasia or have been diagnosed with cancer of the gastrointestinal tract during study AMAN (NCT03518086).\n* Participants diagnosed with clinically important infection including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tub... (truncated)\n\nArms and Interventions: Maintenance Period: Miri Induction Responder (IR) - Placebo (PBO) Subcutaneous (SC) (PLACEBO_COMPARATOR); Maintenance Period: Miri IR - 200 Milligram (mg) Miri SC (EXPERIMENTAL); Maintenance Period: PBO IR - PBO SC (OTHER); Loss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IV (OTHER); Extended Induction: Induction Nonresponders - 300mg Miri IV (OTHER); Open Label Maintenance: Delayed Responders - 200 mg Miri SC (OTHER)\n\nPrimary Outcome Measures: Percentage of Participants in Clinical Remission at Week 40 (Time: Week 40)\n\nSecondary Outcome Measures: Percentage of Participants in Endoscopic Remission at Week 40 (Time: Week 40) | Percentage of Participants With Histologic Remission at Week 40 (Time: Week 40) | Percentage of Participants in Symptomatic Remission at Week 40 (Time: Week 40) | Percentage of Participants in Endoscopic Response at Week 40 (Time: Week 40) | Percentage of Participants in Clinical Response at Week 40 (Time: Week 40) | Change From Baseline to Week 40 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Time: Induction Baseline, Week 40) | Change From Baseline to Week 40 in Fecal Calprotectin (Time: Induction Baseline, Week 40) | Change From Baseline to Week 40 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS) (Time: Induction Baseline, Week 40) | Percentage of Participants Hospitalized for Ulcerative Colitis (UC) (Time: Week 40) | Pharmacokinetics (PK): Clearance of Mirikizumab (Time: Predose: Weeks 0, 4, 12, 24 and 40)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Audit and align container/carton labels and prescribing information with CFR requirements and FDA guidance before trial start; include bold storage temperature, proper expiry format with non-zero day, 'Do not shake', 'No preservative' wording per 21 CFR 610.61(e), linear barcode, Medication Guide pharmacist statement, and consistent manufacturer name. Use these final materials in any usability/medication error assessments.\nB. No optimization needed - the trial design is adequate\nC. Eliminate blinded independent central endoscopy review and rely exclusively on site investigator Mayo endoscopic subscores collected with local equipment to streamline operations and reduce adjudication timelines\nD. Broaden eligibility to enroll de novo adult ulcerative colitis patients who did not participate in LUCENT-1, randomizing them directly into the maintenance arms to improve external validity and support a wider label\nE. Designate mucosal healing as a co-primary endpoint assessed by full colonoscopy every 4 weeks through Week 52 to capture high-resolution longitudinal healing dynamics and minimize missing data\nF. Iterate device design and IFU prior to pivotal trial: remove cap ridges; add clear needle-end labeling; clarify and emphasize fill window color cue; add explicit end-of-injection cues (clicks and timing) in device and IFU; strengthen refrigeration handling instructions; conduct formative HF studies, then a passing summative HF validation on the to-be-marketed user interface. Include device performance and user-error endpoints in trial or bridging HF study to demonstrate safe use.\nG. Complete CMC validation for final formulation and device prior to pivotal trial or establish a predefined, FDA-aligned bridging plan. Conduct in vitro pyrogenicity/endotoxin risk assessments and, if applicable, rabbit pyrogen spiking studies or validated alternatives before trial. Ensure the clinical supply matches the intended commercial presentation to avoid post hoc bridging.\nH. Enhance IFU and labeling pre-trial to increase prominence of Important Information regarding pediatric exposure and device safety checks; include storage and safety statements in both IFU and carton; validate through HF testing that users comprehend and can act on these warnings.\nI. Implement an adaptive, response-guided re-randomization at Weeks 8 and 16 that reallocates participants with rising fecal calprotectin or CRP to the IV mirikizumab arm, using matched IV placebos to preserve nominal blinding and enhance exposure\u2013response characterization\nJ. Redesign IFU before trial: bold critical warnings; label figures (A, B, C\u2026) mapped to steps; correct anatomical injection-site depictions; add a post-injection 'lift pen' step illustration; revalidate with HF testing to acceptable error thresholds. Ensure the pivotal study uses the finalized IFU and captures real-world users.", "answer": "A, F, G, H, J"} |
| {"_id": "trial_opt_adv_0005", "nctid": "NCT04150068", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance\n\nBrief Summary: The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen (functional monotherapy) in people with human immunodeficiency virus (HIV) (PWH) with multi-drug resistance (MDR).\n\nConditions: HIV-1-infection\n\nInterventions: DRUG: Oral Lenacapavir; DRUG: Oral Lenacapavir Placebo; DRUG: Subcutaneous Lenacapavir; DRUG: Failing ARV Regimen; DRUG: Optimized Background Regimen (OBR)\n\nPhase: PHASE2, PHASE3\n\nEnrollment: 72.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: SEQUENTIAL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Key Inclusion Criteria:\n\n* Adult aged \u2265 18 years (at all sites) or adolescent aged \u2265 12 and weighing \u2265 35 kg (at sites in North America and Dominican Republic)\n* Currently receiving a stable failing ARV regimen for \\> 8 weeks\n* Have HIV-1 RNA \u2265 400 copies/mL at screening\n* Have multidrug resistance (resistance to \u22652 agents from \u22653 of the 4 main classes of ARV)\n* Have no more than 2 fully active ARV remaining from the 4 main classes that can be effectively combined to form a viable regimen\n* Able and willing to receive an OBR together with lenacapavir\n* No Hepatitis C virus (HCV) ongoing infection\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.\n\nArms and Interventions: Cohort 1A: Lenacapavir (EXPERIMENTAL); Cohort 1B: Placebo to Lenacapavir (PLACEBO_COMPARATOR); Cohort 2: Lenacapavir (EXPERIMENTAL)\n\nPrimary Outcome Measures: Percentage of Participants in Cohort 1 Achieving a Reduction of \u2265 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Time: Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15)\n\nSecondary Outcome Measures: Percentage of Participants in Cohort 1 With Plasma HIV-1 RNA < 50 Copies/mL at Week 26 Based on the US FDA-defined Snapshot Algorithm (Time: Week 26 (26 weeks after first dose of subcutaneous lenacapavir)) | Percentage of Participants in Cohort 1 With Plasma HIV-1 RNA < 200 Copies/mL at Week 26 Based on the US FDA-defined Snapshot Algorithm (Time: Week 26 (26 weeks after first dose of subcutaneous lenacapavir)) | Percentage of Participants in Cohort 1 With Plasma HIV-1 RNA < 50 Copies/mL at Week 52 Based on the US FDA-defined Snapshot Algorithm (Time: Week 52) | Percentage of Participants in Cohort 1 With Plasma HIV-1 RNA < 200 Copies/mL at Week 52 Based on the US FDA-defined Snapshot Algorithm (Time: Week 52) | Percentage of Participants in Combined Cohorts 1 and 2 With Plasma HIV-1 RNA < 50 Copies/mL From the First Subcutaneous (SC) Dose of Lenacapavir Based on the US FDA-defined Snapshot Algorithm (Time: Week 104) | Percentage of Participants in Combined Cohorts 1 and 2 With Plasma HIV-1 RNA < 200 Copies/mL From the First SC Dose of Lenacapavir Based on the US FDA-defined Snapshot Algorithm (Time: Week 104) | Percentage of Participants in Combined Cohorts 1 and 2 With Plasma HIV-1 RNA < 50 Copies/mL From the First SC Dose of Lenacapavir Based on the US FDA-defined Snapshot Algorithm (Time: Week 156) | Percentage of Participants in Combined Cohorts 1 and 2 With Plasma HIV-1 RNA < 200 Copies/mL From the First SC Dose of Lenacapavir Based on the US FDA-defined Snapshot Algorithm (Time: Week 156)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Standardize the background therapy by replacing individualized OBR selection with a protocol-mandated, uniform regimen (e.g., boosted darunavir plus tenofovir disoproxil fumarate/emtricitabine) for all participants, permitting deviations only for clear contraindications, to reduce heterogeneity and simplify efficacy and safety analyses.\nB. Before trial, implement harmonized AE and discontinuation taxonomy aligned with FDA guidance, prespecify tabulation formats compatible with labeling, and power analyses to detect changes in common AE incidence versus baseline data. Incorporate data standards (CDISC) and adjudication processes to ensure completeness and comparability.\nC. Introduce a mandatory 2\u20134 week washout of all antiretrovirals prior to Day 1 to homogenize baseline viral kinetics and eliminate carryover effects on the primary early virologic endpoint; manage participants during washout with close monitoring, prophylactic antibiotics, and weekly safety labs to mitigate risk.\nD. Conduct preclinical container\u2013closure compatibility studies (chemical resistance, extractables/leachables, surface adsorption, precipitation), stress testing, and CCIT validation on the intended commercial vial type before trial initiation. If incompatibility is detected, select an alternative container (e.g., aluminosilicate or polymer vials) with demonstrated compatibility, update intervention details and labeling accordingly, and include safety monitoring for particulate-related reactions in outcome measures.\nE. Implement response-adaptive randomization during the 14-day functional monotherapy window so that, after an initial interim analysis (e.g., at n=20), allocation probabilities are reweighted to favor the lenacapavir-placebo arm whenever early viral load declines appear similar between arms, with up to 70% assignment to placebo to maximize information about background regimen effects and reduce investigational drug exposure.\nF. No optimization needed - the trial design is adequate\nG. Extend the lenacapavir functional monotherapy window from the conventional 7\u201314 days to a fixed 8-week period, prohibiting any modifications to the failing ARV regimen during that time to cleanly isolate drug-specific antiviral effects; incorporate mandated population sequencing at weeks 2, 4, 6, and 8 and intensive PK/PD sampling to characterize resistance-emergence kinetics under monotherapy.\nH. Align the clinical protocol and commercial strategy pre-trial: study and document both initiation regimens intended for labeling (e.g., with and without oral lead-in), ensure adequate sample sizes and PK/PD bridging, and plan alternative packaging configurations to support each regimen. Include corresponding arms/interventions and SAP components to enable labeling claims.\nI. Before trial, fully validate CCIT methods aligned to worst-case conditions (thermal cycling, shipping vibrations, long-term storage), and document dye ingress protocols with quantitative acceptance criteria and spectrophotometric readouts. Ensure both pressure and vacuum challenge modes are applied. Use validated, GMP-aligned CCIT to select the final container\u2013closure for clinical supply; include monitoring plans for integrity failures in the protocol.\nJ. Pre-specify targeted safety endpoints for particulate-related local and systemic reactions with standardized grading, photography, ultrasound where appropriate, and central adjudication. Power secondary analyses to detect incidence differences across lots/containers. Include eligibility exclusions for high-risk populations (e.g., clotting/immune disorders), and define algorithms for causality assessment tied to lot-level QC data.", "answer": "B, D, H, I, J"} |
| {"_id": "trial_opt_adv_0007", "nctid": "NCT01602380", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.\n\nBrief Summary: The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast cancer who have not had prior hormonal treatment.\n\nConditions: Hormone Receptor Positive Breast Cancer\n\nInterventions: DRUG: faslodex 500mg; DRUG: arimidex 1mg; DRUG: faslodex dummy; DRUG: arimidex dummy\n\nPhase: PHASE3\n\nEnrollment: 462.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Histological confirmation of breast cancer in post menopausal women (age \\>=60). Positive hormone receptor status (ER +ve and/or PgR +ve) of primary or metastatic tumour tissue based on local laboratory assessment.\n* EITHER locally advanced disease (1 line of chemotherapy allowed only if remain unsuitable for therapy of curative intent) OR Metastatic disease. (1 line of chemotherapy for breast cancer allowed only if subsequent evidence of further progressive disease)\n* At least 1 lesion (measurable and/or non-measurable) that can be accurately assessed at baseline and is suitable for repeated assessment.\n* Postmenopausal women, fulfilling 1 of:\n\n * Prior bilateral oophorectomy\n * Age \\>60 years\n * Age \\< 60 years and amenorrheic for 12+months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and FSH and oestradiol in the postmenopausal range\n\nExclusion Criteria:\n\n* Presence of life-threatening metastatic disease\n* Any of:\n\n * Exten... (truncated)\n\nArms and Interventions: faslodex+placebo (EXPERIMENTAL); arimidex +placebo (ACTIVE_COMPARATOR)\n\nPrimary Outcome Measures: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Time: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months))\n\nSecondary Outcome Measures: Comparison of Overall Survival (OS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole; Percentage of Patients With Events (Time: Baseline (Day 0) up to data cut-off for final analysis (up to approximately 116 months). Following disease progression, patients were to be contacted at 12 weekly intervals to determine survival status) | Objective Response Rate (ORR) for Fulvestrant Treatment Versus Anastrozole Treatment (Time: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)) | Duration of Response (DoR) for Fulvestrant Treatment Versus Anastrozole Treatment (Time: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)) | Expected Duration of Response (EDoR) for Fulvestrant Treatment Versus Anastrozole Treatment (Time: Baseline RECIST 1.1 assessments and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)) | Clinical Benefit Rate (CBR) for Fulvestrant Treatment Versus Anastrozole Treatment (Time: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)) | Duration of Clinical Benefit (DoCB) for Fulvestrant Treatment Versus Anastrozole Treatment (Time: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)) | Expected Duration of Clinical Benefit (EDoCB) for Fulvestrant Treatment Versus Anastrozole Treatment (Time: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)) | Comparison of the Effect of Fulvestrant Treatment Versus Anastrozole Treatment on Time to Deterioration of Health-Related Quality of Life (HRQoL) (Time: Quality of life questionnaires administered at 3 months post objective disease progression, then at 6-monthly intervals (approximately 75 months))\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Conduct formative HF analyses (task analysis, known-use error review) and plan a summative HF validation study with representative users and use environments; include usability endpoints or separate HF study prior to clinical trial using the final or human-factors\u2013representative device.\nB. Define and verify critical performance attributes (breakloose and glide force ranges, plunger rod tensile/elongation) and include stability verification of these attributes over shelf life; ensure final device used in trial meets these specs or include bridging data if not.\nC. Adopt a Bayesian response-adaptive randomization scheme that reallocates enrollment toward the arm demonstrating higher 8-week RECIST response rates, with interim updates every 4 weeks and blinded sample size re-estimation to improve efficiency\nD. No optimization needed - the trial design is adequate\nE. Broaden eligibility to include patients with prior endocrine therapy (adjuvant or first-line) and prior chemotherapy for metastatic disease, and rely on pre-specified subgroup analyses by line of therapy to preserve interpretability while enhancing generalizability\nF. Before trial start, select an excipient level/composition supported by prior IM products and preclinical data; generate and reference excipient safety rationale (e.g., local tolerance studies with the exact MCT grade/FA composition and concentration to be used clinically) and include outcome measures to detect local injection-site reactions and PK differences in the protocol.\nG. Institute a mandatory cross-over at first radiographic progression, designate overall survival as the primary endpoint, and extend minimum follow-up to 5 years to capture sequencing benefits and late survival effects, relegating progression-free survival to an exploratory outcome\nH. Prospectively include repeated-dose local tolerance endpoints (macro- and microscopic assessments) and TK sampling aligned to dosing schedule; predefine injection-site adverse event grading and imaging/biomarker assessments; power and schedule assessments accordingly.\nI. Streamline operations by converting the double-dummy, quadruple-blind design to single-blind without IM or oral placebos, and mitigate potential bias through independent outcome assessments and centralized imaging review only at the time of database lock\nJ. Complete ISO 10993 biocompatibility testing for patient-contacting components and generate extractables/leachables studies with toxicological risk assessment covering intended shelf life; if leachables could impact safety, include monitoring in the clinical protocol.", "answer": "A, B, F, H, J"} |
| {"_id": "trial_opt_adv_0009", "nctid": "NCT00099437", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Comparison of Fulvestrant (FASLODEX\u2122) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.\n\nBrief Summary: The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment.\n\nConditions: Breast Cancer\n\nInterventions: DRUG: Fulvestrant\n\nPhase: PHASE3\n\nEnrollment: 736.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor\n* Requiring hormonal treatment\n* Postmenopausal women defined as a woman who has stopped having menstrual periods\n* Evidence of positive estrogen receptor hormone sensitivity\n* Written informed consent to participate in the trial\n\nExclusion Criteria:\n\n* Treatment with an investigational or non-approved drug within one month\n* An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures\n* A history of allergies to any active or inactive ingredients of Faslodex (i.e. castor oil)\n* Treatment with more than one regimen of chemotherapy for advanced breast cancer\n* Treatment with more than one regimen of hormonal treatment for advanced breast cancer\n\nArms and Interventions: 1 (EXPERIMENTAL); 2 (EXPERIMENTAL)\n\nPrimary Outcome Measures: Time to Progression (TTP) (Time: RECIST(Response Evaluation Criteria in Solid Tumors ) tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation for study duration (48 months))\n\nSecondary Outcome Measures: Objective Response Rate (ORR) (Time: RECIST tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation for study duration (48 months)) | Clinical Benefit Rate (CBR) (Time: Clinical Benefit from the sequence of RECIST scan data for study duration (48 months) . RECIST (Response Evaluation Criteria in Solid Tumours) scans were performed every 12 weeks (+/- 2 weeks) from randomisation for study duration (48 months)) | Duration of Response (DoR) (Time: RECIST tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation for study duration (48 months)) | Duration of Clinical Benefit (DoCB) (Time: RECIST tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation for study duration (48 months)) | Overall Survival (OS) (Time: Overall Survival is equivalent to time to death. For this endpoint, all deaths occurring for study duration (48 months)) | Change From Randomisation in Trial Outcome Index (TOI) Over the Course of the Study (Time: TOI questionnaires were completed every 4 weeks from randomisation until week 24 and then again at treatment discontinuation, for study duration (48 months)) | Overall Survival (OS) - Follow-up (Time: Median time (in months) from randomisation until death (from any cause),up to 80 months)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Introduce a protocol-mandated cross-over at Cycle 4 (Week 12) for all participants randomized to 250 mg, switching them to 500 mg regardless of progression status to enhance ethical equipoise and exposure to the investigational dose while maintaining blinding with matched syringes and dosing schedules\nB. No optimization needed - the trial design is adequate\nC. Reframe the study as a noninferiority trial with a pre-specified hazard ratio margin of 1.25 for progression-free survival (PFS), implementing a hierarchical testing strategy where noninferiority is assessed first and superiority explored only if noninferiority is met\nD. Before trial start, select an excipient level/composition supported by prior IM products and preclinical data; generate and reference excipient safety rationale (e.g., local tolerance studies with the exact MCT grade/FA composition and concentration to be used clinically) and include outcome measures to detect local injection-site reactions and PK differences in the protocol.\nE. Add co-primary pharmacodynamic endpoints requiring paired fresh tumor biopsies at baseline and Day 14 to quantify ER occupancy and Ki-67 suppression, with statistical powering for both PD endpoints alongside clinical efficacy\nF. Define and verify critical performance attributes (breakloose and glide force ranges, plunger rod tensile/elongation) and include stability verification of these attributes over shelf life; ensure final device used in trial meets these specs or include bridging data if not.\nG. Transition dosing to a decentralized home-administration model where participants self-inject intramuscular fulvestrant after remote training, supported by telemedicine check-ins and video verification, to improve patient convenience and reduce site burden\nH. Complete ISO 10993 biocompatibility testing for patient-contacting components and generate extractables/leachables studies with toxicological risk assessment covering intended shelf life; if leachables could impact safety, include monitoring in the clinical protocol.\nI. Prospectively include repeated-dose local tolerance endpoints (macro- and microscopic assessments) and TK sampling aligned to dosing schedule; predefine injection-site adverse event grading and imaging/biomarker assessments; power and schedule assessments accordingly.\nJ. Conduct formative HF analyses (task analysis, known-use error review) and plan a summative HF validation study with representative users and use environments; include usability endpoints or separate HF study prior to clinical trial using the final or human-factors\u2013representative device.", "answer": "D, F, H, I, J"} |
| {"_id": "trial_opt_adv_0015", "nctid": "NCT03299049", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults\n\nBrief Summary: This Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLAS-2M) study is designed to demonstrate the non-inferior antiviral activity and safety of CAB LA + RPV LA administered every 8 weeks (Q8W) compared to CAB LA + RPV LA administered every 4 weeks (Q4W) over a 48-week treatment period in approximately 1020 adult HIV-1 infected subjects. Subjects will be divided in 2 groups; Group 1 will include subjects receiving current anti-retroviral (ART) standard of care (SOC) therapy whereas group 2 will include subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in both groups will be randomized to receive CAB LA + RPV LA Q4W or Q8W. The study will be carried out in 3 phases including screening phase, maintenance phase and extension phase. Subjects choosing not to enter the Extension phase can complete their study participation at the Week 100 visit and enter into the 52-week Long-Term Follow-Up (LTFU) Phase as required. A sub-study in the ATLAS-2M study will evaluate the pharmacokinetics, tolerability and efficacy of CAB and RPV long acting injections following intramuscular administration in the Vastus Lateralis Muscle (thigh) in HIV-infected Adult Participants who have received at least three years of Gluteal Injections in this ATLAS-2M Study.\n\nConditions: HIV Infections\n\nInterventions: DRUG: Cabotegravir Tablets; DRUG: Rilpivirine Tablets; DRUG: Cabotegravir Injectable Suspension; DRUG: Rilpivirine Injectable Suspension\n\nPhase: PHASE3\n\nEnrollment: 1049.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: NONE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Subjects who will be able to understand and comply with protocol requirements, instructions, and restrictions.\n* Understand the long term commitment to the study and be likely to complete the study as planned\n* Be considered as an appropriate candidate for participation in an investigative clinical trial with oral and intramuscularly injectable medications (e.g., no active substance use disorder, acute major organ disease, or planned long-term work assignments out of the country, etc.).\n* Aged 18 years or older (or \\>=19 where required by local regulatory agencies), at the time of signing the informed consent.\n* A female is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotropin (hCG) test at screen and a negative urine hCG test at Randomization), not lactating, and at least one of the following conditions applies:\n\nNon-reproductive potential defined as: pre-menopausal females with one of the following: docume... (truncated)\n\nArms and Interventions: Subjects in group 1 receiving study treatment once in 4 weeks (EXPERIMENTAL); Subjects in group 1 receiving study treatment once in 8 weeks (EXPERIMENTAL); Subjects in group 2 receiving study treatment once in 4 weeks (EXPERIMENTAL); Subjects in group 2 receiving study treatment once in 8 weeks (EXPERIMENTAL)\n\nPrimary Outcome Measures: Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48 (Time: Week 48)\n\nSecondary Outcome Measures: Percentage of Participants With Plasma HIV-1 RNA <50 c/mL Using FDA Snapshot Algorithm at Week 48 (Time: Week 48) | Percentage of Participants With Plasma HIV-1 RNA <50 c/mL Using FDA Snapshot Algorithm at Week 24 (Time: Week 24) | Percentage of Participants With Protocol Defined Confirmed Virologic Failure (CVF) Through Weeks 24 and 48 (Time: Weeks 24 and 48) | Percentage of Participants With HIV-RNA >=50 c/mL as Per FDA Snapshot Algorithm at Week 24 (Time: Weeks 24) | Absolute Values for HIV-1 RNA at Week 48 (Time: Weeks 48) | Change From Baseline Values for HIV-1 RNA at Week 48 (Time: Baseline (Day 1) and Week 48) | Absolute Values for Cluster of Differentiation 4 Plus (CD4+) at Week 48 (Time: Week 48) | Change From Baseline Values for CD4+ at Week 48 (Time: Baseline (Day 1) and Week 48) | Number of Participants With Non-serious Adverse Events (Non-SAEs >=5% Incidence) and Serious Adverse Events (SAEs)-Maintenance Phase (Time: Up to Week 48) | Number of Participants With Severity of Adverse Events-Maintenance Phase (Time: Up to Week 48) | Number of Participants With Maximum Post-Baseline Chemistry Toxicities-Maintenance Phase (Time: Up to Week 48) | Number of Participants With Maximum Post-Baseline Hematology Toxicities-Maintenance Phase (Time: Up to Week 48) | Percentage of Participants Who Discontinued Treatment Due to Adverse Events-Maintenance Phase (Time: Up to Week 48) | Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and Creatinine Kinase Over Time (Time: Baseline (Day 1) and Weeks 4, 8, 16, 24, 32, 40 and 48) | Change From Baseline in Clinical Chemistry Parameter: Albumin Over Time (Time: Baseline (Day 1) and Weeks 4, 8, 16, 24, 32, 40 and 48) | Change From Baseline in Clinical Chemistry Parameters: Bilirubin and Creatinine Over Time (Time: Baseline (Day 1) and Weeks 4, 8, 16, 24, 32, 40 and 48) | Change From Baseline in Clinical Chemistry Parameters: CO2, Chloride, Phosphate, Potassium, Sodium and Urea Over Time (Time: Baseline (Day 1) and Weeks 4, 8, 16, 24, 32, 40 and 48) | Change From Baseline in Clinical Chemistry Parameters: Cholesterol, Glucose, Direct High Density Lipoprotein (HDL) Cholesterol, LDL Cholesterol Calculation and Triglycerides at Week 48 (Time: Baseline (Day 1) and Week 48) | Change From Baseline in Clinical Chemistry Parameter: GFR From Creatinine Adjusted Using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Over Time (Time: Baseline (Day 1) and Weeks 4, 8, 16, 24, 32, 40 and 48) | Change From Baseline in Clinical Chemistry Parameter: Lipase Over Time (Time: Baseline (Day 1) and Weeks 4, 8, 16, 24, 32, 40 and 48) | Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets Over Time (Time: Baseline (Day 1) and Weeks 4, 8, 16, 24, 32, 40 and 48) | Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume (MCV) Over Time (Time: Baseline (Day 1) and Weeks 4, 8, 16, 24, 32, 40 and 48) | Change From Baseline in Hematology Parameter: Erythrocytes Over Time (Time: Baseline (Day 1) and Weeks 4, 8, 16, 24, 32, 40 and 48) | Change From Baseline in Hematology Parameter: Hematocrit Over Time (Time: Baseline (Day 1) and Weeks 4, 8, 16, 24, 32, 40 and 48) | Change From Baseline in Hematology Parameter: Hemoglobin Over Time (Time: Baseline (Day 1) and Weeks 4, 8, 16, 24, 32, 40 and 48) | Number of Participants With Phenotypic Resistance- Maintenance Phase (Time: Up to Week 48 analysis) | Number of Participants With Genotypic Resistance-Maintenance Phase (Time: Up to Week 48 analysis) | Number of Participants With Their Treatment Preference as Assessed Using Preference Questionnaire at Week 48 Without (w/o) Prior Exposure to CAB+RPV-CAB 600 mg LA +RPV 900 mg LA Q8W Arm Only (Time: Week 48) | Number of Participants With Their Treatment Preference as Assessed Using Preference Questionnaire at Week 48 With >=1 Weeks of Prior Exposure to CAB+RPV-CAB 600 mg LA +RPV 900 mg LA Q8W Arm Only (Time: Week 48) | Number of Participants With Their Treatment Preference as Assessed Using Preference Questionnaire at Week 48-CAB 400 mg LA +RPV 600 mg LA Q4W Arm Only (Time: Week 48) | Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire in Participants With or Without Prior Exposure to CAB+RPV (Time: Baseline (Day 1) and Weeks 24 and 48) | Change From Baseline in HIV Medication, MEDWO Using HATQoL Questionnaire in Participants With or Without Prior Exposure to CAB+RPV (Time: Baseline (Day 1) and Weeks 24 and 48) | Change From Baseline in DISWO Using HATQoL Questionnaire in Participants With or Without Prior Exposure to CAB+RPV (Time: Baseline (Day 1) and Weeks 24 and 48) | Change From Baseline in Total Treatment Satisfaction Score Using HIV Treatment Satisfaction Status Questionnaire (HIVTSQs) at Weeks 24 and 48 (Time: Baseline (Day 1) and Weeks 24 and 48) | Change From Baseline in Individual Item Scores Using HIVTSQs at Weeks 24 and 48 (Time: Baseline (Day 1) and Weeks 24 and 48) | Total Treatment Satisfaction Change Score Using HIV Treatment Satisfaction Change Questionnaire (HIVTSQc) at Week 48 (Time: Week 48) | Change From Week 8 in Dimension Scores Using Perception of Injection (PIN) Questionnaire. (Time: Week 8 and Weeks 24 and 48) | Change From Week 8 in Individual Item Scores (Anxiety Before, Pain, Satisfaction, Anxiety After and Willingness) Using Perception of Injection (PIN) Questionnaire. (Time: Week 8 and Weeks 24 and 48) | Change From Baseline in Treatment Acceptance a Using \"General Acceptance\" Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire in Participants With or Without Prior Exposure to CAB+RPV (Time: Baseline (Day 1) and Weeks 24 and 48) | Plasma Trough Concentration (Ctrough) for CAB LA Evaluable (Time: Pre-dose at Weeks 4, 8, 16, 24, 32, 40 and 48) | Plasma Ctrough for RPV LA Evaluable (Time: Pre-dose at Weeks 4, 8, 16, 24, 32, 40 and 48) | Area Under the Curve (AUC) for CAB LA (Time: Predose at Weeks 4, 8, 13, 24, 32, 40, 48; 1 Week post-dose at Week 9 and 41) | AUC for RPV LA (Time: Predose at Weeks 4, 8, 13, 24, 32, 40, 48; 1 Week post-dose at Week 9 and 41) | Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable (Time: Predose at Weeks 4, 8, 13, 24, 32, 40, 48; 1 Week post-dose at Week 9 and 41) | Cmax in Plasma for RPV LA Evaluable (Time: Predose at Weeks 4, 8, 13, 24, 32, 40, 48; 1 Week post-dose at Week 9 and 41)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Implement a double\u2011blind, double\u2011dummy design by manufacturing matching placebo cabotegravir and rilpivirine long\u2011acting suspensions, and require two gluteal injections at every 4\u2011week visit for all participants. In the Q8W arm, administer active product at Weeks 0, 8, 16, etc., with indistinguishable placebo injections at Weeks 4, 12, 20, etc.; in the Q4W arm, give active every 4 weeks and a visually identical placebo at alternate timepoints to preserve blinding of the dosing interval and minimize performance bias.\nB. Design with an appropriate active comparator reflecting standard of care, ensure adequate sample size and follow-up duration to capture AE/discontinuation events, and prespecify exposure accounting (person-time) for incidence rates to enable robust safety comparisons.\nC. Predefine comprehensive safety endpoints and tabulation conventions in the SAP, aligned with FDA guidance (e.g., MedDRA coding versions, CTCAE grading, treatment-emergent windows, denominators, exposure-adjusted incidence rates). Register these details in ClinicalTrials.gov Outcome Measures and Statistical Analysis Plan fields, including time frames and methods for aggregating across cycles. Pilot the safety tables against historical data to ensure consistency and completeness.\nD. Before launch, embed a detailed safety surveillance plan in the SAP: define AE/SAE grading standards (e.g., CTCAE), adjudication, stopping rules, exposure metrics (person-time), predefined comparisons to historical/original data, and prespecified tables/outputs. Ensure outcomes/time frames capture incidence changes and discontinuations, with CRF fields enabling narratives for deaths and AE-related dropouts.\nE. Prior to trial, align intervention\u2019s critical quality attributes (e.g., particle size distribution for long-acting injectables) with pivotal batch specs; include in the protocol an intervention description referencing release criteria that match clinical material. Coordinate with CMC to ensure trial and commercial specs are consistent to avoid PK/safety drift.\nF. No optimization needed - the trial design is adequate\nG. Add an analytical treatment interruption (ATI) sub-study: after Week 24, randomize a subset in each arm to suspend all injections for 12\u201316 weeks with weekly viral load monitoring, predefined restart criteria (e.g., >200 copies/mL confirmed), and resistance testing at rebound; use time-to-rebound and rebound magnitude as secondary endpoints to compare Q8W versus Q4W durability.\nH. Pretrial, screen and exclude or stratify participants with strong inducers/inhibitors of relevant enzymes; include pharmacogenomic considerations (UGT1A1 variants) and DDI monitoring plans in SAP; collect concomitant medication data systematically and prespecify analyses of AE/discontinuation by DDI/genotype strata.\nI. Before launch, incorporate an external safety dataset plan: map known label AEs and baseline rates, stratify outcome measures by relevant subgroups (e.g., hepatic impairment, concomitant drugs), and power/time frames to detect incidence changes. Predefine comparative tables across indications/populations to contextualize safety.\nJ. Implement full double-blind, double-dummy masking by giving matched sham intramuscular injections to the Q8W arm at intervening monthly visits (placebo depot vehicle with identical syringe/volume) and matched oral placebo tablets during the oral lead-in for both arms to minimize bias in patient-reported outcomes and investigator assessments related to dosing frequency.", "answer": "B, D, E, H, I"} |
| {"_id": "trial_opt_adv_0020", "nctid": "NCT03985982", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)\n\nBrief Summary: The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.\n\nConditions: Glabellar Frown Lines\n\nInterventions: DRUG: Botulinum Toxin A; DRUG: Placebo; DRUG: Botulinum Toxin A\n\nPhase: PHASE3\n\nEnrollment: 410.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: DOUBLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Ages \u2265 18 years or older at time of screening (upper limit 75 years, inclusive).\n* Has moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on FWS) as determined by in-clinic assessments by both the investigator and the subject (where: 0 =\u00b4none\u00b4, 1= \u00b4mild\u00b4, 2= \u00b4moderate\u00b4, 3= \u00b4severe\u00b4).\n\nSubject had a stable medical condition with no uncontrolled systemic disease.\n\n* Female subjects of childbearing potential had to test negative for pregnancy and agree to use effective birth control during the course of the study.\n* Subjects who wear glasses had to be able to adequately self-assess the severity of their glabellar lines (according to the FWS), without glasses obstructing the forehead area.\n* Moderate to severe glabellar lines indicating an important psychological impact on the subject as indicated by scores \\> 0 on either the Emotional or the Social Functioning subscale of the Modified Skindex-16 GL-QoL scale.\n\nExclusion Criteria:\n\n* ... (truncated)\n\nArms and Interventions: Botulinum toxin A (EXPERIMENTAL); Placebo (PLACEBO_COMPARATOR); Botulinum toxin A Open Label Extension Arm (EXPERIMENTAL)\n\nPrimary Outcome Measures: Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of \u2265 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the Investigators\u00b4 and the Subjects\u00b4 In-clinic Assessments. (Time: Week 4)\n\nSecondary Outcome Measures: Extent of Change in Psychological Impact (Emotional and Social Functioning and Concerns Relating to Glabellar Lines) (Time: Week 4) | Percentage of Responders at Maximum Frown at Week 12 (Time: Week 12) | Percentage of Responders at Week 16 (Time: Week 16) | Percentage of Responders at Week 20 (Time: Week 20) | The Percentage of Subjects With a \u2265 1 Point Reduction in Facial Wrinkle Scale (FWS) Score at Rest at Week 4 Based Separately on the Investigators\u00b4 and the Subjects\u00b4 In-clinic Assessments (Time: Week 4) | Responder Rate at Weeks 1, 2 and 8 (Time: Week 1, Week 2 and Week 8) | The Percentage of Subjects With \u2265 2-point and \u2265 1 Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown) (Time: Week 2, 4, 12, 16 and 20) | Time to Onset of Effect in the BoNT/A-DP and Placebo Groups in the First Treatment Cycle (Time: From treatment at Day 0 to Week 4 in Treatment Cycle 1) | Satisfaction With Treatment, During Each Treatment Cycle, as Assessed by the Validated FACE-Q Satisfaction With Outcome Scale. (Time: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)) | The Percentage of Subjects With a \u2265 1 Point Reduction in Facial Wrinkle Scale (FWS) Score at Rest Based on the Independent Rater's Assessment of Photos. (Time: Week 2, Week 4, Week 12, Week 16, Week 20 of Treatment Cycle 1) | Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of \u2265 2 Points in FWS Score (at Maximum Frown) at 4 Weeks After Re-treatment Relative to the Rating at the Preceding End-of-Cycle Visit. (Time: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)) | The Percentage of Subjects With \u2265 1-point Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown) During the First Treatment Cycle at Week 1, 2, 4, 8, 12, 16 and 20 Relative to Baseline (Time: Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20 of Treatment Cycle 1) | The Percentage of Subjects With \u2265 1-point Reduction in Facial Wrinkle Scale (FWS) Score (at Maximum Frown) During Each Re-treatment Cycle at Week 4 Relative to Re-treatment-baseline. (Time: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)) | Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs) and AEs of Special Interest (AESIs) (Time: Through study completion (60 weeks)) | Number of Participants With Neutralizing Anti-Drug Antibodies (Time: Through study completion (60 weeks)) | Change From Baseline of Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets (Time: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)) | Change From Baseline of Alanine Aminotransferase, Alkaline Phosphatase , Aspartate Aminotransferase, Gamma Glutamyl Transpeptidase (Time: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)) | Change From Baseline of Cholesterol, Glucose, Potassium, Sodium, Urea Nitrogen (Time: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)) | Change From to Baseline of Bilirubin, Creatinin (Time: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)) | Change From Baseline of Erythrocytes (Time: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)) | Change From Baseline of Erythrocytes MCV (Time: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)) | Change From Baseline of Erythrocyte MCHC, Hemoglobin (Time: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)) | Change From Baseline of Lymphocytes/Leukocytes, Monocytes/Leukocytes, Neutrophils/Leukocytes, Basophiles/Leukocytes, Eosinophils/Leukocytes (Time: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)) | Change From Baseline of Systolic and Diastolic Blood Pressure (Time: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)) | Change From Baseline of Pulse Rate (Time: Week4 Cycle1(on average 4 Weeks from Baseline, up to Week 7), Week4 Cycle2 (on average 20 Weeks from Baseline, up to Week 52), Week4 Cycle3 (on average 37 Weeks from Baseline, up to Week 53), Week4 Cycle4 (on average 46 Weeks from Baseline, up to Week 56)) | Number of Participants With Normal and Abnormal Electrocardiogram (Time: Week 4 and last visit of Treatment Cycle 1 (End of Cycle procedures), conducted upon confirmation of eligibility for retreatment, assessed starting 12 weeks post-treatment with 4-weekly evaluations up to a max. of 48 weeks post treatment.)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Introduce a mechanistic biomarker package comprising serial EMG of corrugator/procerus, high-resolution facial MRI at baseline and Weeks 2, 8, and 16, and plasma pharmacokinetics for BoNT/A to quantify exposure\u2013response and tissue distribution\nB. Convert the trial to a non-inferiority design against an approved onabotulinumtoxinA comparator, eliminate the placebo arm, and set a narrow non-inferiority margin (e.g., 5%) while gating superiority only to safety endpoints to expedite labeling claims\nC. No optimization needed - the trial design is adequate\nD. Prepare and submit up-to-date SPL-compliant labeling. Not a preventable clinical design issue.\nE. Redesign the Phase 3 to a split-face, within-subject crossover where one half of the glabella receives BoNT/A-DP and the other receives placebo, with a planned crossover after 12 weeks to minimize intersubject variability and increase statistical power\nF. Align roles, register establishments appropriately, and ensure GMP compliance for entities performing release. Not addressable via trial design fields.\nG. Scale and qualify reference standard lots with commutability/bridging to support all analytical methods and stability program prior to filing. Not addressable via ClinicalTrials.gov design elements.\nH. Replace the saline placebo arm with a low-dose BoNT/A 'active placebo' (e.g., 10\u201320% of the therapeutic dose) to better preserve blinding and ethical equipoise, and rely on assay-sensitivity analyses to interpret treatment differences\nI. Implement a validated environmental and in-process bioburden monitoring program per cGMP before manufacturing clinical/registration lots; establish alert/action limits, sampling plans, and trending. Although critical to approval, this is not a trial design issue tied to ClinicalTrials.gov fields.\nJ. Complete ICH-aligned stability studies (long-term, accelerated, stress) on representative commercial configurations and justify any reduced testing with statistical trending prior to submission. Not a clinical trial design fix.", "answer": "D, F, G, I, J"} |
| {"_id": "trial_opt_adv_0022", "nctid": "NCT02407236", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis\n\nBrief Summary: The purpose of this study is to evaluate the efficacy and safety of ustekinumab as intravenous (IV: into the vein) infusion in induction study in participants with moderately to severely active Ulcerative Colitis (UC) and as subcutaneous (SC) administration in maintenance study in participants with moderately to severely active Ulcerative Colitis (UC) who have demonstrated a clinical response to Induction treatment with IV ustekinumab.\n\nConditions: Colitis, Ulcerative; Inflammatory Bowel Diseases\n\nInterventions: DRUG: Placebo IV; DRUG: Placebo SC; DRUG: Ustekinumab IV; DRUG: Ustekinumab SC\n\nPhase: PHASE3\n\nEnrollment: 961.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: DOUBLE\n\nPrimary Purpose: nan\n\nEligibility Criteria: Inclusion Criteria:\n\n* Has a clinical diagnosis of Ulcerative Colitis (UC) at least 3 months before Screening\n* Has moderately to severely active UC, defined as a Baseline (Week 0) Mayo score of 6 to 12, including a Screening endoscopy subscore of the Mayo score greater than or equal to (\\>=) 2 as determined by a central reading of the video endoscopy\n* Have failed biologic therapy, that is, have received treatment with 1 or more tumour necrosis factor (TNF) antagonists or vedolizumab at a dose approved for the treatment of UC, and have a documented history of failure to respond to or tolerate such treatment; OR Be na\u00efve to biologic therapy (TNF antagonists or vedolizumab) or have received biologic therapy but have not demonstrated a history of failure to respond to, or tolerate, a biologic therapy and have a prior or current UC medication history that includes at least 1 of the following: a. Inadequate response to or failure to tolerate current treatment with oral corticosteroids or i... (truncated)\n\nArms and Interventions: Induction Study - Placebo Intravenous (IV) (PLACEBO_COMPARATOR); Induction Study - Ustekinumab 130 milligram (mg) IV (EXPERIMENTAL); Induction Study - Ustekinumab 6 mg/kg IV (EXPERIMENTAL); Induction Study- Placebo- Nonresponsders at Week 8 (OTHER); Induction study-Ustekinumab Nonresponders at Week 8 (OTHER); Maintenance Study - Placebo Subcutaneous (SC) (PLACEBO_COMPARATOR); Maintenance Study - Ustekinumab 90mg SC every 12 weeks (EXPERIMENTAL); Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w) (EXPERIMENTAL); Maintenance Study - Placebo IV - Responder - Placebo SC (OTHER); Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w (OTHER)\n\nPrimary Outcome Measures: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Time: Week 8) | Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per US Definition) (Time: Week 8) | Maintenance Study: Number of Participants With Clinical Remission at Week 44 (As Per Global Definition) (Time: Week 44) | Maintenance Study: Number of Participants With Clinical Remission at Week 44 (as Per US Definition) (Time: Week 44)\n\nSecondary Outcome Measures: Induction Study: Number of Participants With Endoscopic Healing at Week 8 (Time: Week 8) | Induction Study: Number of Participants With Clinical Response at Week 8 (Time: Week 8) | Induction Study - Change From Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 8 (Time: Baseline and Week 8) | Maintenance Study: Number of Participants With Clinical Response up to Week 44 (Time: Up to Week 44) | Maintenance Study: Number of Participants With Endoscopic Healing at Week 44 (Time: Week 44) | Maintenance Study: Number of Participants With Clinical Remission and Not Receiving Concomitant Corticosteroids (Corticosteroid-free Clinical Remission) at Week 44 (As Per Global Definition) (Time: Week 44) | Maintenance Study: Number of Participants With Clinical Remission and Not Receiving Concomitant Corticosteroids (Corticosteroid-free Clinical Remission) at Week 44 (As Per US Definition) (Time: Week 44) | Maintenance Study: Number of Participants With Clinical Remission up to Week 44 Among Participants Who Achieved Clinical Remission at Maintenance Study Baseline (As Per Global Definition) (Time: Up to Week 44) | Maintenance Study: Number of Participants With Clinical Remission up to Week 44 Among Participants Who Achieved Clinical Remission at Maintenance Study Baseline (As Per US Definition) (Time: Up to Week 44) | Induction Study - Number of Participants With Mucosal Healing at Week 8 (Time: Week 8) | Induction Study - Number of Participants in Clinical Remission With a Rectal Bleeding Subscore of 0 at Week 8 (As Per Global Definition) (Time: Week 8) | Induction Study - Number of Participants in Symptomatic Remission at Week 8 (Time: Week 8) | Induction Study - Number of Participants in With Normal or Inactive Mucosal Disease at Week 8 (Time: Week 8) | Induction Study - Change From Baseline in Mayo Score at Week 8 (Time: Baseline and Week 8) | Induction Study - Change From Baseline in Partial Mayo Score Through Week 8 (Time: Baseline through Week 8) | Induction Study - Number of Participants With Individual Mayo Subscore (Stool Frequency) up to Week 8 (Time: Up to Week 8) | Induction Study - Number of Participants With Individual Mayo Subscore (Rectal Bleeding) up to Week 8 (Time: Up to Week 8) | Induction Study - Number of Participants With Individual Mayo Subscore (Endoscopy Findings) at Week 8 (Time: Week 8) | Induction Study - Number of Participants With Individual Mayo Subscore (Physician's Global Assessment) up to Week 8 (Time: Up to Week 8) | Induction Study - Number of Participants With Clinical Remission at Week 8 by Biologic Failure (BF) Status (As Per Global Definition) (Time: Week 8) | Induction Study - Number of Participants With Clinical Remission at Week 8 by Biologic Failure (BF) Status (As Per US Definition) (Time: Week 8) | Induction Study - Number of Participants With Endoscopic Healing at Week 8 by Biologic Failure Status (Time: Week 8) | Induction Study - Number of Participants With Clinical Response at Week 8 by Biologic Failure Status (Time: Week 8) | Induction Study: Number of Participants in Remission Based on Stool Frequency Subscore of 0 or 1, Rectal Bleeding Subscore of 0, and Endoscopy Subscore of 0 or 1 at Week 8 (US Specific) (Time: Week 8) | Induction Study: Number of Participants in Remission Based on Stool Frequency Subscore of 0, Rectal Bleeding Subscore of 0, and Endoscopy Subscore of 0 or 1 at Week 8 (US Specific) (Time: Week 8) | Induction Study - Change From Baseline in C-reactive Protein (CRP) Concentration Through Week 8 (Time: Baseline through Week 8) | Induction Study - Number of Participants With Normalized CRP (<=3 mg/L) up to Week 8 Among Participants With Abnormal CRP (>3 mg/L) at Baseline (Time: Up to Week 8) | Induction Study - Change From Baseline in Fecal Lactoferrin Concentration Through Week 8 (Time: Baseline through Week 8) | Induction Study - Number of Participants With Normalized Fecal Lactoferrin (<=7.24 mcg/g) up to Week 8 Among Participants With Abnormal Fecal Lactoferrin (>7.24 mcg/g) at Baseline (Time: Up to Week 8) | Induction Study - Change From Baseline in Fecal Calprotectin Concentration Through Week 8 (Time: Baseline through Week 8) | Induction Study - Number of Participants With Normalized Fecal Calprotectin (<=250 mg/kg) up to Week 8 Among Participants With Abnormal Fecal Calprotectin (>250 mg/kg) at Baseline (Time: Up to Week 8) | Induction Study - Number of Participants With a >20-point Improvement From Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 8 (Time: Baseline and Week 8) | Induction Study - Change From Baseline in IBDQ Dimension Scores at Week 8 (Time: Baseline and Week 8) | Induction Study - Change From Baseline in 36-Item Short-Form (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) at Week 8 (Time: Baseline and Week 8) | Induction Study - Change From Baseline in Individual Subscales of 36-Item Short-Form (SF-36) at Week 8 (Time: Baseline and Week 8) | Induction Study - Change From Baseline in EuroQOL-5 Dimensions (EQ-5D) Health Questionnaire Index Score at Week 8 (Time: Baseline and Week 8) | Induction Study - Change From Baseline in EuroQOL-5 Dimensions (EQ-5D) Health State Visual Analog Scale (VAS) Score at Week 8 (Time: Baseline and Week 8) | Induction Study - Percentage of Participants With Change From Baseline in EuroQOL-5 Dimensions (EQ-5D) Score at Week 8 (Time: Baseline and Week 8) | Maintenance Study - Change From Maintenance Baseline in Mayo Score at Week 44 (Time: Baseline and Week 44) | Maintenance Study - Change From Induction Baseline in Mayo Score at Week 44 (Time: Induction Baseline and Week 44) | Maintenance Study - Number of Participants With Individual Mayo Subscore (Stool Frequency) up to Week 44 (Time: Up to Week 44) | Maintenance Study - Number of Participants With Individual Mayo Subscore (Rectal Bleeding) up to Week 44 (Time: Up to Week 44) | Maintenance Study - Number of Participants With Individual Mayo Subscore (Endoscopy Findings) at Week 44 (Time: Week 44) | Maintenance Study - Number of Participants With Individual Mayo Subscore (Physician's Global Assessment) up to Week 44 (Time: Up to Week 44) | Maintenance Study - Change From Maintenance Baseline in Partial Mayo Score Through Week 44 (Time: Baseline through Week 44) | Maintenance Study - Change From Induction Baseline in Partial Mayo Score Through Week 44 (Time: Baseline through Week 44) | Maintenance Study: Number of Participants in Remission Based on Stool Frequency Subscore of 0 or 1, Rectal Bleeding Subscore of 0, and Endoscopy Subscore of 0 or 1 at Week 44 (Time: Week 44) | Maintenance Study: Number of Participants in Remission Based on Stool Frequency Subscore of 0, Rectal Bleeding Subscore of 0, and Endoscopy Subscore of 0 or 1 at Week 44 (Time: Week 44) | Maintenance Study: Number of Participants in Symptomatic Remission at Week 44 (Time: Week 44) | Maintenance Study: Number of Participants With Clinical Remission at Week 44 by Biologic Failure Status (As Per Global Definition) (Time: Week 44) | Maintenance Study: Number of Participants With Clinical Remission at Week 44 by Biologic Failure Status (As Per US Definition) (Time: Week 44) | Maintenance Study: Number of Participants With Clinical Response up to Week 44 by Biologic Failure Status (Time: Up to Week 44) | Maintenance Study: Number of Participants With Endoscopic Healing at Week 44 by Biologic Failure Status (Time: Week 44) | Maintenance Study: Number of Participants With Endoscopic Healing at Week 44 Among Participants Who Had Achieved Endoscopic Healing at Maintenance Baseline (Time: Week 44) | Maintenance Study: Number of Participants With Normal or Inactive Mucosal Disease at Week 44 (Time: Week 44) | Maintenance Study: Number of Participants With Clinical Remission at Week 44 and Not Receiving Concomitant Corticosteroids at Week 44 Among Participants Who Received Concomitant Corticosteroids at Maintenance Baseline (Per Global Definition) (Time: Week 44) | Maintenance Study: Number of Participants With Clinical Remission at Week 44 and Not Receiving Concomitant Corticosteroids at Week 44 Among Participants Who Received Concomitant Corticosteroids at Maintenance Baseline (Per US Definition) (Time: Week 44) | MS: Change From Maintenance Baseline in Average Daily P.Eq Corticosteroid Dose Through Week 44 Among Participants Who Received Corticosteroids Other Than Budesonide and Beclomethasone Dipropionate at Maintenance Baseline (Time: Baseline Through Week 44) | Maintenance Study: Number of Participants Not Receiving Concomitant Corticosteroids at Week 44 Among Participants Who Received Concomitant Corticosteroids at Maintenance Baseline (Time: Week 44) | Maintenance Study: Number of Participants Who Maintained 20-point Improvement From Induction Baseline in IBDQ up to Week 44 Among Participants With a >20-point Improvement in IBDQ at Maintenance Baseline (Time: Up to Week 44) | Maintenance Study: Change From Maintenance Baseline in the IBDQ Score at Week 20 and 44 (Time: Baseline, Week 20, and 44) | Maintenance Study: Change From Maintenance Baseline in the IBDQ Dimension Scores at Week 20 and 44 (Time: Baseline, Week 20, and 44) | Maintenance Study: Change From Maintenance Baseline in 36-Item Short-Form (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) at Weeks 20 and 44 (Time: Baseline, Weeks 20, and 44) | Maintenance Study: Change From Maintenance Baseline in Individual Subscales of 36-Item Short-Form (SF-36) at Weeks 20 and 44 (Time: Baseline, Weeks 20, and 44) | Maintenance Study: Change From Maintenance Baseline in EuroQOL-5 Dimensions (EQ-5D) Health Questionnaire Index Score at Weeks 20 and 44 (Time: Baseline, Weeks 20, and 44) | Maintenance Study: Change From Maintenance Baseline in EuroQOL-5 (EQ-5D) Health State Visual Analog Scale (VAS) Score at Weeks 20 and 44 (Time: Baseline, Weeks 20 and 44) | Maintenance Study: Percentage of Participants With Change From Maintenance Baseline in EuroQOL-5 (EQ-5D) Dimensions Score at Weeks 20 and 44 (Time: Baseline, Weeks 20, and 44) | Maintenance Study: Number of Participants With Mucosal Healing at Week 44 (Time: Week 44) | Maintenance Study: Change From Maintenance Baseline in C-reactive Protein (CRP) Concentration at Weeks 8, 24, and 44 (Time: Baseline, Weeks 8, 24, and 44) | Maintenance Study: Change From Maintenance Baseline in Fecal Lactoferrin Concentration at Weeks 8, 24, and 44 (Time: Baseline, Weeks 8, 24, and 44) | Maintenance Study: Change From Maintenance Baseline in Fecal Calprotectin Concentration at Weeks 8, 24, and 44 (Time: Baseline, Weeks 8, 24, and 44)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Audit and align container/carton labels and prescribing information with CFR requirements and FDA guidance before trial start; include bold storage temperature, proper expiry format with non-zero day, 'Do not shake', 'No preservative' wording per 21 CFR 610.61(e), linear barcode, Medication Guide pharmacist statement, and consistent manufacturer name. Use these final materials in any usability/medication error assessments.\nB. Redesign IFU before trial: bold critical warnings; label figures (A, B, C\u2026) mapped to steps; correct anatomical injection-site depictions; add a post-injection 'lift pen' step illustration; revalidate with HF testing to acceptable error thresholds. Ensure the pivotal study uses the finalized IFU and captures real-world users.\nC. Implement retention strategies and stopping rules in the protocol and SAP, include reasons for discontinuation as prespecified outcomes, and power for anticipated attrition; use run-in periods, patient support, and on-treatment follow-up to reduce missing data, with predefined handling of intercurrent events.\nD. Replace the double-blind placebo SC maintenance arm with an open-label standard-of-care comparator (oral corticosteroid taper plus 5-ASA), while keeping induction blinded, to enhance ethical acceptability and retention, and rely on site investigator assessments for efficacy instead of centralized review.\nE. Complete CMC validation for final formulation and device prior to pivotal trial or establish a predefined, FDA-aligned bridging plan. Conduct in vitro pyrogenicity/endotoxin risk assessments and, if applicable, rabbit pyrogen spiking studies or validated alternatives before trial. Ensure the clinical supply matches the intended commercial presentation to avoid post hoc bridging.\nF. No optimization needed - the trial design is adequate\nG. Enhance IFU and labeling pre-trial to increase prominence of Important Information regarding pediatric exposure and device safety checks; include storage and safety statements in both IFU and carton; validate through HF testing that users comprehend and can act on these warnings.\nH. Implement a seamless adaptive Phase 2/3 approach within the maintenance period that uses Bayesian response-adaptive randomization and interim dose titration (e.g., switching between q8w and q12w SC ustekinumab) based solely on patient-reported rectal bleeding and stool frequency subscores, to continuously optimize dosing in real time.\nI. Designate an AI-derived MRI colonography mucosal inflammation index, combined with continuous home fecal calprotectin monitoring via patient-operated kits, as the single primary endpoint and remove centralized endoscopic scoring to reduce invasiveness and streamline operations.\nJ. Iterate device design and IFU prior to pivotal trial: remove cap ridges; add clear needle-end labeling; clarify and emphasize fill window color cue; add explicit end-of-injection cues (clicks and timing) in device and IFU; strengthen refrigeration handling instructions; conduct formative HF studies, then a passing summative HF validation on the to-be-marketed user interface. Include device performance and user-error endpoints in trial or bridging HF study to demonstrate safe use.", "answer": "A, B, E, G, J"} |
| {"_id": "trial_opt_adv_0027", "nctid": "NCT04701203", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism\n\nBrief Summary: During the first 26 weeks of the trial, participants will be randomly assigned to one of two groups: one group will receive TransCon PTH and one group will receive placebo. All subjects will start with study drug at a dose of 18 mcg/day and will be individually and progressively titrated to an optimal dose in dose increments of 3 mcg/day. TransCon PTH or placebo will be administered as a subcutaneous injection using a pre-filled injection pen. Neither trial participants nor their doctors will know who has been assigned to each group. After the 26 weeks, participants will continue in the trial as part of a long-term extension study. During the extension, all participants will receive TransCon PTH, with the dose adjusted to their individual needs. This is a global trial that will be conducted in the United States, Canada, Germany, Denmark, Norway, Italy, and Hungary.\n\nConditions: Hypoparathyroidism; Endocrine System Diseases; Parathyroid Diseases\n\nInterventions: COMBINATION_PRODUCT: TransCon PTH; COMBINATION_PRODUCT: Placebo\n\nPhase: PHASE3\n\nEnrollment: 84.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n1. Males and females, \u226518 years of age\n2. Subjects with postsurgical chronic HP, or auto-immune, genetic, or idiopathic HP for at least 26 weeks. Diagnosis of HP is established based on historic hypocalcemia in the setting of inappropriately low serum PTH levels\n3. Requirement for doses of SoC (e.g., calcitriol, alfacalcidol, calcium supplements) at or above a minimum threshold:\n\n * For countries other than Japan: requirement for a dose of calcitriol \u22650.5 \u03bcg/day, or alfacalcidol \u22651.0 \u03bcg/day and (elemental) calcium \u2265800 mg/day (e.g., calcium citrate, calcium carbonate etc.) for at least 12 weeks prior to Screening. In addition, the dose of calcitriol, or alfacalcidol, or calcium should be stable for at least 5 weeks prior to Screening\n * For Japan: requirement for a dose of calcitriol \u22651.0 \u03bcg/day, or alfacalcidol \u22652.0 \u03bcg/day for at least 12 weeks prior to Screening. In addition, the dose of calcitriol or alfacalcidol should be stable for at least 5 weeks prior t... (truncated)\n\nArms and Interventions: TransCon PTH (EXPERIMENTAL); Placebo (PLACEBO_COMPARATOR)\n\nPrimary Outcome Measures: Efficacy - Primary Endpoint During the Blinded Period (Time: 26 weeks)\n\nSecondary Outcome Measures: Change From Baseline to Week 26 in HPES Symptom - Physical Domain Score (Time: 26 weeks) | Change From Baseline to Week 26 in HPES Symptom - Cognitive Domain Score (Time: 26 weeks) | Change From Baseline to Week 26 in HPES Impact - Physical Functioning Domain Score (Time: 26 weeks) | Change From Baseline to Week 26 in HPES Impact - Daily Life Domain Score (Time: 26 weeks) | Change From Baseline to Week 26 in SF-36 Physical Functioning Subscale Score (Time: 26 weeks)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Introduce a two-week open-label TransCon PTH lead-in to determine each participant\u2019s individualized maintenance dose before randomization, then randomize to continue active therapy versus matched placebo at that established dose to reduce titration-related variability and improve precision of efficacy estimates\nB. Elevate patient-reported outcomes (e.g., SF-36 and a hypoparathyroidism-specific symptom diary) to the sole primary endpoint at Week 26, relegating biochemical control metrics (serum calcium/phosphate and urinary calcium) to secondary endpoints to emphasize patient-centric benefit\nC. Prior to trial, establish and register a pregnancy/lactation exposure registry or global descriptive study protocol, include exclusion criteria and contraception requirements where appropriate, and predefine maternal/fetal safety monitoring endpoints and reporting procedures.\nD. Before trial launch, conduct and publish rigorous preclinical and engineering validation of the delivery device and assay (accuracy, precision, repeatability across dose settings and environmental conditions), set acceptance criteria aligned with industry/device standards, and reflect validated dose delivery performance in the ClinicalTrials.gov intervention description and SAP (including monitoring plans for dose verification and predefined handling of mis-delivery).\nE. Define and control concomitant therapy use in eligibility and protocol (e.g., stable background therapy run-in); stratify randomization by key background treatments; prespecify subgroup analyses; collect adherence data to reduce confounding.\nF. No optimization needed - the trial design is adequate\nG. Convert the parallel-group design into a double-blind, 2-period crossover (two 13-week treatment periods separated by a 2-week washout), with subjects re-initiating at 18 mcg/day and retitrated in 3 mcg/day increments in each period so each participant serves as their own control and variability is reduced\nH. Perform design-for-manufacture and process validation studies to ensure acceptable batch yield and specification compliance; include contingency supply planning and lot-release criteria. Pre-register manufacturing quality controls and PK bridging plans to ensure consistent product availability for the trial.\nI. Complete ICH-aligned stability program (long-term, accelerated, in-use) for the exact formulation/device and dose specification prior to trial, and register storage/handling instructions and shelf-life constraints; design trial logistics to ensure product used remains within validated stability windows.\nJ. Align trial safety endpoints/time frames and interim analyses with known class risks and regulatory expectations; predefine safety data aggregation and update schedules, ensuring new safety data from ongoing/parallel studies are incorporated and ready for regulatory submission.", "answer": "C, D, H, I, J"} |
| {"_id": "trial_opt_adv_0035", "nctid": "NCT03926130", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease\n\nBrief Summary: The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.\n\nConditions: Crohn's Disease\n\nInterventions: DRUG: Mirikizumab; DRUG: Mirikizumab; DRUG: Ustekinumab; DRUG: Ustekinumab; DRUG: Placebo; DRUG: Placebo\n\nPhase: PHASE3\n\nEnrollment: 1158.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: TRIPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Diagnosis of CD for at least 3 months prior to baseline\n* Confirmed diagnosis of moderate to severe CD as assessed by SF, AP score, and SES-CD\n* Demonstrated intolerance, loss of response or inadequate response to conventional or to biologic therapy for CD\n* If female, subject must meet the contraception recommendations\n\nExclusion Criteria:\n\n* Have a current diagnosis of ulcerative colitis, inflammatory bowel disease-unclassified (IBD-U) (formerly known as indeterminate colitis) or short bowel syndrome\n* Currently have or are suspected to have an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained, adequately treated and resolved at least 3 weeks prior to baseline or 8 weeks prior to baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery\n* Have a stoma, ileoanal pouch or ostomy\n* Have had a bowel resection within 6 months, or any kind of intra-abdominal or extra abdominal surgery wit... (truncated)\n\nArms and Interventions: Placebo (PLACEBO_COMPARATOR); 300 mg Mirikizumab (EXPERIMENTAL); 90 mg Ustekinumab (ACTIVE_COMPARATOR); 300 mg Mirikizumab (Adolescents) (EXPERIMENTAL)\n\nPrimary Outcome Measures: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Time: Week 12 to Week 52) | Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab) (Time: Week 12 to Week 52)\n\nSecondary Outcome Measures: Percentage of Adult Participants Achieving Endoscopic Response at Week 12 (Placebo and Mirikizumab) (Time: Week 12) | Percentage of Adult Participants Achieving Endoscopic Response at Week 52 (Time: Week 52) | Percentage of Adult Participants Achieving Clinical Remission at Week 12 (Placebo and Mirikizumab) (Time: Week 12) | Percentage of Adult Participants Achieving Clinical Remission at Week 52 (Time: Week 52) | Percentage of Adult Participants Achieving Endoscopic Remission at Week 12 (Placebo and Mirikizumab) (Time: Week 12) | Change From Baseline in Urgency Numeric Rating Scale (NRS) at Week 12 in Adult Participants (Placebo and Mirikizumab) (Time: Baseline, Week 12) | Change From Baseline in Urgency NRS at Week 52 in Adult Participants (Placebo and Mirikizumab) (Time: Baseline, Week 52) | Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission by PRO at Week 52 (Placebo and Mirikizumab) (Time: Week 12 to Week 52) | Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Remission at Week 52 (Placebo and Mirikizumab) (Time: Week 12 to Week 52) | Percentage of Adult Participants Achieving Clinical Response at Week 12 and Corticosteroid-free Clinical Remission at Week 52 (Placebo and Mirikizumab) (Time: Week 12 to Week 52) | Change From Baseline in C-Reactive Protein (CRP) at Week 52 in Adult Participants (Placebo and Mirikizumab) (Time: Baseline, Week 52) | Change From Baseline in Fecal Calprotectin at Week 52 in Adult Participants (Placebo and Mirikizumab) (Time: Baseline, Week 52) | Percentage of Adult Participants Achieving Clinical Response at Week 12 and Resolution of Baseline Extraintestinal Manifestations (EIMs) at Week 52 (Placebo and Mirikizumab) (Time: Week 12 to Week 52) | Percentage of Adult Participants Achieving Clinical Response at Week 12 and \u226550% Reduction in Number of Draining Cutaneous Fistulae at Week 52 in Participants With Draining Cutaneous Fistulae at Baseline (Placebo and Mirikizumab) (Time: Week 12 to Week 52) | Change From Baseline in Health Related Quality of Life at Week 52 in Adult Participants: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Placebo and Mirikizumab) (Time: Baseline, Week 52) | Adult Population Pharmacokinetics (PopPK): Area Under the Concentration Time Curve (AUC) of Mirikizumab (Time: 900 mg Mirikizumab: Week 4: Predose; Week 4, Day 1: Postdose; Week 8, 12: Predose 300 mg Mirikizumab: Week 16, 24, 36: Predose; Week 52)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Redefine the primary efficacy endpoint to rely solely on patient-reported outcomes (e.g., daily electronic stool frequency and abdominal pain scores) and remove central endoscopic assessments and biomarker endpoints, to minimize invasiveness and improve retention in this Phase 3 population.\nB. Audit and align container/carton labels and prescribing information with CFR requirements and FDA guidance before trial start; include bold storage temperature, proper expiry format with non-zero day, 'Do not shake', 'No preservative' wording per 21 CFR 610.61(e), linear barcode, Medication Guide pharmacist statement, and consistent manufacturer name. Use these final materials in any usability/medication error assessments.\nC. Convert the study to a two-period, two-sequence crossover design (mirikizumab\u2192ustekinumab vs ustekinumab\u2192mirikizumab) with 12-week treatment periods and an 8-week washout to reduce inter-patient variability and improve statistical efficiency, while maintaining triple masking and using intra-patient CDAI change as the primary endpoint.\nD. Eliminate the randomized ustekinumab arm and replace it with a rigorously matched synthetic control constructed from prior registrational trials and real-world cohorts using propensity scores or MAIC, retaining only mirikizumab and placebo as randomized arms to reduce cost and accelerate timelines.\nE. No optimization needed - the trial design is adequate\nF. Tighten eligibility to include only biologic-na\u00efve, corticosteroid-free participants with disease duration under two years and minimal comorbidities, to maximize effect size and reduce variability, with stratification limited to baseline CDAI only.\nG. Redesign IFU before trial: bold critical warnings; label figures (A, B, C\u2026) mapped to steps; correct anatomical injection-site depictions; add a post-injection 'lift pen' step illustration; revalidate with HF testing to acceptable error thresholds. Ensure the pivotal study uses the finalized IFU and captures real-world users.\nH. Complete CMC validation for final formulation and device prior to pivotal trial or establish a predefined, FDA-aligned bridging plan. Conduct in vitro pyrogenicity/endotoxin risk assessments and, if applicable, rabbit pyrogen spiking studies or validated alternatives before trial. Ensure the clinical supply matches the intended commercial presentation to avoid post hoc bridging.\nI. Enhance IFU and labeling pre-trial to increase prominence of Important Information regarding pediatric exposure and device safety checks; include storage and safety statements in both IFU and carton; validate through HF testing that users comprehend and can act on these warnings.\nJ. Iterate device design and IFU prior to pivotal trial: remove cap ridges; add clear needle-end labeling; clarify and emphasize fill window color cue; add explicit end-of-injection cues (clicks and timing) in device and IFU; strengthen refrigeration handling instructions; conduct formative HF studies, then a passing summative HF validation on the to-be-marketed user interface. Include device performance and user-error endpoints in trial or bridging HF study to demonstrate safe use.", "answer": "B, G, H, I, J"} |
| {"_id": "trial_opt_adv_0039", "nctid": "NCT02751931", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity\n\nBrief Summary: The objective of the study was to evaluate the efficacy, safety, tolerability and pharmacokinetics of mirabegron after multiple-dose administration in the pediatric population.\n\nConditions: Neurogenic Detrusor Overactivity\n\nInterventions: DRUG: Mirabegron\n\nPhase: PHASE3\n\nEnrollment: 91.0\n\nDesign Allocation: NON_RANDOMIZED\n\nIntervention Model: SINGLE_GROUP\n\nMasking: NONE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Subject has a body weight of greater than or equal to 11 kg.\n* Subject suffers from NDO confirmed by urodynamic investigation at baseline. The diagnosis of NDO must be confirmed by the presence of at least 1 involuntary detrusor contraction \\> 15 cm H2O from baseline detrusor pressure, and/or a decrease in compliance leading to an increase in baseline detrusor pressure of \\> 20 cm H2O.\n* Subject has been using CIC for at least 4 weeks prior to visit 1/screening.\n* Subject has a current indication for drug therapy to manage NDO.\n* Subject is able to take the study drug in accordance with the protocol\n\nExclusion Criteria:\n\n* Subject has a known genitourinary condition (other than NDO) that may cause overactive contractions or incontinence or kidney/bladder stones or another persistent urinary tract pathology that may cause symptoms.\n* Subject has one of the following gastrointestinal problems: partial or complete obstruction, decreased motility such as paralytic il... (truncated)\n\nArms and Interventions: Children (3 to < 12 Years) (EXPERIMENTAL); Adolescents (12 to < 18 Years) (EXPERIMENTAL)\n\nPrimary Outcome Measures: Change From Baseline in Maximum Cystometric Capacity (MCC) at Week 24 (Time: Baseline and week 24)\n\nSecondary Outcome Measures: Change From Baseline in Bladder Compliance (\u0394V/\u0394P) (Time: Baseline and weeks 4 and 24) | Change From Baseline in Maximum Cystometric Capacity at Week 4 (Time: Baseline and week 4) | Change From Baseline in Number of Overactive Detrusor Contractions (> 15 cm H20) Until End of Filling (Time: Baseline and weeks 4 and 24) | Change From Baseline in Detrusor Pressure at End of Filling (Time: Baseline and weeks 4 and 24) | Change From Baseline in Filling Bladder Volume Until First Overactive Detrusor Contraction (> 15 cm H20) (Time: Baseline and weeks 4 and 24) | Change From Baseline in Filling Bladder Volume Until First Overactive Detrusor Contraction (> 15 cm H20): Wilcoxon Signed-rank Test Updated Analysis (Time: Baseline and weeks 4 and 24) | Change From Baseline in Filling Bladder Volume Until First Overactive Detrusor Contraction (> 15 cm H20): Paired T-test (Time: Baseline and weeks 4 and 24) | Change From Baseline in Average Catheterized Volume Per Catheterization (Time: Baseline and weeks 2, 4, 8, 12, 24, 36 and 52) | Change From Baseline in Maximum Catheterized Volume (Time: Baseline and weeks 2, 4, 8, 12, 24, 36 and 52) | Change From Baseline in Maximum Catheterized Daytime Volume (MCDV) (Time: Baseline and weeks 2, 4, 8, 12, 24, 36 and 52) | Change From Baseline in Average Morning Catheterized Volume (Time: Baseline and weeks 2, 4, 8, 12, 24, 36 and 52) | Change From Baseline in Mean Number of Leakage Episodes Per Day (Time: Baseline and weeks 2, 4, 8, 12, 24, 36 and 52) | Change From Baseline in Mean Number of Leakage Episodes Per Day: Updated Analysis (Time: Baseline and weeks 2, 4, 8, 12, 24, 36 and 52) | Change From Baseline in Number of Dry Days Per 7 Days (Day and Night Time) (Time: Baseline and weeks 2, 4, 8, 12, 24, 36 and 52) | Change From Baseline in Pediatric Incontinence Questionnaire (PIN-Q) Score (Time: Baseline and weeks 24 and 52) | Change From Baseline in Patient Global Impression of Severity Scale (PGI-S) (Time: Baseline and weeks 24 and 52) | Number of Participants With Clinician Global Impression of Change (CGI-C) (Time: Weeks 24 and 52) | Number of Participants With Study Drug Acceptability for Tablets at Week 4 (Time: Week 4) | Number of Participants With Study Drug Acceptability for Tablets at Week 24 (Time: Week 24) | Number of Participants With Study Drug Acceptability for Tablets at Week 52 (Time: Week 52) | Number of Participants With Study Drug Acceptability for Oral Suspension at Week 4 (Time: Week 4) | Number of Participants With Study Drug Acceptability for Oral Suspension at Week 24 (Time: Week 24) | Number of Participants With Study Drug Acceptability for Oral Suspension at Week 52 (Time: Week 52) | Number of Participants With Adverse Events (AEs) (Time: From the first dose of study drug administration up to end-of-treatment (EoT) (up to week 52)) | Maximum Plasma Concentration (Cmax) of Mirabegron (Time: A total of 4 samples were collected over 2 sampling days at 2 separate visits at any of week 4, 8, 12, 24, 36, or 52, at the following time points: Sampling day 1- Predose; Sampling day 2- Predose and 2 samples 2-5 hours postdose more than 1 hour apart.) | Time to Reach Maximum Plasma Concentration of Mirabegron Following Drug Administration (Tmax) (Time: A total of 4 samples were collected over 2 sampling days at 2 separate visits at any of week 4, 8, 12, 24, 36, or 52, at the following time points: Sampling day 1- Predose; Sampling day 2- Predose and 2 samples 2-5 hours postdose more than 1 hour apart.) | Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC24) for Mirabegron (Time: A total of 4 samples were collected over 2 sampling days at 2 separate visits at any of week 4, 8, 12, 24, 36, or 52, at the following time points: Sampling day 1- Predose; Sampling day 2- Predose and 2 samples 2-5 hours postdose more than 1 hour apart.) | Plasma Concentration of Mirabegron at the End of a Dosing Interval at Steady State (Ctrough) (Time: A total of 4 samples were collected over 2 sampling days at 2 separate visits at any of week 4, 8, 12, 24, 36, or 52, at the following time points: Sampling day 1- Predose; Sampling day 2- Predose and 2 samples 2-5 hours postdose more than 1 hour apart.) | Apparent Total Clearance of Mirabegron From Plasma After Oral Administration (CL/F) (Time: A total of 4 samples were collected over 2 sampling days at 2 separate visits at any of week 4, 8, 12, 24, 36, or 52, at the following time points: Sampling day 1- Predose; Sampling day 2- Predose and 2 samples 2-5 hours postdose more than 1 hour apart.) | Apparent Volume of Distribution After Non-intravenous Administration (Vz/F) of Mirabegron (Time: A total of 4 samples were collected over 2 sampling days at 2 separate visits at any of week 4, 8, 12, 24, 36, or 52, at the following time points: Sampling day 1- Predose; Sampling day 2- Predose and 2 samples 2-5 hours postdose more than 1 hour apart.)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Strengthen retention strategies, minimize burden, use remote assessments where valid, specify robust missing data plans (MI, MMRM, pattern-mixture), and include rescue/escape handling rules that preserve interpretability; set realistic enrollment targets with contingency for attrition.\nB. Before trial launch, align the product specification with compendial and FDA expectations by defining and validating microbial limits/objectionable organisms testing, method suitability, acceptance criteria, and in-process controls; reflect these controls in the trial materials section and safety monitoring plan on ClinicalTrials.gov and in the SAP (e.g., lot release criteria, procedures for handling potential contamination findings).\nC. Before initiation, define comprehensive safety endpoints and tabulation schemes consistent with FDA expectations: specify AE/SAE coding (e.g., MedDRA), exposure-adjusted incidence rates, discontinuation reasons, death narratives, and interim/pooled analyses across studies; ensure adequate follow-up duration to capture class-specific risks and plan for global safety data integration.\nD. Embed a two-stage enrichment strategy: a 2-week single-blind placebo run-in to identify and exclude high placebo responders, followed by a 4-week mid-study randomized withdrawal (mirabegron vs placebo) within the enrolled cohort to estimate placebo-adjusted effects, all while maintaining the overarching single-group designation. To minimize carryover, require an 8\u201312 week anticholinergic washout prior to the run-in period.\nE. No optimization needed - the trial design is adequate\nF. Reprioritize the primary endpoint to a caregiver-completed 3-day bladder diary (micturition frequency and incontinence episodes) at Week 4, making invasive urodynamic assessments optional at baseline and limited to a 15\u201320% sentinel subset for exploratory confirmation. This patient-centric approach should reduce procedural burden and accelerate enrollment while preserving face-validity of outcomes across sites.\nG. Reposition the primary efficacy endpoint to patient- and caregiver-reported overactive bladder PROs (e.g., OAB-q, ICIQ-OAB, and 3-day urgency/incontinence diaries) across ages 3 to <18 years, using proxy reporting for non-verbal children; minimize invasive urodynamic testing to baseline and end-of-study only in a small subset, and define response thresholds using adult minimal clinically important difference values to streamline regulatory claims.\nH. Select validated primary/secondary safety endpoints with appropriate time frames based on label precedents and literature; base power and exposure-adjusted analyses on realistic event rates from RWD; predefine multiplicity control and exposure summaries (person-time) in the SAP.\nI. Predefine and validate tighter incoming raw material specs and critical quality attribute controls (e.g., viscosity ranges linked to clinical performance), include lot release criteria and contingency plans in the operational aspects of the trial, and specify in the SAP how to handle data if product-quality deviations occur (e.g., sensitivity analyses by compliant lots).\nJ. Use prior trials and RWD to model expected discontinuation rates; inflate sample size, extend follow-up, pre-specify robust missing data handling (e.g., multiple imputation, tipping-point analyses), and capture structured reasons for discontinuation as a predefined outcome measure.", "answer": "B, C, H, I, J"} |
| {"_id": "trial_opt_adv_0041", "nctid": "NCT04949399", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence\n\nBrief Summary: The purpose of the study is to evaluate the safety and effects of onabotulinumtoxinA (BOTOX) for the temporary improvement in the appearance of platysma prominence.\n\nStudy doctors will randomize participants into 1 of the 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 400 participants will be enrolled in the study in the United States and Canada.\n\nParticipants will receive a single treatment of intramuscular injection of onabotulinumtoxinA (BOTOX) or placebo on Day 1 during this 4 month long study.\n\nParticipants will attend regular monthly visits during the study at the study site.\n\nConditions: Platysma Prominence\n\nInterventions: DRUG: OnabotulinumtoxinA; DRUG: Placebo\n\nPhase: PHASE3\n\nEnrollment: 408.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: TRIPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Participants must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study specific procedures\n* Are willing and able to comply with procedures required in the protocol\n* Adult male or female, at least 18 years old at the time of signing the informed consent\n* Good health as determined by medical history, physical examination, vital signs, and investigator's judgment\n\nExclusion Criteria:\n\n* Any medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function\n* Participant has an anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention)\n* Anticipated need for surgery or o... (truncated)\n\nArms and Interventions: BOTOX (EXPERIMENTAL); Placebo (PLACEBO_COMPARATOR)\n\nPrimary Outcome Measures: Number of Participants With Adverse Events (Time: Enrollment to Day 120) | Composite Achievement of Grade 1 or 2 (Minimal or Mild) and at Least a 2-Grade Improvement From Baseline Based on Both Investigator's Assessment Using C-APPS and Participant's Self-Assessment Using P-APPS, at Maximum Contraction at Day 14 (Time: Day 14) | Achievement of at Least a 2-grade Improvement From Baseline Based on the Investigator's Assessment Using C-APPS at Maximum Contraction at Day 14 (Time: Day 14) | Achievement of at Least a 2-grade Improvement From Baseline Based on the Participant's Self- Assessment Using P-APPS at Maximum Contraction at Day 14 (Time: Day 14)\n\nSecondary Outcome Measures: Percentage of Participants Who Achieved Grade 1 or 2 (Minimal or Mild) According to Investigator's Assessment Using C-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120 (Time: Day 14, 30, 60, 90, and 120) | Percentage of Participants Who Achieved Grade 1 or 2 (Minimal or Mild) According to Participant's Assessment Using P-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120 (Time: Day 14, 30, 60, 90, and 120) | Percentage of Participants With Responses of \"Satisfied\" or \"Very Satisfied\" on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Satisfaction (Follow-up) Item 5 (Effect of Treatment) at Day 14 (Time: Day 14) | Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the Bother Assessment Scale - Platysma Prominence (BAS-PP) Scale Item 2 (Jawline) at Day 14 (Time: Day 14) | Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 1 (Vertical Neck Bands) at Day 14 (Time: Day 14) | Change From Baseline on the Appearance of Neck and Lower Face Questionnaire (ANLFQ): Impacts Summary Score at Day 14 (Time: Day 14) | Percentage of Participants Who Achieved at Least 1-Grade Improvement From Baseline Based on Investigator's Assessment Using C-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120 (Time: Day 14, 30, 60, 90, and 120) | Percentage of Participants Who Achieved at Least 1-Grade Improvement From Baseline Based on Participant's Assessment Using P-APPS at Maximum Contraction at Days 14, 30, 60, 90, and 120 (Time: Day 14, 30, 60, 90, and 120) | Percentage of Participants Who Achieved a Rating of Minimal or Mild According to Participant's Assessment Using P-APPS at Maximum Contraction at Days 14 (Time: Day 14) | Percentage of Participants With Responses of \"Satisfied\" or \"Very Satisfied\" on the ANLFQ: Satisfaction (Follow-up) Item 5 (Effect of Treatment) at Day 14 (Time: Day 14) | Percentage of Participants With Responses of 'Not at All Bothered' or 'A Little Bothered' on the BAS-PP Scale Item 2 (Jawline) at Day 14 (Time: Day 14) | Change From Baseline on the ANLFQ: Impacts Summary Score at Days 30, 60, and 90 (Time: Days 30, 60, and 90)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Scale and qualify reference standard lots with commutability/bridging to support all analytical methods and stability program prior to filing. Not addressable via ClinicalTrials.gov design elements.\nB. Implement a validated environmental and in-process bioburden monitoring program per cGMP before manufacturing clinical/registration lots; establish alert/action limits, sampling plans, and trending. Although critical to approval, this is not a trial design issue tied to ClinicalTrials.gov fields.\nC. Convert the study to a non-inferiority design against an active comparator (e.g., incobotulinumtoxinA), eliminating the placebo arm and powering to demonstrate equivalence in platysma prominence reduction across standardized injection patterns\nD. Adopt electromyography and ultrasound-based platysma thickness measurements as co-primary endpoints, with mandatory serial EMG assessments at Days 7, 30, and 90, and downgrade clinician and participant aesthetic ratings to exploratory outcomes\nE. Prepare and submit up-to-date SPL-compliant labeling. Not a preventable clinical design issue.\nF. Align roles, register establishments appropriately, and ensure GMP compliance for entities performing release. Not addressable via trial design fields.\nG. Complete ICH-aligned stability studies (long-term, accelerated, stress) on representative commercial configurations and justify any reduced testing with statistical trending prior to submission. Not a clinical trial design fix.\nH. Allow concomitant minimally invasive neck procedures (e.g., radiofrequency microneedling, thread lifting, lipolytic injections) during the study period and prespecify stratified analyses by procedure type to enhance real-world generalizability\nI. No optimization needed - the trial design is adequate\nJ. Redefine the primary endpoint to sustained aesthetic response at 12 months post-single injection without retreatment, with secondary endpoints at 15 and 18 months to capture late durability signals", "answer": "A, B, E, F, G"} |
| {"_id": "trial_opt_adv_0042", "nctid": "NCT02181413", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant\n\nBrief Summary: The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a response (complete response \\[CR\\], very good partial response \\[VGPR\\], or partial response \\[PR\\]) to induction therapy followed by high-dose therapy (HDT) and autologous stem cell transplant (ASCT).\n\nConditions: Multiple Myeloma; Autologous Stem Cell Transplant\n\nInterventions: DRUG: Ixazomib Citrate; DRUG: Placebo\n\nPhase: PHASE3\n\nEnrollment: 656.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n1. Adult male or female participants 18 years or older with a confirmed diagnosis of symptomatic multiple myeloma according to standard criteria.\n2. Documented results of cytogenetics/ fluorescence in situ hybridization (FISH) obtained at any time before transplant, and International Staging System (ISS) staging at the time of diagnosis available.\n3. Underwent standard of care (SOC) induction therapy (induction therapy must include proteasome inhibitor (PI) and/or immunomodulating drugs (IMiD)-based regimens as primary therapy for multiple myeloma), followed by a single autologous stem cell transplant (ASCT) with a high-dose melphalan (200 mg/m\\^2) conditioning regimen, within 12 months of diagnosis. Vincristine, Adriamycin \\[doxorubicin\\], and dexamethasone (VAD) is not an acceptable induction therapy for this trial.\n4. Started screening no earlier than 75 days after transplant, completed screening within 15 days, and randomized no later than 115 days after transp... (truncated)\n\nArms and Interventions: Placebo (PLACEBO_COMPARATOR); Ixazomib Citrate (EXPERIMENTAL)\n\nPrimary Outcome Measures: Progression Free Survival (PFS) (Time: Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months))\n\nSecondary Outcome Measures: Overall Survival (OS) (Time: Randomization up to end of follow up period (up to 107 months)) | Percentage of Participants With Any Best Response Category Before PD or Subsequent Therapy (Time: Randomization up to EOT (up to 24 months) and thereafter every 4 weeks until initiation of the next line of therapy (up to 107 months)) | Time to Progression (TTP) (Time: Randomization up to PD (up to 107 months)) | Second Progression Free Survival (PFS2) (Time: Randomization up to EOT (24 months); thereafter followed up every 4 weeks until initiation of next-line therapy and then every 12 weeks until second progressive disease (PD2) or death (up to 107 months)) | Time to Start of the Next Line of Therapy (Time: Randomization up to 107 months) | Time to End of the Next Line of Therapy (Time: Randomization up to 107 months) | Duration of the Next Line of Therapy (Time: Up to 107 months) | Percentage of Participants Who Develop a New Primary Malignancy (Time: Up to 107 months) | Number of Participants With Conversion to Minimal Residual Disease (MRD) Negative (Time: Baseline up to EOT (up to 24 months)) | Number of Participants With Maintenance of MRD Negativity (Time: Up to EOT (up to 24 months)) | Correlation Between MRD Status and Progression Free Survival (PFS) (Time: From randomization up to 107 months) | Correlation Between MRD Status and Overall Survival (OS) (Time: From randomization up to 107 months) | OS Benefits in a High-Risk Population (Time: Randomization up to 107 months) | PFS Benefits in a High-Risk Population (Time: Randomization up to 107 months) | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status Score (Time: Baseline up to EOT (up to Month 24)) | Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) or Serious Adverse Events (SAEs) (Time: Up to 107 months) | Number of Participants With Markedly Abnormal Clinical Laboratory Values Reported as TEAEs (Time: Up to 107 months) | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) Domain Score (Time: Baseline up to EOT (up to Month 24)) | Plasma Concentration of Ixazomib (Time: Day 1 of Cycle 1: 1 hour and 4 hours post-dose; Predose on Days 8 and 15 of Cycle 1, Days 1 and 8 of Cycle 2, Day 1 of Cycles 3 through 10 (each cycle length= 28 days)) | Time to Resolution of Peripheral Neuropathy (PN) Events (Time: Up to 107 months) | Time to Improvement of PN Events (Time: Up to 107 months)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Before launch, use PK/PD and label/class data to set exclusion criteria for strong inhibitors/inducers, organ dysfunction, QT risk, etc.; specify proactive monitoring schedules (labs, ECGs), dose adjustments, and DDI management in protocol and registry fields.\nB. No optimization needed - the trial design is adequate\nC. Permit background lenalidomide maintenance at investigator discretion or per local standard, randomizing participants to ixazomib or placebo as add-on therapy and stratifying by concurrent lenalidomide use; analyze treatment effect using inverse probability weighting and marginal structural models to adjust for time-varying treatment patterns and improve generalizability.\nD. Before launch, specify in the SAP and protocol family a harmonized safety data model across trials (MedDRA coding version, AE/SAE definitions, TEAE windows, exposure metrics like person-time, discontinuation reasons), prespecify integrated summaries of safety (ISS) shell tables, and ensure CRF fields capture all data needed for narratives and comparisons. Power the safety database (enrollment) to meet expected FDA thresholds for common AEs and discontinuations.\nE. Elevate overall survival (OS) to the primary endpoint with hierarchical testing of PFS only after OS achieves statistical significance, and institute protocol-mandated crossover from placebo to ixazomib at first objective progression to enhance ethical equipoise; extend follow-up until at least 70% OS events accrue and reallocate alpha to secondary endpoints (MRD, TTNT) via a gatekeeping strategy.\nF. Use RWD and prior class experience to estimate required person-time to characterize common AEs and discontinuations with adequate precision; set enrollment targets and exposure duration accordingly in ClinicalTrials.gov. Ensure dose-exposure consistency and sufficient follow-up windows to capture delayed AEs.\nG. Predefine in SAP cross-study safety comparison methods (common data standards, pooled vs stratified analyses, handling of differing follow-up, multiplicity control for key AEs of interest). Register these high-level plans on ClinicalTrials.gov to ensure consistency and traceability.\nH. Before trial, include protocol/SAP requirements and CRF fields to enable rapid narrative generation (chronology, concomitant meds, labs, causality assessments, management, outcomes). Align site training and data standards to ensure completeness for all deaths, SAEs, and discontinuations.\nI. Pre-specify robust handling of missing data (MMRM, multiple imputation, estimand framework); plan visit windows and backup sampling; set monitoring thresholds to minimize missingness; ensure sample size accounts for anticipated missing data.\nJ. Adopt a Bayesian response-adaptive randomization scheme starting after the first 100 participants, using early biomarkers (e.g., 8-week M-protein or free light chain reduction and 3-month MRD conversion) to reweight allocation up to 2:1 in favor of ixazomib within cytogenetic-risk strata, with weekly IWRS updates while maintaining the quadruple blind; include sample size re-estimation tied to adaptive allocation efficiency.", "answer": "A, D, F, G, H"} |
| {"_id": "trial_opt_adv_0047", "nctid": "NCT01575834", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis\n\nBrief Summary: The purpose of this study is to determine if treatment with romosozumab is effective in preventing fractures in women with postmenopausal osteoporosis\n\nConditions: Postmenopausal Osteoporosis\n\nInterventions: DRUG: Romosozumab; DRUG: Placebo; DRUG: Denosumab\n\nPhase: PHASE3\n\nEnrollment: 7180.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n\\- Postmenopausal women with osteoporosis, defined as low bone mineral density (BMD T-score at the total hip or femoral neck of \u2264 -2.50)\n\nExclusion Criteria:\n\n* BMD T-score of \u2264 -3.50 at the total hip or femoral neck\n* History of hip fracture\n* Any severe or more than 2 moderate vertebral fractures, as assessed by the central imaging based on lateral spine x-rays\n* Use of agents affecting bone metabolism\n* History of metabolic or bone disease (except osteoporosis)\n* Vitamin D insufficiency (vitamin D repletion and rescreening is permitted)\n* Current hyper- or hypocalcemia\n* Current, uncontrolled hyper- or hypothyroidism\n* Current, uncontrolled hyper- or hypoparathyroidism\n\nArms and Interventions: Romosozumab (EXPERIMENTAL); Placebo (PLACEBO_COMPARATOR)\n\nPrimary Outcome Measures: Percentage of Participants With New Vertebral Fracture Through Month 12 (Time: 12 Months) | Percentage of Participants With New Vertebral Fracture Through Month 24 (Time: 24 months)\n\nSecondary Outcome Measures: Percentage of Participants With a Clinical Fracture Through Month 12 (Time: 12 Months) | Percentage of Participants With a Nonvertebral Fracture Through Month 12 (Time: 12 Months) | Percentage of Participants With a Nonvertebral Fracture Through Month 24 (Time: 24 Months) | Percentage of Participants With a Clinical Fracture Through Month 24 (Time: 24 Months) | Percentage of Participants With a Major Nonvertebral Fracture Through Month 12 (Time: 12 Months) | Percentage of Participants With a Major Nonvertebral Fracture Through Month 24 (Time: 24 Months) | Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 12 (Time: 12 Months) | Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24 (Time: 24 Months) | Percentage of Participants With a Hip Fracture Through Month 12 (Time: 12 Months) | Percentage of Participants With a Hip Fracture Through Month 24 (Time: 24 Months) | Percentage of Participants With a Major Osteoporotic Fracture Through Month 12 (Time: 12 Months) | Percentage of Participants With a Major Osteoporotic Fracture Through Month 24 (Time: 24 Months) | Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12 (Time: 12 Months) | Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24 (Time: 24 Months) | Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12 (Time: Baseline and Month 12) | Percent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 24 (Time: Baseline and Month 24) | Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 12 (Time: Baseline and Month 12) | Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24 (Time: Baseline and Month 24) | Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 12 (Time: Baseline and Month 12) | Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 24 (Time: Baseline and Month 24)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Convert to a cluster-randomized design at the site level with rotating 3-month assignment blocks (romosozumab, denosumab, placebo) to streamline logistics, maintaining identical packaging to preserve blinding; restrict stratification to geographic region, eliminate individual-level stratification by baseline cardiovascular risk, and rely primarily on passive fracture ascertainment via administrative claims and EHR algorithms instead of active surveillance to minimize monitoring complexity.\nB. Standardize cardiovascular prophylaxis across arms by mandating low-dose aspirin (81 mg daily) and a moderate-intensity statin for all participants beginning 4 weeks before randomization; include patients with recent myocardial infarction or stroke (within the past 6 months) to improve generalizability; treat MACE as an exploratory endpoint without central adjudication and limit cardiovascular assessments to baseline and end-of-study ECGs to reduce operational burden.\nC. Design a three-arm study (romosozumab vs alendronate vs placebo/standard care where ethical) or include an external control framework; alternatively, use active comparator with similar skeletal efficacy and known CV profile and pre-specify noninferiority margins for safety; ensure balanced randomization and stratification by CV risk factors.\nD. Use real-world baseline MACE rates to size the safety cohort and set follow-up duration sufficient to detect clinically meaningful risk differences; predefine composite MACE endpoints with clear definitions; include stratification by baseline CV risk; incorporate group sequential safety monitoring.\nE. Predefine exposure accrual and person-time calculations; ensure database and SAP include incidence rate denominators (per 100 patient-years) and exposure-adjusted analyses; monitor dropouts and discontinuations to maintain interpretable person-time.\nF. Before launch, incorporate cardiovascular risk minimization: exclude recent MI/stroke and high ASCVD risk patients; pre-specify MACE as a key safety endpoint with blinded, independent adjudication; add baseline and on-treatment cardiovascular assessments; plan interim safety monitoring with stopping rules; power safety analyses adequately; select a comparator and population where CV risk is balanced or add a placebo-controlled arm to contextualize risk.\nG. No optimization needed - the trial design is adequate\nH. Predefine detailed safety data capture: standardized AE reporting, adjudication committees for deaths/MACE, narrative requirements for serious AEs and discontinuations; plan periodic worldwide safety summaries; align data standards with FDA expectations to enable timely benefit\u2013risk assessment.\nI. Select validated, clinically meaningful primary endpoints with established effect sizes; predefine hierarchical testing and multiplicity control; ensure adequate sample size/power based on real-world baseline rates and prior trials; align SAP with FDA guidance for the indication and conduct a Type B meeting to confirm adequacy.\nJ. Redefine the primary efficacy endpoint to a biomarker-driven composite: percent change in lumbar spine and total hip BMD at 12 months combined with early changes in serum P1NP and CTX at 3 months, using hierarchical testing and an adaptive enrichment algorithm that discontinues non-responders by month 3; shorten total follow-up to 12 months and power the trial on BMD variance rather than fracture incidence to expedite readout.", "answer": "C, D, E, F, H"} |
| {"_id": "trial_opt_adv_0048", "nctid": "NCT03930615", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)\n\nBrief Summary: The purpose of this study was to evaluate the safety and efficacy of letermovir (LET) versus placebo when cytomegalovirus (CMV) prophylaxis was extended from 100 days to 200 days post-transplant in CMV seropositive participants who received an allogenic hematopoietic stem cell transplant (HSCT). It was hypothesized that LET is superior to placebo in the prevention of clinically-significant CMV infection when LET prophylaxis is extended from 100 to 200 days.\n\nConditions: Cytomegalovirus Infection\n\nInterventions: DRUG: Letermovir; DRUG: Placebo\n\nPhase: PHASE3\n\nEnrollment: 220.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: PREVENTION\n\nEligibility Criteria: Inclusion Criteria:\n\n* have documented positive CMV serostatus (CMV immunoglobulin G \\[IgG\\] seropositive) for recipient (R+) at the time of transplant\n* has a history of allogeneic HSCT (bone marrow, peripheral blood stem cell, or cord blood transplant) within \\~100 days prior to randomization\n* has undetectable CMV deoxyribonucleic acid (DNA) or detectable/not quantifiable CMV DNA from a plasma sample collected within 14 days prior to randomization\n* has received LET as primary prophylaxis that started within 28 days of HSCT and continued through Week 14 post-transplant (\u00b1 1 week) prior to randomization\n* is at high risk of CMV disease, defined as meeting one or more of the following criteria:\n* has a related donor with at least 1 mismatch at 1 of the specified 3 human leukocyte antigen (HLA) gene loci (HLA-A, B, or DR)\n* has an unrelated donor with at least one mismatch at one of the specified four HLA gene loci (HLA-A, B, C, and DRB1)\n* has a haploidentical donor\n* has umbilical co... (truncated)\n\nArms and Interventions: Letermovir (EXPERIMENTAL); Placebo (PLACEBO_COMPARATOR)\n\nPrimary Outcome Measures: Percentage of Participants With Clinically Significant CMV Infection From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant (Time: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks))\n\nSecondary Outcome Measures: Percentage of Participants Experiencing \u22651 Adverse Events (AEs) From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant (Time: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)) | Percentage of Participants Withdrawing From Study Drug Due to an AE From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant (Time: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)) | Percentage of Participants With Clinically Significant CMV Infection From Week 14 Post-transplant Through Week 38 Post-transplant (Time: From Week 14 post-transplant to Week 38 post-transplant (approximately 24 weeks)) | Percentage of Participants With Clinically Significant CMV Infection From Week 14 Post-transplant Through Week 48 Post-transplant (Time: From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)) | Time to Onset of Clinically Significant CMV Infection From Week 14 Post-transplant to Week 28 Post-transplant (Time: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)) | Time to Onset of Clinically Significant CMV Infection From Week 14 Post-transplant to Week 48 Post-transplant (Time: From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)) | Percentage of Participants With CMV Viremia Who Started PET From Week 14 Post-transplant to Week 28 Post-transplant (Time: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)) | Percentage of Participants With CMV Viremia Who Started PET From Week 14 Post-transplant to Week 48 Post-transplant (Time: From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)) | Percentage of Participants With All-cause Mortality From Week 14 Post-transplant to Week 28 Post-transplant (Time: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)) | Percentage of Participants With All-cause Mortality From Week 14 Post-transplant to Week 48 Post-transplant (Time: From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks)) | Time to All-cause Mortality From Week 14 Post-transplant to Week 28 Post-transplant (Time: From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)) | Time to All-cause Mortality From Week 14 Post-transplant to Week 48 Post-transplant (Time: From Week 14 post-transplant to Week 48 post-transplant (approximately 34 weeks))\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Replace the primary endpoint of clinically significant CMV infection through extended follow-up with a surrogate virologic endpoint (proportion with detectable plasma CMV DNAemia >137 IU/mL at Day 120) and truncate follow-up to Day 140 to expedite the readout; use supportive historical data to bridge to clinical outcomes.\nB. Implement validated assay methods and tighter in-process and release specifications to ensure the drug product meets the target concentration before trial dosing; incorporate batch certification requirements in the protocol to prevent dosing with out-of-spec lots.\nC. Before trial launch, establish a comprehensive safety data aggregation plan covering all studies of the drug (any indication, dose, and form), ensure PI and SPL drafts conform to 21 CFR 201.56/201.57 and 314.50, and align safety endpoints and data capture in the protocol to meet labeling requirements.\nD. Broaden eligibility to include CMV-seronegative HSCT recipients, autologous HSCT recipients, and solid organ transplant recipients on comparable immunosuppression, using stratified randomization by transplant type and serostatus to enhance external validity and accelerate accrual.\nE. Predefine comprehensive safety outcome measures and analysis plans consistent with labeling requirements; ensure CRFs and data systems capture necessary safety details and time frames to support PI sections on adverse reactions and discontinuations.\nF. Reconfigure the study as a Bayesian adaptive platform trial with response-adaptive randomization, adding concurrent arms for alternative letermovir durations (Day 100\u2013150 and Day 100\u2013250) and an active comparator (valganciclovir), using a shared placebo control and seamless adaptation rules based on interim CMV virologic response.\nG. Introduce real-time therapeutic drug monitoring (TDM) of letermovir with predefined trough targets (e.g., 2\u20134 \u00b5g/mL) from Day 100 to Day 200, mandating weekly PK sampling and on-protocol dose titration in \u00b150 mg increments; implement a central lab with 48-hour turnaround and mirrored placebo dose adjustments to preserve blinding while optimizing individual exposure.\nH. Set impurity acceptance criteria to NMT 0.2% for specified/unspecified impurities per ICH Q3B or prequalify with toxicology data; require use of only compliant lots in the trial and document specs within the protocol and investigational product handling plan.\nI. Conduct or compile sufficient nonclinical toxicology studies for impurities exceeding 0.2% before trial initiation, or reduce impurity levels below qualification thresholds; update protocol to reflect qualified safety margins and monitoring.\nJ. No optimization needed - the trial design is adequate", "answer": "B, C, E, H, I"} |
| {"_id": "trial_opt_adv_0049", "nctid": "NCT04740905", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion\n\nBrief Summary: This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals until Week 24, followed by a double-masked period of study without active control to evaluate faricimab administered according to a personalized treatment interval (PTI) dosing regimen in participants with macular edema due to branch retinal vein occlusion (BRVO).\n\nConditions: Macular Edema; Branch Retinal Vein Occlusion\n\nInterventions: DRUG: Faricimab; DRUG: Aflibercept; PROCEDURE: Sham Procedure\n\nPhase: PHASE3\n\nEnrollment: 553.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: TRIPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Foveal center-involved macular edema due to branch retinal vein occlusion (BRVO), diagnosed no longer than 4 months prior to the screening visit\n* Best-corrected visual acuity (BCVA) of 73 to 19 letters, inclusive (20/40 to 20/400 approximate Snellen equivalent) on Day 1\n* Sufficiently clear ocular media and adequate pupillary dilatation to allow acquisition of good quality retinal images to confirm diagnosis\n* For women of childbearing potential: agreement to remain abstinent or use contraception, and agreement to refrain from donating eggs during the treatment period and for 3 months after the final dose of study treatment\n\nExclusion Criteria:\n\n* Any major illness or major surgical procedure within 1 month before screening\n* Uncontrolled blood pressure\n* Stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to Day 1\n* Pregnant or breastfeeding, or intending to become pregnant during the study\n\nOcular Exclusion Criteria for Study Eye... (truncated)\n\nArms and Interventions: Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2) (EXPERIMENTAL); Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2) (ACTIVE_COMPARATOR)\n\nPrimary Outcome Measures: Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 (Time: From Baseline through Week 24)\n\nSecondary Outcome Measures: Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants Gaining \u226515 Letters in BCVA From Baseline in the Study Eye at Week 24 (Time: Baseline and Week 24) | Part 1: Percentage of Participants Gaining \u226515 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants Gaining \u226510 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants Gaining \u22655 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants Avoiding a Loss of \u226515 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants Avoiding a Loss of \u226510 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants Avoiding a Loss of \u22655 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants Achieving \u226584 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants Achieving \u226569 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants With \u226438 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24 (Time: Baseline, Weeks 4, 8, 12, 16, 20, and 24) | Part 1: Change From Baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) Composite Score at Week 24 (Time: Baseline and Week 24) | Parts 1 and 2: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants Gaining \u226515 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants Gaining \u226510 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants Gaining \u22655 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants Avoiding a Loss of \u226515 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants Avoiding a Loss of \u226510 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants Avoiding a Loss of \u22655 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants Achieving \u226584 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants Achieving \u226569 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants With \u226438 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Change From Baseline in NEI VFQ-25 Questionnaire Composite Score at Specified Timepoints Through Week 72 (Time: Baseline and Weeks 24, 48, and 72) | Parts 1 and 2: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Parts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72 (Time: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Part 2: Change From Week 24 in BCVA in the Study Eye at Specified Timepoints Through Week 72 (Time: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Part 2: Percentage of Participants Avoiding a Loss of \u226515 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72 (Time: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Part 2: Percentage of Participants Avoiding a Loss of \u226510 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72 (Time: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Part 2: Percentage of Participants Avoiding a Loss of \u22655 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72 (Time: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Part 2: Percentage of Participants Avoiding a Loss of >0 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72 (Time: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72) | Part 2: Percentage of Participants on Different Treatment Intervals at Week 68 (Time: Week 68) | Part 2: Number of Study Drug Injections Received in the Study Eye From Week 24 Through Week 72 (Time: From Week 24 to Week 72) | Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale (Time: Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72) | Incidence of Ocular Adverse Events in the Fellow Eye (Time: Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72) | Incidence of Non-Ocular Adverse Events (Time: Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72) | Plasma Concentration of Faricimab Over Time (Time: Predose at Day 1 (Baseline), Weeks 4, 24, 28, 52, and 72) | Number of Participants With Anti-Drug Antibodies (ADAs) to Faricimab at Baseline and Post-Baseline During the Study (Time: Predose at Day 1 (Baseline), Weeks 4, 24, 28, 52, and 72)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Before initiation, define comprehensive safety endpoints and tabulation schemes consistent with FDA expectations: specify AE/SAE coding (e.g., MedDRA), exposure-adjusted incidence rates, discontinuation reasons, death narratives, and interim/pooled analyses across studies; ensure adequate follow-up duration to capture class-specific risks and plan for global safety data integration.\nB. Replace the aflibercept active comparator with bevacizumab sourced from qualified compounding pharmacies to better reflect real-world practice and lower study costs; standardize aliquot preparation to 1.25 mg/0.05 mL across sites and document compounding SOPs in the protocol and CT.gov entry.\nC. Verify and document GMP-compliant manufacturing and quality systems prior to trial launch; include product quality monitoring steps in the protocol (lot release specs, in-trial stability checks, sterility/endotoxin testing for parenterals), and reflect these controls in CT.gov fields (intervention description and monitoring plans). Delay enrollment until GMP readiness is confirmed.\nD. No optimization needed - the trial design is adequate\nE. Redefine the primary efficacy endpoint to a composite of OCT-angiography metrics (e.g., change in perfused macular vessel density and foveal avascular zone area) at Week 24, relegating BCVA change and central subfield thickness to secondary endpoints to reduce subjectivity and align outcomes with the drug\u2019s mechanism of action.\nF. Broaden inclusion criteria to enroll all retinal vein occlusion subtypes (branch, hemiretinal, and central RVO) under a unified RVO cohort, with stratified randomization by occlusion type to increase generalizability and accelerate enrollment without changing the dosing schedule.\nG. Permit investigator-discretion concomitant macular laser photocoagulation and intravitreal corticosteroids beginning at Week 8 to mirror routine practice, recording these as concomitant medications; include sensitivity analyses that adjust for co-interventions rather than prohibiting them to enhance pragmatic generalizability.\nH. Conduct and document forced-degradation and worst-case shipping simulations (temperature excursions, vibration, duration, route/mode, packing configs) for the final DP and container-closure before trial start; incorporate stability controls in the protocol (cold-chain verification, temperature loggers, expiry dating aligned with treatment duration), and update CT.gov intervention details to reflect tested packaging/handling procedures.\nI. Conduct a pre-launch name safety assessment (phonetic/orthographic similarity, international use, error reports), select a non-confusable temporary clinical trial name/identifier, and implement clear labeling/dispensing procedures documented in CT.gov intervention and design fields.\nJ. Pre-specify chain-of-custody and excursion handling SOPs, site capability requirements, and data capture of shipment conditions; include SAP plans to account for excursions; ensure intervention description includes storage/shipping requirements verified by testing.", "answer": "C, H, I, J"} |
| {"_id": "trial_opt_adv_0052", "nctid": "NCT03948646", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)\n\nBrief Summary: Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of the sweat glands.\n\nCurrent therapies have limited effectiveness, significant side effects, and can be invasive and costly. Sofpironium bromide (BBI-4000) is a novel soft-drug in development for the topical treatment of hyperhidrosis.\n\nThis Phase 3 study will assess the safety and efficacy of sofpironium bromide, 15% gel versus vehicle (2 treatment arms), applied for the treatment of axillary hyperhidrosis.\n\nConditions: Axillary Hyperhidrosis\n\nInterventions: DRUG: Sofpironium Bromide, 15%; DRUG: Vehicle\n\nPhase: PHASE3\n\nEnrollment: 351.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Male or female subject \u2265 9 years of age.\n* Diagnosis of primary axillary hyperhidrosis that meets the following criteria: (a) symptoms of hyperhidrosis for at least 6 months' duration, (b) HDSM-Ax of 3 - 4 and (c) a minimum GSP of 50 mg in each axilla with a combined total of at least 150 mg.\n* The ability to understand and follow all study-related procedures including study drug administration.\n* Sexually active female of childbearing potential (FOCBP)\\* must agree to periodic pregnancy testing and use a medically acceptable method of contraception while receiving protocol-assigned product.\n\nExclusion Criteria:\n\n* In the Investigators opinion, any skin or subcutaneous tissue conditions of the axilla(e).\n* Prior use of any prohibited medication(s) or procedure(s) within the specified timeframe for the treatment of axillary hyperhidrosis.\n* Anticholinergic agents used to treat conditions such as, but not limited to, hyperhidrosis, asthma, incontinence, gastrointes... (truncated)\n\nArms and Interventions: Active (EXPERIMENTAL); Vehicle (PLACEBO_COMPARATOR)\n\nPrimary Outcome Measures: Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed \u22652-point Improvement in Hyperhidrosis Disease Severity Measure-Axillary-7 Item Total Score From Baseline to End of Treatment (Time: Total Trial Participation was approximately 11-15 weeks; outcome measure time frame: Baseline (and treatment start) through to end of treatment, taking approximately 6 weeks.) | Observed Change in Participant (Vehicle Arm vs SB Gel 15% Arm) Ranked Gravimetric Sweat Production From Baseline to End of Treatment (Time: Total Trial Participation was approximately 11-15 weeks; outcome measure time frame: Baseline (and treatment start) through to end of treatment, taking approximately 6 weeks.)\n\nSecondary Outcome Measures: nan\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Conduct formative HF studies early (iterative design, task analysis, critical task identification), redesign applicator and IFU (clear labeling on device, concise, salient steps, unfoldable/visible layout, pictograms), add prominent hand-washing instruction on PDP, and run a robust HF validation study demonstrating acceptable user performance before starting pivotal efficacy/safety trials.\nB. Include representative intended users in formative and validation phases and incorporate user performance and comprehension measures as prespecified outcomes. Ensure instructions and device labeling are tested and finalized before pivotal trials start.\nC. Introduce a 4-week single-blind vehicle run-in to exclude nonadherent participants and reduce placebo response; only randomize subjects who demonstrate at least a 20% reduction in gravimetric sweat rate during run-in and maintain high eDiary compliance.\nD. Adopt a bilateral within-subject design in which each participant applies sofpironium bromide 15% to one axilla and vehicle to the contralateral axilla, with randomized side assignment and a brief wash-in period, to reduce inter-individual variability and increase statistical efficiency.\nE. Modify applicator to control orientation (e.g., angled head, flow restrictor, valve), add physical cues to maintain correct angle, and verify via formative and validation HF testing that spillage risk is mitigated before trial.\nF. Embed a thorough QT and pharmacokinetic safety module for all randomized subjects, including serial plasma sampling at pre-dose and 0.5, 1, 2, 4, 8, 12, and 24 hours plus 24-hour Holter monitoring at Weeks 1 and 4, to comprehensively characterize systemic exposure and cardiac risk from topical anticholinergic activity.\nG. Predefine safety endpoints and monitoring for misuse/inadvertent transfer, include targeted AE checklists (ocular, anticholinergic symptoms), collect handling/use data, and power/timeframe to detect incidence. Incorporate mitigation training and confirm adherence; include protocols for preventing transfer to others.\nH. Implement stratified randomization based on prespecified cholinergic pathway genotypes (e.g., CHRM3 and SLC18A3/VAChT polymorphisms), and power the trial to detect genotype-by-treatment interactions to enable pharmacogenomic subgroup claims and individualized dosing recommendations.\nI. Perform label comprehension and IFU usability testing pre-trial, streamline content with salient, step-wise visuals, prevent folding that obscures steps (e.g., booklet or peel-open design), and confirm via validation that IFU supports correct use.\nJ. No optimization needed - the trial design is adequate", "answer": "A, B, E, G, I"} |
| {"_id": "trial_opt_adv_0053", "nctid": "NCT03836287", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)\n\nBrief Summary: Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of the sweat glands.\n\nCurrent therapies have limited effectiveness, significant side effects, and can be invasive and costly. Sofpironium bromide (BBI-4000) is a novel soft-drug in development for the topical treatment of hyperhidrosis.\n\nThis Phase 3 study will assess the safety and efficacy of sofpironium bromide, 15% gel versus vehicle (2 treatment arms), applied for the treatment of axillary hyperhidrosis.\n\nConditions: Axillary Hyperhidrosis\n\nInterventions: DRUG: Sofpironium Bromide Gel, 15%; DRUG: Vehicle\n\nPhase: PHASE3\n\nEnrollment: 350.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Male or female subject \u2265 9 years of age.\n* Diagnosis of primary axillary hyperhidrosis that meets the following criteria: (a) symptoms of hyperhidrosis for at least 6 months' duration, (b) HDSM-Ax of 3 - 4 and (c) a minimum GSP of 50 mg in each axilla with a combined total of at least 150 mg.\n* The ability to understand and follow all study-related procedures including study drug administration.\n* Sexually active female of childbearing potential (FOCBP)\\* must agree to periodic pregnancy testing and use a medically acceptable method of contraception while receiving protocol-assigned product.\n\nExclusion Criteria:\n\n* In the Investigators opinion, any skin or subcutaneous tissue conditions of the axilla(e).\n* Prior use of any prohibited medication(s) or procedure(s) within the specified timeframe for the treatment of axillary hyperhidrosis.\n* Anticholinergic agents used to treat conditions such as, but not limited to, hyperhidrosis, asthma, incontinence, gastrointes... (truncated)\n\nArms and Interventions: Active (EXPERIMENTAL); Vehicle (PLACEBO_COMPARATOR)\n\nPrimary Outcome Measures: Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed \u22652-point Improvement in Hyperhidrosis Disease Severity Measure-Axillary-7 Item Total Score From Baseline to End of Treatment (Time: Total Trial Participation was approximately 11-15 weeks; outcome measure time frame: Baseline (and treatment start) through to end of treatment, taking approximately 6 weeks.) | Observed Change in Participant (Vehicle Arm vs SB Gel 15% Arm) Ranked Gravimetric Sweat Production From Baseline to End of Treatment (Time: Total Trial Participation was approximately 11-15 weeks; outcome measure time frame: Baseline (and treatment start) through to end of treatment, taking approximately 6 weeks.)\n\nSecondary Outcome Measures: nan\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Replace the gravimetric axillary sweat measurement and validated patient-reported scales (e.g., HDSS) as the primary endpoint with continuous data from wearable galvanic skin response patches worn 24/7, summarizing efficacy via area-under-the-curve perspiration metrics collected remotely through a smartphone app.\nB. Modify applicator to control orientation (e.g., angled head, flow restrictor, valve), add physical cues to maintain correct angle, and verify via formative and validation HF testing that spillage risk is mitigated before trial.\nC. Conduct formative HF studies early (iterative design, task analysis, critical task identification), redesign applicator and IFU (clear labeling on device, concise, salient steps, unfoldable/visible layout, pictograms), add prominent hand-washing instruction on PDP, and run a robust HF validation study demonstrating acceptable user performance before starting pivotal efficacy/safety trials.\nD. No optimization needed - the trial design is adequate\nE. Include representative intended users in formative and validation phases and incorporate user performance and comprehension measures as prespecified outcomes. Ensure instructions and device labeling are tested and finalized before pivotal trials start.\nF. Incorporate response-adaptive randomization with three active-dose arms (10%, 15%, 20% sofpironium bromide gel) and an interim Bayesian analysis to up-weight allocation toward the most efficacious concentration, allowing protocol-defined mid-trial dose escalation or de-escalation for participants to optimize individual outcomes.\nG. Predefine safety endpoints and monitoring for misuse/inadvertent transfer, include targeted AE checklists (ocular, anticholinergic symptoms), collect handling/use data, and power/timeframe to detect incidence. Incorporate mitigation training and confirm adherence; include protocols for preventing transfer to others.\nH. Perform label comprehension and IFU usability testing pre-trial, streamline content with salient, step-wise visuals, prevent folding that obscures steps (e.g., booklet or peel-open design), and confirm via validation that IFU supports correct use.\nI. Simplify the control arm to a no-treatment/sham control to enhance ecological validity and reduce operational complexity, eliminating vehicle manufacturing and instead instructing control participants to maintain their usual hygiene routine while preserving blinding through standardized visit procedures.\nJ. Embed an intensive systemic pharmacokinetic program across the entire Phase 3 cohort, with serial 12-hour plasma concentration profiles for sofpironium bromide and all known metabolites at baseline, Weeks 1, 4, and 8, coupled with anticholinergic biomarker panels (pupilometry, salivary flow assays) and population PK/PD modeling to link exposure to sweat reduction.", "answer": "B, C, E, G, H"} |
| {"_id": "trial_opt_adv_0055", "nctid": "NCT01624142", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders\n\nBrief Summary: A study to assess the long term safety and tolerability of evolocumab (AMG 145) in adolescents and adults with severe familial hypercholesterolemia.\n\nConditions: Severe Familial Hypercholesterolemia\n\nInterventions: BIOLOGICAL: Evolocumab\n\nPhase: PHASE2, PHASE3\n\nEnrollment: 300.0\n\nDesign Allocation: nan\n\nIntervention Model: SINGLE_GROUP\n\nMasking: NONE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n\\- Participated in Study 20110233 (NCT01588496) or another qualifying evolocumab parent protocol and have a diagnosis of familial hypercholesterolemia.\n\nOR\n\n* Have a diagnosis of familial hypercholesterolemia AND\n* Males and females \u2265 12 to \u2264 80 years of age\n* Stable low-fat diet and lipid-lowering therapies for at least 4 weeks\n* Low-density lipoprotein cholesterol (LDL-C) \\>= 130 mg/dl (3.4 mmol/L) for subjects without diagnosed coronary heart disease (CHD)/CHD risk equivalent OR LDL-C \\>= 100 mg/dl (2.6 mmol/L) for subjects with diagnosed CHD or CHD risk equivalent OR apheresis patients have no LDL-C entry requirement\n* Fasting triglycerides \u2264 400 mg/dL(4.5 mmol/L)\n* Body weight of \\> 40 kg or greater at screening for subjects less than 18 years of age\n\nExclusion Criteria:\n\n* New York Heart Failure Association (NYHA) class III or IV or last known left ventricular ejection fraction \\< 30%\n* Myocardial infarction, unstable angina, percutaneous coronary interventio... (truncated)\n\nArms and Interventions: Evolocumab (EXPERIMENTAL)\n\nPrimary Outcome Measures: Number of Participants With Adverse Events (Time: From first dose of study drug in Study 20110271 up to 30 days after the last dose or until the end of study date, whichever was earlier; median duration of treatment was 48.7 months.)\n\nSecondary Outcome Measures: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) (Time: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216) | Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) (Time: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216) | Percent Change From Baseline in Lipoprotein (a) (Time: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216) | Percent Change From Baseline in Apolipoprotein B (Time: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216) | Percent Change From Baseline in Total Cholesterol/HDL-C Ratio (Time: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216) | Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio (Time: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216) | Percentage of Participants With a 15% or Greater Reduction in LDL-C (Time: Baseline and weeks 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Include a comprehensive, prespecified safety monitoring and analysis plan: standardized AE definitions, active surveillance windows, adjudication procedures, and statistical methods to compare AE incidence over time and across cohorts.\nB. Design a global safety database strategy before launch: harmonize CRFs across regions, plan periodic safety summary reporting, and predefine integration of foreign study and labeling safety information.\nC. Refine eligibility by excluding any subjects receiving LDL apheresis at baseline or anticipated during the study to avoid confounding of lipid outcomes and simplify interpretation of drug-specific effects on LDL-C trajectories\nD. Predefine standardized discontinuation reason categories in CRFs, require narrative summaries for AE-related discontinuations, and plan analyses/reporting tables to summarize discontinuation causes by treatment arm.\nE. Pre-specify and adequately power a dedicated arm for 420 mg Q2W in HoFH, with stratification by background lipid-lowering therapies; include PK/PD bridging to justify regimen, and prospectively define primary/secondary endpoints and minimal clinically important difference for LDL-C reduction at Q2W.\nF. Reconfigure the study to an event-driven design with a composite MACE primary endpoint (CV death, MI, stroke) and power the trial to 200 events, expanding enrollment to at least 1,000 participants and extending follow-up until the event target is met to demonstrate long-term clinical benefit beyond LDL-C changes\nG. No optimization needed - the trial design is adequate\nH. Implement a genotype- and immunogenicity-guided dosing algorithm in which evolocumab administration frequency (Q2W vs Q4W) and dose are titrated monthly based on LDLR mutation class, baseline PCSK9 levels, and anti-drug antibody (ADA) status, with dose reductions for ADA positivity and escalations for null LDLR genotypes\nI. Define and control concomitant therapy use in eligibility and protocol (e.g., stable background therapy run-in); stratify randomization by key background treatments; prespecify subgroup analyses; collect adherence data to reduce confounding.\nJ. Limit study conduct to US-based sites only and standardize safety reporting to FDA-centric definitions and timelines, excluding EU and Asia-Pacific centers to reduce variability in safety data capture and regulatory requirements", "answer": "A, B, D, E, I"} |
| {"_id": "trial_opt_adv_0060", "nctid": "NCT00847613", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate\n\nBrief Summary: This study is designed to provide safety and efficacy data to support the development of CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate.\n\nConditions: Arthritis, Rheumatoid\n\nInterventions: DRUG: CP-690,550; DRUG: CP-690,550; DRUG: CP-690,550; DRUG: CP-690,550; DRUG: Placebo; DRUG: CP-690,550; DRUG: Placebo; DRUG: CP-690,550\n\nPhase: PHASE3\n\nEnrollment: 800.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate\n\nExclusion Criteria:\n\n* Pregnancy, severe acute or chronic medical conditions, including serious infections or clinically significant laboratory abnormalities.\n\nArms and Interventions: Sequence 1 (EXPERIMENTAL); Sequence 2 (EXPERIMENTAL); Sequence 3 (PLACEBO_COMPARATOR); Sequence 4 (PLACEBO_COMPARATOR)\n\nPrimary Outcome Measures: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6 (Time: Month 6) | Changes From Baseline in Modified Total Sharp Score (mTSS) at Month 6 (Time: Baseline, Month 6) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3 (Time: Baseline, Month 3) | Percentage of Participant With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 6 (Time: Month 6)\n\nSecondary Outcome Measures: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) at Month 1 and 3 (Time: Month 1, 3) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) at Month 9, 12, 15, 18, 21 and 24 (Time: Month 9, 12, 15, 18, 21, 24) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) at Month 1, 3 and 6 (Time: Month 1, 3, 6) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) at Month 9, 12, 15, 18, 21 and 24 (Time: Month 9, 12, 15, 18, 21, 24) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) at Month 1, 3 and 6 (Time: Month 1, 3, 6) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) at Month 9, 12, 15, 18, 21 and 24 (Time: Month 9, 12, 15, 18, 21, 24) | Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Month 1, 3 and 6 (Time: Baseline, Month 1, 3, 6) | Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 9, 12, 15, 18, 21 and 24 (Time: Month 9, 12, 15, 18, 21, 24) | Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline, Month 1, 3 and 6 (Time: Baseline, Month 1, 3, 6) | Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 9, 12, 15, 18, 21 and 24 (Time: Month 9, 12, 15, 18, 21, 24) | Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) (Time: Baseline, Month 1, 3, 6, 9, 12, 15, 18, 21, 24) | Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR]) (Time: Baseline, Month 1, 3, 6, 9, 12, 15, 18, 21, 24) | Modified Total Sharp Scores (mTSS) at Baseline (Time: Baseline) | Modified Total Sharp Scores (mTSS) at Month 12 and 24 (Time: Month 12, 24) | Health Assessment Questionnaire Disability Index (HAQ-DI) at Baseline, Month 1, 3 and 6 (Time: Baseline, Month 1, 3, 6) | Health Assessment Questionnaire Disability Index (HAQ-DI) at Month 9, 12, 15, 18, 21 and 24 (Time: Month 9, 12, 15, 18, 21, 24) | Patient Assessment of Arthritis Pain at Baseline, Month 1, 3 and 6 (Time: Baseline, Month 1, 3, 6) | Patient Assessment of Arthritis Pain at Month 9, 12, 15, 18, 21 and 24 (Time: Month 9, 12, 15, 18, 21, 24) | Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Month 1, 3, and 6 (Time: Baseline, Month 1, 3, 6) | Patient Global Assessment (PtGA) of Arthritis Pain at Month 9, 12, 15, 18, 21 and 24 (Time: Month 9, 12, 15, 18, 21, 24) | Physician Global Assessment (PGA) of Arthritis at Baseline, Month 1, 3 and 6 (Time: Baseline, Month 1, 3, 6) | Physician Global Assessment (PGA) of Arthritis at Month 9, 12, 15, 18, 21 and 24 (Time: Month 9, 12, 15, 18, 21, 24) | 36-Item Short-Form Health Survey (SF-36) at Baseline, Month 1, 3 and 6 (Time: Baseline, Month 1, 3, 6) | 36-Item Short-Form Health Survey (SF-36) at Month 9, 12, 15, 18, 21 and 24 (Time: Month 9, 12, 15, 18, 21, 24) | Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6 (Time: Baseline, Month 1, 3, 6) | Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6 (Time: Baseline, Month 1, 3, 6) | Medical Outcomes Study Sleep Scale (MOS-SS) at Month 12, 18 and 24 (Time: Month 12, 18, 24) | Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Month 12, 18 and 24 (Time: Month 12, 18, 24) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Baseline, Month 1, 3, and 6 (Time: Baseline, Month 1, 3, 6) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Month 12, 18 and 24 (Time: Month 12, 18, 24) | Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Baseline, Month 3 and 6 (Time: Baseline, Month 3, 6) | Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Month 12, 18 and 24 (Time: Month 12, 18, 24) | Work Limitations Questionnaire (WLQ) Score at Baseline, Month 3 and 6 (Time: Baseline, Month 3, 6) | Work Limitations Questionnaire (WLQ) Score at Month 12, 18 and 24 (Time: Month 12, 18, 24) | Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline, Month 3 and 6 (Time: Baseline, Month 3, 6) | Work Productivity and Healthcare Resource Utilization (HCRU) at Month 12, 18 and 24 (Time: Month 12, 18, 24) | Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline, Month 3 and 6 (Time: Baseline, Month 3, 6) | Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 12, 18 and 24 (Time: Month 12, 18, 24) | Number of Days as Assessed Using RA-HCRU at Baseline, Month 3 and 6 (Time: Baseline, Month 1, 3, 6) | Number of Days as Assessed Using RA-HCRU at Month 12, 18 and 24 (Time: Month 12, 18, 24) | Number of Hours Per Day as Assessed RA-HCRU at Baseline, Month 3 and 6 (Time: Baseline, Month 1, 3, 6) | Number of Hours Per Day as Assessed RA-HCRU at Month 12, 18 and 24 (Time: Month 12, 18, 24) | Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline, Month 3 and 6 (Time: Baseline, Month 1, 3, 6) | Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 12, 18 and 24 (Time: Month 12, 18, 24)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Redesign IFU before trial: bold critical warnings; label figures (A, B, C\u2026) mapped to steps; correct anatomical injection-site depictions; add a post-injection 'lift pen' step illustration; revalidate with HF testing to acceptable error thresholds. Ensure the pivotal study uses the finalized IFU and captures real-world users.\nB. Iterate device design and IFU prior to pivotal trial: remove cap ridges; add clear needle-end labeling; clarify and emphasize fill window color cue; add explicit end-of-injection cues (clicks and timing) in device and IFU; strengthen refrigeration handling instructions; conduct formative HF studies, then a passing summative HF validation on the to-be-marketed user interface. Include device performance and user-error endpoints in trial or bridging HF study to demonstrate safe use.\nC. Broaden concomitant therapy allowances by permitting any csDMARDs (e.g., leflunomide, sulfasalazine, hydroxychloroquine) and selected biologics at baseline, with treat\u2011to\u2011target switching during the study per local practice. Do not stratify randomization by background regimen; instead, capture concomitant medication changes in exploratory analyses to reflect real\u2011world use and improve generalizability.\nD. No optimization needed - the trial design is adequate\nE. Extend the placebo-controlled period to 52 weeks without escape or rescue therapy to thoroughly characterize long-term safety and durability versus placebo on background methotrexate, powering the study for superiority on sustained response at one year.\nF. Complete CMC validation for final formulation and device prior to pivotal trial or establish a predefined, FDA-aligned bridging plan. Conduct in vitro pyrogenicity/endotoxin risk assessments and, if applicable, rabbit pyrogen spiking studies or validated alternatives before trial. Ensure the clinical supply matches the intended commercial presentation to avoid post hoc bridging.\nG. Convert the study to a pragmatic, cluster-randomized, open-label design by randomizing sites rather than individuals and allowing investigators to titrate background methotrexate and short courses of corticosteroids per routine care; analyze outcomes using mixed-effects models with cluster-level covariates to improve generalizability and operational efficiency.\nH. Designate whole-body MRI\u2013quantified synovitis/osteitis burden as the sole primary endpoint at 104 weeks, with required serial MRI scans (baseline, Week 26, Week 52, Week 104) and blinded central reading, relegating ACR20/50/70 and DAS28 remission to secondary endpoints to capture structural disease modification more sensitively.\nI. Audit and align container/carton labels and prescribing information with CFR requirements and FDA guidance before trial start; include bold storage temperature, proper expiry format with non-zero day, 'Do not shake', 'No preservative' wording per 21 CFR 610.61(e), linear barcode, Medication Guide pharmacist statement, and consistent manufacturer name. Use these final materials in any usability/medication error assessments.\nJ. Enhance IFU and labeling pre-trial to increase prominence of Important Information regarding pediatric exposure and device safety checks; include storage and safety statements in both IFU and carton; validate through HF testing that users comprehend and can act on these warnings.", "answer": "A, B, F, I, J"} |
| {"_id": "trial_opt_adv_0061", "nctid": "NCT01782131", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)\n\nBrief Summary: The purpose of this study is to evaluate the safety and efficacy of posaconazole (POS) versus voriconazole (VOR) in the treatment of adults and adolescents with invasive aspergillosis (IA). The primary hypothesis is that the all-cause mortality through Day 42 in the POS treatment group is non-inferior to that in the VOR treatment group.\n\nConditions: Fungal Infections; Invasive Pulmonary Aspergillosis\n\nInterventions: DRUG: Posaconazole; DRUG: Voriconazole; DRUG: Placebo\n\nPhase: PHASE3\n\nEnrollment: 585.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Weight \\>40 kg (88 lb) and \u2264150 kg (330 lb); if between 13 and 14 years of age must weigh \\>= 50 kg (110 lb)\n* Must meet the criteria for proven, probable, or possible IA as per 2008 European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) disease definitions at the time of randomization. Proven IA will include those participants with the demonstration of fungal elements (by cytology, microscopy, or culture) in diseased tissue (sterile sampling). Probable IA includes participants with at least 1 host factor, clinical criteria, as well as mycological criteria including both direct and indirect methods. Possible IA includes participants with at least 1 host factor and clinical criteria but without mycological criteria. A modification to the 2008 EORTC/MSG criteria regarding risk factors has been made to allow for the inclusion... (truncated)\n\nArms and Interventions: Posaconazole (POS) (EXPERIMENTAL); Voriconazole (ACTIVE_COMPARATOR)\n\nPrimary Outcome Measures: Percentage of Participants Who Died Through Day 42 in the Intention to Treat Population (Time: Up to ~42 days)\n\nSecondary Outcome Measures: Percentage of Participants Who Died Through Day 42 in the Full Analysis Set Population (Time: Up to ~42 days) | Percentage of Participants Who Died Through Day 84 in the ITT Population (Time: Up to ~84 days) | Percentage of Participants Who Died Through Day 84 in the FAS Population (Time: Up to ~ 84 days) | Percentage of Participants Achieving Global Clinical Response at Week 12 in the FAS Population (Time: Up to 12 weeks (\u00b1 4 weeks)) | Percentage of Participants Achieving Global Clinical Response at Week 6 in the FAS Population (Time: Up to 6 weeks (\u00b1 2 weeks)) | Number of Participants Experiencing Mortality at Day 42, Day 84, and Day 114 in the FAS Population (Kaplan-Meier Time To Death Estimate) (Time: Up to ~16 weeks (\u00b1 2 weeks)) | Number of Participants Who Died Due to Invasive Aspergillosis Through Day 42 in the FAS Population (Time: Up to 42 days) | Number of Participants Who Died Due to Invasive Aspergillosis Through Day 84 in the FAS Population (Time: Up to 84 days) | Percentage of Participants With Tier 1 Treatment Emergent Adverse Events (Time: Up to ~16 weeks (\u00b1 2 weeks)) | Percentage of Participants With at Least One Adverse Event (Time: Up to ~16 weeks (\u00b1 2 weeks)) | Percentage of Participants With at Least One Drug Related Adverse Event (Time: Up to ~16 weeks (\u00b1 2 weeks)) | Percentage of Participants With at Least One Serious Adverse Event (Time: Up to ~16 weeks (\u00b1 2 weeks)) | Percentage of Participants With at Least One Serious Drug Related Adverse Event (Time: Up to ~16 weeks (\u00b1 2 weeks)) | Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event (Time: Up to ~12 weeks) | Steady State Average Concentration (Cavg) of Posaconazole With Food Intake (Time: Baseline, and at pre-dose on Day 7, Week 2, Week 4, Week 6, and Week 12)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Relax exclusion criteria for concomitant medications by permitting strong CYP3A4/P-gp inducers and inhibitors, with predefined dose escalations of posaconazole (up to a 200% increase) to offset interactions, while keeping voriconazole at standard fixed dosing; collect concomitant medication data for covariate adjustment instead of excluding these participants.\nB. Implement genotype- and TDM-guided optimization exclusively for voriconazole: require baseline CYP2C19 genotyping with dose adjustments per metabolizer status, and mandate trough monitoring on Days 3, 7, and 14 targeting 2\u20135 mg/L with protocolized dose titration; maintain posaconazole at fixed dosing without TDM to reflect typical use, employing sham TDM draws for the posaconazole arm to preserve blinding.\nC. Expand eligibility to include participants with suspected or documented non-Aspergillus molds (e.g., mucormycosis and Fusarium spp.) to enhance generalizability and enrollment speed; plan post hoc stratification by pathogen in the primary analysis rather than excluding these cases at screening.\nD. Implement validated assay methods and tighter in-process and release specifications to ensure the drug product meets the target concentration before trial dosing; incorporate batch certification requirements in the protocol to prevent dosing with out-of-spec lots.\nE. No optimization needed - the trial design is adequate\nF. Conduct or compile sufficient nonclinical toxicology studies for impurities exceeding 0.2% before trial initiation, or reduce impurity levels below qualification thresholds; update protocol to reflect qualified safety margins and monitoring.\nG. Redefine the primary endpoint as a composite of radiographic response (\u226550% reduction in lesion size on chest CT), resolution of key respiratory symptoms, and serum galactomannan index <0.5 at Day 28, replacing all-cause mortality through Day 42; shorten follow-up accordingly and recalibrate the non-inferiority margin to \u22125% to enable a smaller sample size and faster readout.\nH. Set impurity acceptance criteria to NMT 0.2% for specified/unspecified impurities per ICH Q3B or prequalify with toxicology data; require use of only compliant lots in the trial and document specs within the protocol and investigational product handling plan.\nI. Before trial launch, establish a comprehensive safety data aggregation plan covering all studies of the drug (any indication, dose, and form), ensure PI and SPL drafts conform to 21 CFR 201.56/201.57 and 314.50, and align safety endpoints and data capture in the protocol to meet labeling requirements.\nJ. Predefine comprehensive safety outcome measures and analysis plans consistent with labeling requirements; ensure CRFs and data systems capture necessary safety details and time frames to support PI sections on adverse reactions and discontinuations.", "answer": "D, F, H, I, J"} |
| {"_id": "trial_opt_adv_0062", "nctid": "NCT04381936", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Randomised Evaluation of COVID-19 Therapy\n\nBrief Summary: RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia.\n\nThe treatments being investigated are:\n\nCOVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only)\n\nInfluenza: Baloxavir marboxil, Oseltamivir, Low-dose corticosteroids - Dexamethasone\n\nCommunity-acquired pneumonia: Low-dose corticosteroids - Dexamethasone\n\nConditions: Severe Acute Respiratory Syndrome\n\nInterventions: DRUG: Lopinavir-Ritonavir; DRUG: Corticosteroid; DRUG: Hydroxychloroquine; DRUG: Azithromycin; BIOLOGICAL: Convalescent plasma; DRUG: Tocilizumab; BIOLOGICAL: Immunoglobulin; DRUG: Synthetic neutralising antibodies; DRUG: Aspirin; DRUG: Colchicine; DRUG: Baricitinib; DRUG: Anakinra; DRUG: Dimethyl fumarate; DRUG: High Dose Corticosteroid; DRUG: Empagliflozin; DRUG: Sotrovimab; DRUG: Molnupiravir; DRUG: Paxlovid; DRUG: Baloxavir Marboxil; DRUG: Oseltamivir; DRUG: Low-dose corticosteroids: Dexamethasone; DRUG: Low-dose corticosteroids: Dexamethasone\n\nPhase: PHASE3\n\nEnrollment: 70000.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: FACTORIAL\n\nMasking: NONE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\nPatients are eligible for the study if all of the following are true:\n\n(i) Hospitalised\n\n(ii) Pneumonia syndrome\n\nIn general, pneumonia should be suspected when a patient presents with:\n\n1. typical symptoms of a new respiratory tract infection (e.g. influenza-like illness with fever and muscle pain, or respiratory illness with cough and shortness of breath); and\n2. objective evidence of acute lung disease (e.g. consolidation or ground-glass shadowing on X-ray or CT, hypoxia, or compatible clinical examination); and\n3. alternative causes have been considered unlikely or excluded (e.g. heart failure).\n\nHowever, the diagnosis remains a clinical one based on the opinion of the managing doctor (the above criteria are just a guide).\n\n(iii) One of the following diagnoses:\n\n1. Confirmed SARS-CoV-2 infection (including patients with influenza co-infection)\n2. Confirmed influenza A or B infection (including patients with SARS-CoV-2 co-infection)\n3. Community-acquired pneumon... (truncated)\n\nArms and Interventions: Standard Care (NO_INTERVENTION); Low dose corticosteroids (ACTIVE_COMPARATOR); Hydroxychloroquine (ACTIVE_COMPARATOR); Lopinavir-Ritonavir (ACTIVE_COMPARATOR); Azithromycin (ACTIVE_COMPARATOR); Convalescent plasma (ACTIVE_COMPARATOR); Tocilizumab (ACTIVE_COMPARATOR); Intravenous Immunoglobulin (ACTIVE_COMPARATOR); Synthetic neutralising antibodies (ACTIVE_COMPARATOR); Aspirin (ACTIVE_COMPARATOR); Colchicine (ACTIVE_COMPARATOR); Baricitinib (ACTIVE_COMPARATOR); Anakinra (ACTIVE_COMPARATOR); Dimethyl fumarate (ACTIVE_COMPARATOR); High Dose Corticosteroids (ACTIVE_COMPARATOR); Empagliflozin (ACTIVE_COMPARATOR); Sotrovimab (ACTIVE_COMPARATOR); Molnupiravir (ACTIVE_COMPARATOR); Paxlovid (ACTIVE_COMPARATOR); Baloxavir marboxil (ACTIVE_COMPARATOR); Oseltamivir (ACTIVE_COMPARATOR); Low-dose corticosteroids: Dexamethasone (influenza arm) (ACTIVE_COMPARATOR); Low-dose corticosteroids: Dexamethasone (pneumonia arm) (ACTIVE_COMPARATOR)\n\nPrimary Outcome Measures: All-cause mortality (Time: Within 28 days after randomisation) | Influenza co-primary outcome: All-cause mortality (with subsidiary analysis of cause of death and death at various timepoints following discharge) (Time: Within 28 days after randomisation) | Influenza co-primary outcome: Time to discharge alive from hospital (Time: Within the first 28-days)\n\nSecondary Outcome Measures: COVID-19 & community-acquired pneumonia: Duration of hospital stay (Time: Within 28 days and up to 6 months after the main randomisation) | COVID-19 & community-acquired pneumonia: Composite endpoint of death or need for mechanical ventilation or ECMO (Time: Within 28 days and up to 6 months after the main randomisation) | Influenza: Composite endpoint of death or need for mechanical ventilation or ECMO (Time: Within 28 days and up to 6 months after the main randomisation)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Require validated bioavailability for the suspension versus reference product; include PK bridging or population PK substudy to confirm exposure; restrict enrollment to patients where administration route and gastric pH conditions allow reliable delivery; incorporate monitoring of preparation fidelity and exclude sites lacking compounding capability.\nB. Redefine the primary endpoint to virologic response (time to RT-PCR negativity and \u22652 log10 reduction in nasopharyngeal SARS-CoV-2 viral load by day 7), with scheduled swabs at baseline, days 3, 5, 7, and 14; retain all-cause mortality as an exploratory endpoint to accelerate decision-making across arms.\nC. Quantify and justify sodium bicarbonate exposure with stability-supported assays; include eligibility criteria to mitigate risk (e.g., exclude patients with severe electrolyte imbalance or fluid overload), and prespecify monitoring of acid-base status; confirm consistent deliverable volume and concentration prior to trial.\nD. Implement mandatory pre-randomization pharmacogenomic profiling (CYP3A4, CYP2D6, CYP2C19, ABCB1, SLCO1B1, IL6R, ACE2 variants) with central lab turnaround \u226448 hours, and stratify randomization and dose adjustments by genotype; exclude participants without successful genotyping to standardize exposure across interventions.\nE. No optimization needed - the trial design is adequate\nF. Use validated, objective outcome definitions (e.g., clinically significant UGIB with hemoglobin drop and endoscopic confirmation) and power the study with accurate baseline event rates; tie dosing and administration to a proven-stable formulation to avoid misclassification and dilution of effect; pre-specify sensitivity analyses and monitoring for dose delivery fidelity.\nG. Pre-specify comparator consistent with standard of care; stratify randomization by key co-interventions (anticoagulants, mechanical ventilation, renal failure); define exclusion criteria for conflicting therapies; prespecify covariate adjustment and sensitivity analyses.\nH. Convert the platform to a fully double-blind, double-dummy design by manufacturing matched placebos for every oral, IV, and subcutaneous agent (including sham infusions and inactive tablets) and centralizing pharmacy kit preparation so that bedside administration is visually indistinguishable across all arms.\nI. Before trial launch, lock a validated formulation with concordant analytical methods across development and stability studies; generate batch release data and \u22656 months long-term and accelerated stability for all fill configurations; confirm target fill weights/volumes to reliably achieve label claim concentrations; include particle size distribution monitoring and evidence of no particle size reduction; align assay procedures across studies; pre-specify in the protocol the preparation steps and in-use stability window supported by data.\nJ. Narrow inclusion to adults aged 18\u201360 without major comorbidities (e.g., diabetes, CKD, COPD, CAD) and not requiring mechanical ventilation at baseline, to minimize heterogeneity and confounding and thereby increase assay sensitivity for treatment effects.", "answer": "A, C, F, G, I"} |
| {"_id": "trial_opt_adv_0063", "nctid": "NCT03370133", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis\n\nBrief Summary: This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).\n\nConditions: Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis; Psoriatic Arthritis\n\nInterventions: DRUG: Bimekizumab; DRUG: Ustekinumab; OTHER: Placebo\n\nPhase: PHASE3\n\nEnrollment: 567.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Must be at least 18 years of age\n* Chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening Visit\n* Psoriasis Area Severity Index (PASI) \\>=12 and body surface area (BSA) affected by PSO \\>=10% and Investigator's Global Assessment (IGA) score \\>=3 on a 5-point scale\n* Subject is a candidate for systemic PSO therapy and/or phototherapy\n* Female subject of child bearing potential must be willing to use highly effective method of contraception\n\nExclusion Criteria:\n\n* Subject has an active infection (except common cold), a recent serious infection, or a history of opportunistic or recurrent chronic infections\n* Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection\n* Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection\n* Subject has any other condition, including medical or psychiatr... (truncated)\n\nArms and Interventions: Bimekizumab cohort (EXPERIMENTAL); Ustekinumab cohort (ACTIVE_COMPARATOR); Placebo (PLACEBO_COMPARATOR)\n\nPrimary Outcome Measures: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Time: Week 16) | Percentage of Participants With an Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 16 (Time: Week 16)\n\nSecondary Outcome Measures: Percentage of Participants With a PASI100 Response at Week 16 (Time: Week 16) | Percentage of Participants With an IGA 0 Response at Week 16 (Time: Week 16) | Percentage of Participants With a PASI75 Response at Week 4 (Time: Week 4) | Percentage of Participants With a Patient Symptom Diary Response for Pain at Week 16 (Time: Week 16) | Percentage of Participants With a Patient Symptom Diary Response for Itch at Week 16 (Time: Week 16) | Percentage of Participants With a Patient Symptom Diary Response for Scaling at Week 16 (Time: Week 16) | Percentage of Participants With a Scalp IGA Response (Clear or Almost Clear) at Week 16 for Participants With Scalp Psoriasis (PSO) >=2 at Baseline (Time: Week 16) | Percentage of Participants With a PASI90 Response at Week 12 (Time: Week 12) | Percentage of Participants With a PASI90 Response at Week 52 (Time: Week 52) | Percentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 12 (Time: Week 12) | Percentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 52 (Time: Week 52) | Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period (Time: From Baseline to end of Initial Treatment Period, including the Safety Follow-Up visit for those withdrawn from IMP (up to 36 weeks)) | Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period (Time: From Baseline to end of Initial Treatment Period, including the Safety Follow-Up visit for those withdrawn from IMP (up to 36 weeks)) | Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period (Time: From Baseline to end of Initial Treatment Period, including the Safety Follow-Up visit for those withdrawn from IMP (up to 36 weeks)) | Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period (Time: From Week 16 to Safety Follow-Up (up to 52 weeks duration)) | Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period (Time: From Week 16 to Safety Follow-Up (up to 52 weeks duration)) | Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period (Time: From Week 16 to Safety Follow-Up (up to 52 weeks duration))\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. No optimization needed - the trial design is adequate\nB. Permit stable background systemic anti-psoriatic therapies (e.g., methotrexate \u226415 mg/week, cyclosporine \u22643 mg/kg/day, apremilast at label doses) and low- to mid-potency topical corticosteroids during the double-blind period, with stratification by baseline concomitant therapy and covariate adjustment in the ANCOVA model to enhance external validity and mimic real-world practice.\nC. Use RWD and historical trials to estimate discontinuation and AE rates; increase sample size accordingly; incorporate tolerability run-in, adherence/retention plans, rescue criteria, and PRO safety monitoring; predefine estimands and sensitivity analyses to handle intercurrent events and missing data; ensure time frames capture events long enough to compare with prior data.\nD. Introduce Bayesian response-adaptive randomization across the three arms: conduct interim analyses after approximately n=150 and n=300 using posterior probabilities of PASI75 superiority to upweight allocation toward bimekizumab (e.g., adjust from 1:1:1 to 2:1:1 if Pr>0.80), apply alpha-spending to maintain overall type I error, and authorize the DMC to update allocation ratios while keeping sites blinded.\nE. Before launch, screen labels and PK/PD data to identify contraindications and DDIs; tighten eligibility (exclude high-risk comeds/organ impairment), include dose-adjustment rules, monitoring schedules (e.g., LFTs, QTc), and predefined stopping rules; include a DDI mitigation plan and stratify by key concomitant meds.\nF. Replace investigator-assessed PASI as the primary efficacy endpoint with a centralized AI-driven digital dermatology measure: implement standardized smartphone photography at each visit and compute a Total Lesion Area Index (TLAI) via a locked algorithm; prespecify TLAI\u226570% improvement at Week 16 as the primary endpoint, relegating PASI to secondary status to reduce assessor variability.\nG. Expand the protocol to formally target psoriatic arthritis as a co-primary disease domain: enrich enrollment to \u226540% subjects with active PsA, add ACR20 at Week 24 as a co-primary endpoint alongside PASI90 at Week 16, stratify randomization by baseline tender/swollen joint counts, and incorporate a musculoskeletal MRI substudy to support a combined psoriasis/PsA label claim.\nH. Conduct feasibility assessments; simplify visit schedules; use remote monitoring; include pragmatic elements; employ enrichment and a tolerability run-in to reduce early discontinuations; adjust enrollment targets to maintain power after anticipated attrition.\nI. Standardize safety taxonomy and coding (e.g., MedDRA version lock), harmonize AE severity/causality grading, and align case report form fields across trials; prespecify pooling rules and derivations in SAP; charter an independent DMC with uniform stopping boundaries.\nJ. Before launch, align the safety data collection and analysis plan with FDA expectations: predefine safety tables matching CTD Module 2.7.4/2.7.3 formats; include narrative case report requirements for deaths and AE discontinuations; specify adjudication processes; plan comparative AE frequency tables versus historical data; include prespecified algorithms for retabulating discontinuation reasons across pooled studies.", "answer": "C, E, H, I, J"} |
| {"_id": "trial_opt_adv_0070", "nctid": "NCT02312258", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)\n\nBrief Summary: The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression free survival (PFS) compared with placebo, in participants with NDMM who have had a major response (complete response \\[CR\\], very good partial response \\[VGPR\\], or partial response \\[PR\\]) to initial therapy and who have not undergone SCT.\n\nConditions: Multiple Myeloma\n\nInterventions: DRUG: Placebo; DRUG: Ixazomib\n\nPhase: PHASE3\n\nEnrollment: 706.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n1. Adult male or female participants 18 years or older with a confirmed diagnosis of symptomatic newly diagnosed multiple myeloma (NDMM) according to standard criteria.\n2. Completed 6 to 12 months (\u00b1 2 weeks) of initial therapy, during which the participant was treated to best response, defined as the best response maintained for 2 cycles after the M-protein nadir is reached.\n3. Documented major response (PR, VGPR, CR) according to the International Myeloma Working Group (IMWG) uniform response criteria, version 2011, after this initial therapy.\n4. Female participants who:\n\n * Are postmenopausal for at least 1 year before the screening visit, OR\n * Are surgically sterile, OR\n * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study drug, OR\n * Agree to practice true abstinence, when this is in line with the pre... (truncated)\n\nArms and Interventions: Placebo (PLACEBO_COMPARATOR); Ixazomib (EXPERIMENTAL)\n\nPrimary Outcome Measures: Progression Free Survival (PFS) (Time: From randomization until PD or death (up to 52 months))\n\nSecondary Outcome Measures: Overall Survival (OS) (Time: From the date of randomization and every 12 weeks after PD on next-line therapy until death (up to 88 months)) | Percentage of Participants Who Achieve or Maintain Any Best Response Category During the Treatment Period (Time: Up to 27 months) | Time to Progression (TTP) (Time: From randomization until PD or death (up to 52 months)) | Progression Free Survival 2 (PFS2) (Time: From the date of randomization to every 12 weeks until second PD or death (up to 88 months)) | Time to Next Line Therapy (TTNT) (Time: From randomization until PD or death (up to 52 months)) | Time to End of the Next-line of Therapy After Study Treatment (Time: From randomization until PD or death (up to 52 months)) | Duration of Next-line Therapy (Time: From randomization until PD or death (up to 52 months)) | Percentage of Participants Who Develop a New Primary Malignancy (Time: From randomization until PD or death (up to 52 months)) | Percentage of Participants With Conversion From Minimal Residual Disease (MRD) Positive to MRD Negative (Time: Up to 52 months) | Correlation of MRD Status With PFS and OS (Time: From randomization up to 52 months) | OS in a High-risk Population (Time: From the date of randomization and every 12 weeks after PD on next-line therapy until death (up to 88 months)) | PFS in a High-risk Population (Time: From randomization until PD or death (up to 52 months)) | Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status (Time: Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26, progression free survival follow-up (PFSFU)- Visit 37 and progressive disease follow-up (PDFU)- Visit 26 (cycle length=28 days)) | Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Time: First dose of study drug through 30 days after last dose of study drug (up to 88 months)) | Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) as Measured by the Global Health Status (GHS) (Time: Baseline, Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26 (cycle length=28 days)) | Correlation Between Frailty Status and PFS and OS (Time: From randomization up to 52 months) | Pharmacokinetic Parameter: Plasma Concentration of Ixazomib (Time: Cycle 1 (1 and 4 hours post-dose Day 1, Days 8 and 15 pre-dose); Cycle 2 and 5 (Days 1 and 8 pre-dose) and Cycles 3, 4, 6 to 10 (Day 1 pre-dose) (cycle length=28 days)) | Time to Resolution of Peripheral Neuropathy (PN) Events (Time: Up to 52 months) | Time to Improvement of PN Events (Time: Up to 52 months)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Before launch, specify in the SAP and protocol family a harmonized safety data model across trials (MedDRA coding version, AE/SAE definitions, TEAE windows, exposure metrics like person-time, discontinuation reasons), prespecify integrated summaries of safety (ISS) shell tables, and ensure CRF fields capture all data needed for narratives and comparisons. Power the safety database (enrollment) to meet expected FDA thresholds for common AEs and discontinuations.\nB. Redefine the primary endpoint from progression-free survival to independently adjudicated objective response rate (ORR) per IMWG criteria, with centralized review of serial M-protein, FLC, and PET-CT every 8\u201312 weeks to shorten study duration and reduce sample size requirements\nC. Use RWD and prior class experience to estimate required person-time to characterize common AEs and discontinuations with adequate precision; set enrollment targets and exposure duration accordingly in ClinicalTrials.gov. Ensure dose-exposure consistency and sufficient follow-up windows to capture delayed AEs.\nD. Before launch, use PK/PD and label/class data to set exclusion criteria for strong inhibitors/inducers, organ dysfunction, QT risk, etc.; specify proactive monitoring schedules (labs, ECGs), dose adjustments, and DDI management in protocol and registry fields.\nE. No optimization needed - the trial design is adequate\nF. Introduce an ethical escape clause permitting blinded early cross-over from placebo to ixazomib upon centrally confirmed 25% biochemical rise in M-protein or conversion from MRD-negative to MRD-positive, even if IMWG progression criteria are not met, with stratified analyses to account for cross-over effects.\nG. Before trial, include protocol/SAP requirements and CRF fields to enable rapid narrative generation (chronology, concomitant meds, labs, causality assessments, management, outcomes). Align site training and data standards to ensure completeness for all deaths, SAEs, and discontinuations.\nH. Introduce minimal residual disease (MRD) negativity as a co-primary endpoint alongside PFS, with monthly bone marrow biopsies for the first 12 months to assess MRD by multiparameter flow cytometry and NGS at 10^-6 sensitivity. Use hierarchical testing (MRD first, then PFS) and recalibrate sample size to power for both endpoints, with protocol-mandated re-biopsy for any biochemical changes.\nI. Predefine in SAP cross-study safety comparison methods (common data standards, pooled vs stratified analyses, handling of differing follow-up, multiplicity control for key AEs of interest). Register these high-level plans on ClinicalTrials.gov to ensure consistency and traceability.\nJ. Incorporate an ethical crossover provision allowing participants randomized to placebo to switch to open-label ixazomib at the first protocol-defined biochemical relapse (\u226525% rise in M-protein from nadir and absolute increase \u22650.5 g/dL), without requiring IMWG progression or central confirmation. Censor PFS at crossover and plan to use rank-preserving structural failure time models to adjust for treatment switching in secondary analyses.", "answer": "A, C, D, G, I"} |
| {"_id": "trial_opt_adv_0071", "nctid": "NCT01682083", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).\n\nBrief Summary: This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus two placebos in the adjuvant treatment of melanoma after surgical resection. Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk \\[Stage IIIa (lymph node metastasis \\>1 mm), IIIb or IIIc\\] cutaneous melanoma were screened for eligibility. Subjects were randomized to receive either dabrafenib (150 milligram (mg) twice daily \\[BID\\]) and trametinib (2 mg once daily \\[QD\\]) combination therapy or two placebos for 12 months.\n\nConditions: Melanoma\n\nInterventions: DRUG: Dabrafenib; DRUG: Trametinib; DRUG: Placebos\n\nPhase: PHASE3\n\nEnrollment: 870.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: DOUBLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Key Inclusion Criteria:\n\n* Completely resected histologically confirmed high-risk \\[Stage IIIa (LN metastasis more than 1 mm), IIIb or IIIc cutaneous melanoma determined to be V600E/K mutation positive by a central laboratory. Patients presenting with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma are eligible.\n* Surgically rendered free of disease no more than 12 weeks before randomization.\n* Recovered from definitive surgery (e.g. no uncontrolled wound infections or indwelling drains).\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.\n* Adequate hematologic, hepatic, renal and cardiac function.\n\nKey Exclusion Criteria:\n\n* Known mucosal or ocular melanoma or the presence of unresectable in-transit metastases.\n* Evidence of distant metastatic disease.\n* Prior systemic anti-cancer treatment and radiotherapy for melanoma; prior surgery for melanoma is allowed.\n* History of another malignancy or concurrent malignancy including pri... (truncated)\n\nArms and Interventions: Dabrafenib and trametinib (EXPERIMENTAL); Dabrafenib and trametinib placebos (PLACEBO_COMPARATOR)\n\nPrimary Outcome Measures: Relapse-free Survival (RFS) (Time: Approximately 3.5 years)\n\nSecondary Outcome Measures: Overall Survival (Time: approximately 3.5 years) | Distant Metastasis-free Survival (Time: approximately 3.5 years) | Freedom From Relapse (Time: approximately 3.5 years)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Redesign the trial as a non-inferiority study versus placebo with a hazard ratio margin of 1.20\u20131.25 on recurrence-free survival (RFS), enabling a reduced sample size and earlier decision-making; allocate a small alpha (e.g., 0.01) to overall survival (OS) as a supportive endpoint and use a closed testing procedure to preserve type I error.\nB. Exclude recent hemoptysis and high-risk anatomy; stratify or stage pediatric enrollment after adult safety signal clearance; use pediatric-appropriate dosing/titration; prespecify pediatric DSMB thresholds and interim analyses; capture hemoptysis as a primary safety endpoint with adjudication.\nC. Convert to an open-label design to improve adherence and AE management with targeted therapies, while preserving objectivity by implementing a blinded independent central adjudication (BICR) of recurrence and death; standardize surveillance imaging every 12 weeks and mandate uniform management algorithms for pyrexia to offset potential detection bias.\nD. Require a standardized, validated bronchoprovocation/tolerance test with clear pass/fail criteria before randomization; exclude patients with airway hyperresponsiveness or recent severe bronchospasm; implement pre-treatment bronchodilator protocol; include early safety stopping rules and sentinel dosing; plan intensive early spirometry monitoring.\nE. Conduct formative HF studies to refine instructions, training, and usability; prespecify critical tasks, error rates, and acceptance criteria; validate MTT in representative users/settings before pivotal trials; embed competency checks and decision aids; if unresolved, avoid relying on MTT for eligibility.\nF. Adopt early minimal residual disease (MRD) dynamics as the primary endpoint by measuring BRAF V600\u2013specific circulating tumor DNA (ctDNA) at baseline and week 8; define primary success as a \u22652-log drop or clearance of ctDNA irrespective of imaging, with RFS relegated to a key secondary endpoint; include an adaptive early-stopping rule for efficacy if ctDNA response exceeds a 20% absolute difference.\nG. No optimization needed - the trial design is adequate\nH. Iterate device design and IFU prior to pivotal trial: remove cap ridges; add clear needle-end labeling; clarify and emphasize fill window color cue; add explicit end-of-injection cues (clicks and timing) in device and IFU; strengthen refrigeration handling instructions; conduct formative HF studies, then a passing summative HF validation on the to-be-marketed user interface. Include device performance and user-error endpoints in trial or bridging HF study to demonstrate safe use.\nI. Prespecify estimands distinguishing treatment-related discontinuation; use appropriate methods (e.g., multiple imputation with delta adjustments, joint models, or pattern-mixture models); plan sensitivity analyses that do not assign favorable outcomes to discontinuers; include a single-blind tolerability run-in before randomization to reduce post-randomization dropouts.\nJ. Select a validated, clinically meaningful primary endpoint with realistic expected effect size; power for conservative assumptions; prespecify robust missing data strategies (e.g., treatment-policy estimand, mixed models with appropriate missingness assumptions, tipping-point analyses); include adherence support to minimize early discontinuation; extend follow-up to capture durable effects.", "answer": "B, D, E, I, J"} |
| {"_id": "trial_opt_adv_0078", "nctid": "NCT04372186", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia\n\nBrief Summary: This study (EMPACTA) will a) evaluate the efficacy and safety of tocilizumab (TCZ) compared with a placebo in combination with standard of care (SOC) in hospitalized participants with COVID-19 pneumonia, and b) include an optional long-term extension for eligible participants to explore the long-term sequelae of resolved COVID-19 pneumonia.\n\nConditions: COVID-19 Pneumonia\n\nInterventions: DRUG: Placebo; DRUG: Tocilizumab\n\nPhase: PHASE3\n\nEnrollment: 377.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: DOUBLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria\n\n* Hospitalized\n* COVID-19 pneumonia confirmed by a positive polymerase chain reaction (PCR) of any specimen and radiographic imaging\n* SpO2 \\< 94% while on ambient air\n\nInclusion Criteria Specific to Long-Term Extension\n\n* Participated in Study ML42528 (EMPACTA) (includes participants who completed or discontinued early from the main study)\n\nExclusion Criteria\n\n* Known severe allergic reactions to TCZ or other monoclonal antibodies\n* Require continuous positive airway pressure (CPAP), bilevel positive airway pressure (BIPAP), or invasive mechanical ventilation\n* Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)\n* In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments\n* Immunocompromised (besides well-controlled HIV) or on immunosuppressive therapy (except for steroids for COVID), advanced cancer\n* Have received oral anti-rejection or immu... (truncated)\n\nArms and Interventions: Placebo (PLACEBO_COMPARATOR); Tocilizumab (EXPERIMENTAL)\n\nPrimary Outcome Measures: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Time: Up to Day 28)\n\nSecondary Outcome Measures: Time to Hospital Discharge or \"Ready for Discharge\" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or >/= 2 Liters (L) Supplemental Oxygen) (Time: Up to Day 28) | Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status (Time: Up to Day 28) | Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (Whichever Occurred First) (Time: Up to Day 28) | Mortality Rate by Day 28 (Time: Up to Day 28) | Clinical Status on 7-Category Ordinal Scale at Day 28 (Time: Day 28) | Percentage of Participants With Adverse Events (Time: Up to Day 60)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Pre-specify comparator consistent with standard of care; stratify randomization by key co-interventions (anticoagulants, mechanical ventilation, renal failure); define exclusion criteria for conflicting therapies; prespecify covariate adjustment and sensitivity analyses.\nB. Broaden eligibility to include ambulatory, non-hospitalized COVID-19 patients with radiographic pneumonia and SpO2 \u226594% on room air, and enable home administration via subcutaneous injection supported by visiting nurses; rely on telemedicine follow-up and remote pulse oximetry as the primary safety monitoring.\nC. Convert the study to an open-label pragmatic design and permit investigator-directed dosing (IV or SC) of tocilizumab guided by daily CRP and ferritin thresholds; lift blinding to allow real-time titration and embed adaptive dosing rules into a site-level algorithm to mirror dynamic standard-of-care practices.\nD. Before trial launch, lock a validated formulation with concordant analytical methods across development and stability studies; generate batch release data and \u22656 months long-term and accelerated stability for all fill configurations; confirm target fill weights/volumes to reliably achieve label claim concentrations; include particle size distribution monitoring and evidence of no particle size reduction; align assay procedures across studies; pre-specify in the protocol the preparation steps and in-use stability window supported by data.\nE. Use validated, objective outcome definitions (e.g., clinically significant UGIB with hemoglobin drop and endoscopic confirmation) and power the study with accurate baseline event rates; tie dosing and administration to a proven-stable formulation to avoid misclassification and dilution of effect; pre-specify sensitivity analyses and monitoring for dose delivery fidelity.\nF. No optimization needed - the trial design is adequate\nG. Redefine the primary endpoint to a composite biomarker outcome (central-lab normalized CRP and \u226550% reduction in plasma IL-6 within 48 hours post-dose), with 28-day clinical status and need for mechanical ventilation relegated to exploratory endpoints; calculate sample size based on expected biomarker effect size to improve efficiency.\nH. Standardize the background care by prohibiting systemic corticosteroids, remdesivir, and therapeutic anticoagulation during the index hospitalization to minimize confounding; enforce a uniform supportive-care protocol limited to oxygen therapy and fluids to isolate the drug\u2019s effect.\nI. Quantify and justify sodium bicarbonate exposure with stability-supported assays; include eligibility criteria to mitigate risk (e.g., exclude patients with severe electrolyte imbalance or fluid overload), and prespecify monitoring of acid-base status; confirm consistent deliverable volume and concentration prior to trial.\nJ. Require validated bioavailability for the suspension versus reference product; include PK bridging or population PK substudy to confirm exposure; restrict enrollment to patients where administration route and gastric pH conditions allow reliable delivery; incorporate monitoring of preparation fidelity and exclude sites lacking compounding capability.", "answer": "A, D, E, I, J"} |
| {"_id": "trial_opt_adv_0080", "nctid": "NCT03608397", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)\n\nBrief Summary: This is a randomized, double-blind, placebo-controlled, parallel group, multi-center trial of two doses of daxibotulinumtoxinA (DAXI) for injection (high-dose; low-dose in adult subjects with isolated (primary) cervical dystonia (CD).\n\nConditions: Cervical Dystonia\n\nInterventions: BIOLOGICAL: DaxibotulinumtoxinA for injection; BIOLOGICAL: Placebo\n\nPhase: PHASE3\n\nEnrollment: 301.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Adults, 18 to 80 years of age\n* Meets diagnostic criteria for isolated CD (idiopathic; dystonic symptoms localized to the head, neck, shoulder areas) with at least moderate severity at Baseline (Day 1), defined as a TWSTRS-total score of at least 20, with at least 15 on the TWSTRS-Severity subscale, at least 3 on the TWSTRS-Disability subscale, and at least 1 on the TWSTRS-Pain subscale\n\nExclusion Criteria:\n\n* Cervical dystonia attributable to an underlying etiology, (e.g., traumatic torticollis or tardive torticollis)\n* Predominant retrocollis or anterocollis CD\n* Significant dystonia in other body areas, or is currently being treated with BoNT for dystonia in areas other than those associated with isolated CD\n* Severe dysphagia (Grade 3 or 4 on the Dysphagia Severity Scale) at Screening or Baseline (prior to study treatment)\n* Any neuromuscular neurological conditions that may place the subject at increased risk of morbidity with exposure to BoNT, including per... (truncated)\n\nArms and Interventions: DAXI for injection low dose (EXPERIMENTAL); DAXI for injection high dose (EXPERIMENTAL); Placebo (PLACEBO_COMPARATOR)\n\nPrimary Outcome Measures: Change from Baseline Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-total score (Time: Week 4 and Week 6)\n\nSecondary Outcome Measures: Change from Baseline TWSTRS-total score (Time: Up to 36 Weeks) | Duration of effect (Time: Up to 36 Weeks) | Patient Global Impression of Change (PGIC) Improvement (Time: Week 4 or Week 6) | Incidence of treatment-emergent adverse events (Safety) (Time: Up to 36 Weeks)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Complete ICH-aligned stability studies (long-term, accelerated, stress) on representative commercial configurations and justify any reduced testing with statistical trending prior to submission. Not a clinical trial design fix.\nB. Institute a protocol requirement that all participants fully discontinue concomitant dystonia-related medications (anticholinergics, benzodiazepines, muscle relaxants, analgesics) for at least 12 weeks prior to randomization and maintain complete abstinence throughout the double-blind period to isolate DAXI\u2019s treatment effect.\nC. No optimization needed - the trial design is adequate\nD. Designate patient-reported outcomes (daily eDiary spasm severity and treatment satisfaction) as the sole primary endpoint and remove clinician-rated scales such as TWSTRS to enhance patient centricity and reduce rater burden.\nE. Align roles, register establishments appropriately, and ensure GMP compliance for entities performing release. Not addressable via trial design fields.\nF. Broaden eligibility to include adolescents (12\u201317 years), adults with secondary cervical dystonia (e.g., post-traumatic or associated with neurodegenerative disease), and patients with significant neurologic comorbidities to improve generalizability and accelerate enrollment.\nG. Implement a validated environmental and in-process bioburden monitoring program per cGMP before manufacturing clinical/registration lots; establish alert/action limits, sampling plans, and trending. Although critical to approval, this is not a trial design issue tied to ClinicalTrials.gov fields.\nH. Scale and qualify reference standard lots with commutability/bridging to support all analytical methods and stability program prior to filing. Not addressable via ClinicalTrials.gov design elements.\nI. Prepare and submit up-to-date SPL-compliant labeling. Not a preventable clinical design issue.\nJ. Convert the confirmatory parallel-group phase 3 into a Bayesian adaptive dose-finding study with response-adaptive randomization across five DAXI dose levels (including supra-therapeutic), and permit dynamic changes to injection patterns and muscle targeting based on interim EMG readouts to optimize dosing in real time.", "answer": "A, E, G, H, I"} |
| {"_id": "trial_opt_adv_0081", "nctid": "NCT00330759", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.\n\nBrief Summary: The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa\u00ae) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple myeloma (excluding breast and prostate cancer)\n\nConditions: Bone Metastases\n\nInterventions: BIOLOGICAL: Denosumab; DRUG: Zoledronic Acid\n\nPhase: PHASE3\n\nEnrollment: 1779.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: DOUBLE\n\nPrimary Purpose: SUPPORTIVE_CARE\n\nEligibility Criteria: Inclusion Criteria:\n\n* Adults with histologically/cystologically confirmed advanced cancers including solid tumors, multiple myeloma, and lymphoma\n* Radiographic evidence of at least one bone metastasis (or lytic bone lesion from multiple myeloma); ECOG performance status 0, 1, or 2\n* Adequate organ function\n\nExclusion Criteria:\n\n* Diagnosis of breast or prostate cancer\n* Current or prior intravenous bisphosphonate administration\n* Current or prior oral bisphosphonates for bone metastases, life expectancy of less than 6 months\n* Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw\n\nArms and Interventions: zoledronic acid (ACTIVE_COMPARATOR); denosumab (EXPERIMENTAL)\n\nPrimary Outcome Measures: Time to the First On-Study Skeletal-Related Event (Non-Inferiority) (Time: up to 33 months)\n\nSecondary Outcome Measures: Time to First On-Study Skeletal-Related Event (Superiority) (Time: up to 33 months) | Time to the First-and-Subsequent On-Study Skeletal-Related Event (Time: up to 33 months)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Use RWD and prior class experience to estimate required person-time to characterize common AEs and discontinuations with adequate precision; set enrollment targets and exposure duration accordingly in ClinicalTrials.gov. Ensure dose-exposure consistency and sufficient follow-up windows to capture delayed AEs.\nB. Before launch, specify in the SAP and protocol family a harmonized safety data model across trials (MedDRA coding version, AE/SAE definitions, TEAE windows, exposure metrics like person-time, discontinuation reasons), prespecify integrated summaries of safety (ISS) shell tables, and ensure CRF fields capture all data needed for narratives and comparisons. Power the safety database (enrollment) to meet expected FDA thresholds for common AEs and discontinuations.\nC. No optimization needed - the trial design is adequate\nD. Introduce a prespecified biomarker-guided rescue algorithm at weeks 4 and 8 using serum CTX/NTX thresholds (e.g., <50% reduction from baseline) to mandate early switching to the alternate agent, while retaining patients in the intention-to-treat primary analysis and handling crossovers via sensitivity analyses.\nE. Broaden eligibility to include patients with breast and prostate cancer bone metastases to increase generalizability and accelerate accrual. Implement stratified randomization by tumor category (breast, prostate, other solid tumors, multiple myeloma) and define tumor-type\u2013specific noninferiority margins in the SAP to support a pooled primary analysis and prespecified subgroup claims within a single registrational dataset.\nF. Before trial, include protocol/SAP requirements and CRF fields to enable rapid narrative generation (chronology, concomitant meds, labs, causality assessments, management, outcomes). Align site training and data standards to ensure completeness for all deaths, SAEs, and discontinuations.\nG. Predefine in SAP cross-study safety comparison methods (common data standards, pooled vs stratified analyses, handling of differing follow-up, multiplicity control for key AEs of interest). Register these high-level plans on ClinicalTrials.gov to ensure consistency and traceability.\nH. Implement a response-adaptive randomization design that shifts allocation from 1:1 up to 3:1 in favor of the arm with the lower observed interim skeletal-related event (SRE) rate, with Bayesian updating every 100 accrued SREs and the option for early superiority stopping while retaining a non-inferiority objective for the final analysis\nI. Before launch, use PK/PD and label/class data to set exclusion criteria for strong inhibitors/inducers, organ dysfunction, QT risk, etc.; specify proactive monitoring schedules (labs, ECGs), dose adjustments, and DDI management in protocol and registry fields.\nJ. Broaden eligibility to include breast and prostate cancer patients to boost accrual and enhance generalizability, with stratification by tumor type and planned subgroup analyses to control for disease heterogeneity", "answer": "A, B, F, G, I"} |
| {"_id": "trial_opt_adv_0082", "nctid": "NCT00321464", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.\n\nBrief Summary: The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer.\n\nConditions: Bone Metastases\n\nInterventions: BIOLOGICAL: Denosumab; DRUG: Zoledronic Acid\n\nPhase: PHASE3\n\nEnrollment: 2049.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: TRIPLE\n\nPrimary Purpose: SUPPORTIVE_CARE\n\nEligibility Criteria: Inclusion Criteria:\n\n* Adults with histologically or cytologically confirmed breast adenocarcinoma\n* radiographic evidence of at least one bone mets\n* Easter Cooperative Oncology Group status of 0, 1 or 2;\n* adequate organ function\n\nExclusion Criteria:\n\n* Current or prior IV bisphosphonate administration\n* current or prior oral bisphosphonates for bone mets\n* life expectancy of less than 6 months\n\nArms and Interventions: zoledronic acid (ACTIVE_COMPARATOR); denosumab (EXPERIMENTAL)\n\nPrimary Outcome Measures: Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority) (Time: Up to 34 months)\n\nSecondary Outcome Measures: Time to First On-Study Skeletal-Related Event (Superiority) (Time: Up to 34 months) | Time to First and Subsequent On-Study Skeletal-Related Event (Time: Up to 34 months)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Implement an adaptive sample size re-estimation at month 6 driven by interim differences in bone turnover biomarkers (serum CTX and urine NTX), using an inverse-normal alpha-spending function tied to biomarker conditional power for the SRE endpoint. Increase total enrollment and extend follow-up if the biomarker separation is smaller than expected, with monthly biomarker sampling to stabilize variance estimates for the adaptation.\nB. Conduct pretrial model-informed drug development: integrate PK/PD, exposure\u2013response for efficacy and safety, simulate dosing regimens, and prespecify adaptive dosing rules. Choose a regimen with modeled probability of achieving target exposure linked to biological effect on HO formation.\nC. Introduce a co-primary efficacy endpoint of radiographic objective response (ORR) per RECIST 1.1, with mandatory baseline and q8\u201312 week CT/MRI of all measurable lesions including bone sites, centralized blinded imaging review, and a predefined 20% non-inferiority margin for ORR alongside the skeletal-related event endpoint. Stratify randomization by visceral metastases vs bone-only disease to balance imaging burden across arms.\nD. Before launch, use PK/PD and label/class data to set exclusion criteria for strong inhibitors/inducers, organ dysfunction, QT risk, etc.; specify proactive monitoring schedules (labs, ECGs), dose adjustments, and DDI management in protocol and registry fields.\nE. Replace the zoledronic acid comparator with a weekly oral bisphosphonate (e.g., alendronate 70 mg) to enhance patient convenience and retention, standardize administration across global sites, and reduce infusion-related logistics. Define class exposure equivalence criteria and protocolized switch rules between oral agents to maintain comparability, while preserving the triple-blind procedures with matched oral placebos.\nF. No optimization needed - the trial design is adequate\nG. Before launch, specify in the SAP and protocol family a harmonized safety data model across trials (MedDRA coding version, AE/SAE definitions, TEAE windows, exposure metrics like person-time, discontinuation reasons), prespecify integrated summaries of safety (ISS) shell tables, and ensure CRF fields capture all data needed for narratives and comparisons. Power the safety database (enrollment) to meet expected FDA thresholds for common AEs and discontinuations.\nH. Use RWD and prior class experience to estimate required person-time to characterize common AEs and discontinuations with adequate precision; set enrollment targets and exposure duration accordingly in ClinicalTrials.gov. Ensure dose-exposure consistency and sufficient follow-up windows to capture delayed AEs.\nI. Before trial, include protocol/SAP requirements and CRF fields to enable rapid narrative generation (chronology, concomitant meds, labs, causality assessments, management, outcomes). Align site training and data standards to ensure completeness for all deaths, SAEs, and discontinuations.\nJ. Predefine in SAP cross-study safety comparison methods (common data standards, pooled vs stratified analyses, handling of differing follow-up, multiplicity control for key AEs of interest). Register these high-level plans on ClinicalTrials.gov to ensure consistency and traceability.", "answer": "D, G, H, I, J"} |
| {"_id": "trial_opt_adv_0088", "nctid": "NCT04380142", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease\n\nBrief Summary: Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study measures the efficacy, safety, and tolerability of ABBV-951 versus oral Levodopa (LD)/Carbidopa (CD) \\[LD/CD\\] in advanced PD participants to achieve reduction in motor fluctuations.\n\nABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given subcutaneously (under the skin) for the treatment of Parkinson's Disease. Adult participants with advanced PD will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 80 sites across the world.\n\nIn one arm, participants will receive ABBV-951 solution as a continuous infusion under the skin plus oral placebo capsules for LD/CD. In the second arm, participants will receive placebo solution for ABBV-951 as a continuous infusion under the skin plus oral capsules containing LD/CD tablets. The treatment duration is 12 weeks.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.\n\nConditions: Parkinson's Disease (PD)\n\nInterventions: DRUG: ABBV-951; DRUG: Placebo for Levodopa/Carbidopa (LD/CD); DRUG: Levodopa/Carbidopa (LD/CD); DRUG: Placebo for ABBV-951\n\nPhase: PHASE3\n\nEnrollment: 174.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: QUADRUPLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Diagnosis of idiopathic Parkinson's Disease (PD) that is levodopa-responsive.\n* Participant must be taking a minimum of 400 milligrams/day (mg/day) of Levodopa (LD) equivalents and be judged by the investigator to have motor symptoms inadequately controlled by current therapy, have a recognizable/identifiable \"Off\" and \"On\" states (motor fluctuations), and have an average \"Off\" time of at least 2.5 hours/day over 3 consecutive PD Diary days with a minimum of 2 hours each day.\n* Participant or caregiver, if applicable, demonstrates the understanding and correct use of the delivery system, including the insertion of the cannula into the participant's abdomen, as assessed by the investigator or designee during the Screening period.\n\nExclusion Criteria:\n\n* Clinically significant, unstable medical conditions or any other reason that the investigator determines would interfere with the participant's participation in this study or would make the participant an unsuitabl... (truncated)\n\nArms and Interventions: ABBV-951 + Placebo for Levodopa/Carbidopa (LD/CD) (EXPERIMENTAL); Levodopa/Carbidopa (LD/CD) + Placebo for ABBV-951 (ACTIVE_COMPARATOR)\n\nPrimary Outcome Measures: Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized \"On\" Time Without Troublesome Dyskinesia (Time: Baseline (Week 0) up to Week 12 of the double-blind treatment period)\n\nSecondary Outcome Measures: Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized \"Off\" Time (Hours) (Time: Baseline (Week 0) up to Week 12 of the double-blind treatment period) | Change From Baseline to Week 12 of the Double-Blind Treatment Period in Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Score (Time: Baseline (Week 0) up to Week 12 of the double-blind treatment period) | Early Morning \"Off\" Status (Morning Akinesia) at Week 12 of the Double-Blind Treatment Period (Time: Week 12 of the double-blind treatment period) | Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized \"On\" Time Without Dyskinesia (Hours) (Time: Baseline, Week 12 of the double-blind treatment period) | Change From Baseline to Week 12 of the Double-Blind Treatment Period in Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score (Time: Baseline (Week 0) up to Week 12 of the double-blind treatment period) | Change From Baseline to Week 12 of the Double-Blind Treatment Period in Quality of Life Assessed by Parkinson's Disease Questionnaire 39 Item (PDQ-39) Summary Index Score (Time: Baseline (Week 0) up to Week 12 of the double-blind treatment period) | Change From Baseline to Week 12 of the Double-Blind Treatment Period in Quality of Life Assessed by the EuroQol 5-Dimension Questionnaire (EQ-5D-5L) Summary Index (Time: Baseline (Week 0) up to Week 12 of the double-blind treatment period) | Change From Baseline to Week 12 of the Double-Blind Treatment Period in Median Bradykinesia Score (BK50) as Assessed by the Parkinson's KinetiGraph/Personal KinetiGraph (PKG) Wearable Device (Time: Baseline (Week 0) up to Week 12 of the double-blind treatment period) | Change From Baseline to Week 12 of the Double-Blind Treatment Period in Interquartile Range of Bradykinesia Score (BK75-BK25) as Assessed by the PKG Wearable Device (Time: Baseline (Week 0) up to Week 12 of the double-blind treatment period) | Change From Baseline to Week 12 of the Double-Blind Treatment Period in Median Dyskinesia Score (DK50) as Assessed by the PKG Wearable Device (Time: Baseline (Week 0) up to Week 12 of the double-blind treatment period) | Change From Baseline to Week 12 of the Double-Blind Treatment Period in Interquartile Range of Dyskinesia Score (DK75-DK25) as Assessed by the PKG Wearable Device (Time: Baseline (Week 0) up to Week 12 of the double-blind treatment period) | Number of Participants With Irritation Grade Numeric Grade >= 5 or Letter Grade >= D on the Infusion Site Irritation Scale Across All Study Post-Baseline Visits (Time: Day 2 up to Week 12 of the double-blind treatment period plus 30 days) | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) During the Oral LD/CD Stabilization Period (Time: From first dose of stabilization period treatment up to the first dose of the double-blind treatment period) | Number of Participants With TEAEs During the Double-Blind Treatment Period (Time: From first dose of double-blind treatment up to Week 12 of the double-blind treatment period plus 30 days) | Number of Participants With Potentially Clinically Significant Changes From Baseline in Hematology, Chemistry, Urinalysis, Special Laboratory Parameters, Vital Signs, and Electrocardiograms (ECGs) (Time: Screening up to Week 12 of the double-blind treatment period) | Number of Participants With Affirmative Responses on the Columbia-Suicide Severity Rating Scale (C-SSRS) Across All Study Post-Baseline Visits During the Double-Blind Treatment Period (Time: Screening up to Week 12 of the double-blind treatment period) | Number of Participants With a Subscore > 5 For Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Ration Scale (QUIP-RS) at Any Time During the Double-Blind Treatment Period (Time: Baseline (Week 0) up to Week 12 of the double-blind treatment period)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. No optimization needed - the trial design is adequate\nB. Before trial launch, design and complete bench and simulated-use validation across specified operating ranges (temperature, viscosity, pressure, head height/backpressure) at clinically relevant flow rates and durations. Define accuracy endpoints and time windows (e.g., mL delivered per 24 hours and shorter intervals relevant to clinical use) and include them in the protocol and registration.\nC. Adopt an enriched-enrollment randomized withdrawal (EERW) design: conduct an 8-week open-label ABBV-951 titration to identify responders (e.g., \u22652-hour reduction in OFF-time), then randomize responders to ABBV-951 vs oral LD/CD for a 12-week double-dummy withdrawal phase, with non-responders discontinued to streamline efficacy signal detection\nD. Specify time-based accuracy metrics (e.g., \u00b1X% over 1 h, 8 h, 24 h) aligned to clinical dosing schedules; incorporate these as primary/secondary device performance outcomes and ensure protocol/statistical plan can assess them.\nE. Align draft PI/IFU/carton/container labeling with FDA regulations and device guidance before trial start; include operational parameters (head height/backpressure) and clear MG requirements. Ensure training uses finalized labeling.\nF. Redefine the primary endpoint to change in striatal DAT-SPECT binding at Week 12, with standardized acquisition protocols and central blinded imaging review, while relegating diary-based OFF-time to an exploratory outcome to minimize subjectivity and enhance objectivity of efficacy assessment\nG. Conduct comprehensive HF validation prior to trial; update user interface and training materials; include HF/usability endpoints and alarm response procedures in the protocol. Train sites/users and monitor alarm-related events proactively.\nH. Introduce a 10\u201314 day washout period of all dopaminergic therapies prior to randomization to standardize baseline motor fluctuation assessments and isolate device/drug effects; allow only minimal PRN rescue doses under strict criteria, with protocolized monitoring to ensure safety\nI. Include vibration and shock exposure testing (bench and simulated clinical scenarios) with predefined accuracy thresholds and monitoring. Add corresponding performance endpoints to the protocol and register them as outcome measures.\nJ. Introduce a third arm with double placebo (sham subcutaneous infusion plus placebo LD/CD tablets), randomizing participants 1:1:1 to ABBV-951, LD/CD, or pure placebo to quantify the placebo contribution to motor fluctuation outcomes; permit rescue therapy only under predefined criteria for severe OFF episodes", "answer": "B, D, E, G, I"} |
| {"_id": "trial_opt_adv_0089", "nctid": "NCT03347396", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)\n\nBrief Summary: The purpose of Part A was to determine whether sutimlimab administration resulted in a greater than or equal to (\\>=) 2 grams per deciliter (g/dL) increase in hemoglobin (Hgb) levels or increased Hgb to \\>= 12 g/dL and obviated the need for blood transfusion during treatment in participants with primary cold agglutinin disease (CAD) who had a recent history of blood transfusion. The purpose of Part B was to evaluate the long-term safety and tolerability of sutimlimab in participants with CAD.\n\nConditions: Agglutinin Disease, Cold\n\nInterventions: DRUG: BIVV009\n\nPhase: PHASE3\n\nEnrollment: 24.0\n\nDesign Allocation: nan\n\nIntervention Model: SINGLE_GROUP\n\nMasking: NONE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* Body weight of \\>= 39 kg at screening.\n* Confirmed diagnosis of primary CAD based on the following criteria: a) Chronic hemolysis; b) Polyspecific direct antiglobulin test (DAT) positive; c) Monospecific DAT strongly positive for C3d; d) Cold agglutinin titer \\>= 64 at 4 degree celsius; e) Immunoglobulin G (IgG) DAT less than or equal to (\\<=) 1+, and f) No overt malignant disease.\n* History of at least one documented blood transfusion within 6 months of enrollment.\n* Hemoglobin level \\<= 10.0 g/dL.\n* Bilirubin level above the normal reference range, including participants with Gilbert's Syndrome.\n\nExclusion Criteria:\n\n* Cold agglutinin syndrome secondary to infection, rheumatologic disease, or active hematologic malignancy.\n* Clinically relevant infection of any kind within the month preceding enrollment (e.g., active hepatitis C, pneumonia).\n* Clinical diagnosis of systemic lupus erythematosus; or other autoimmune disorders with anti-nuclear antibodies at Scree... (truncated)\n\nArms and Interventions: BIVV009 (EXPERIMENTAL)\n\nPrimary Outcome Measures: Part A: Percentage of Participants With Response to Treatment (Time: From Week 5 through Week 26) | Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) (Time: Part B, 6.5 g cohort: From first dose (Week 27) up to 143 weeks of treatment + 9 weeks of follow-up (i.e., up to Week 179); Part B, 7.5 g cohort: From first dose (Week 27) up to 149 weeks of treatment + 9 weeks of follow-up (i.e., up to Week 185))\n\nSecondary Outcome Measures: Part A: Mean Change From Baseline in Bilirubin Levels at the Treatment Assessment Timepoint (Time: Baseline, treatment assessment timepoint (i.e., average of Week 23, 25 and 26)) | Part A: Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score (Quality of Life) at Treatment Assessment Timepoint (Time: Baseline, treatment assessment timepoint (i.e., average of Week 23, 25 and 26)) | Part A: Mean Change From Baseline in Lactate Dehydrogenase (LDH) at the Treatment Assessment Timepoint (Time: Baseline, treatment assessment timepoint (i.e., average of Week 23, 25 and 26)) | Part A: Number of Blood Transfusions Per Participant (Time: From Week 5 up to Week 26) | Part A: Number of Blood Units Transfused Per Participant (Time: From Week 5 up to Week 26) | Part A: Mean Change From Baseline in Hemoglobin (Hgb) Level at the Treatment Assessment Timepoint (Time: Baseline, treatment assessment timepoint (i.e., average of Week 23, 25 and 26)) | Part B: Change From Baseline in Hemoglobin (Hgb) Level at Each Specified Time Points (Time: Baseline, Weeks 27,29,31,33,35,37,39,41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 83, 87, 91, 95, 99, 103, 107, 111, 115, 119, 123, 127, 131, 135, 139, 143, 147, 151, 155, 159, 163, 167, 171, 175, ET/SFU (up to Week 185)) | Part B: Change From Baseline in Bilirubin Levels at Each Specified Time Points (Time: Baseline, Weeks 27,29,31,33,35,37,39,41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 83, 87, 91, 95, 99, 103, 107, 111, 115, 119, 123, 127, 131, 135, 139, 143, 147, 151, 155, 159, 163, 167, 171, 175, ET/SFU (up to Week 185)) | Part B: Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score (Quality of Life) at Weeks 39, 51, 63, 75, 87, 99, 111, 123, 135, 147,159, 171 and Early Termination (ET) Visit/Safety Follow-up Visit (Time: Baseline, Weeks 39, 51, 63, 75, 87, 99, 111, 123, 135, 147,159, 171 and ET Visit/SFU visit (i.e., up to Week 185)) | Part B: Change From Baseline in 12-Item Short-Form Survey (SF-12) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores at Each Specified Time Points (Time: Baseline, Weeks 39, 51, 63, 75, 87, 99, 111, 123, 135 and ET Visit/SFU visit (i.e., up to Week 185)) | Part B: Change From Baseline in 5-level European Quality of Life 5-Dimensions 5-Level Questionnaire (EQ-5D-5L) Health State Utility Index and VAS Scores at Weeks 39, 51, 63, 75, 87, 99, 111, 123, 135, 147,159, 171 and ET Visit/SFU Visit (Time: Baseline, Weeks 39, 51, 63, 75, 87, 99, 111, 123, 135, 147,159, 171 and ET Visit/SFU visit (i.e., up to Week 185)) | Part B: Number of Participants With Response to Participant's Global Impression of (Fatigue) Severity (PGIS) Questionnaire at Weeks 39, 51, 63, 75, 87, 99, 111, 123, 135, 147,159, 171 and at ET Visit/SFU Visit (Time: At Weeks 39, 51, 63, 75, 87, 99, 111, 123, 135, 147,159, 171 and at ET Visit/SFU visit (i.e., up to Week 185)) | Part B: Number of Participants With Response to Participant's Global Impression of Change (PGIC) Questionnaire at Weeks 39, 51, 63, 75, 87, 99, 111, 123, 135, 147,159, 171 and at ET Visit/SFU Visit (Time: At Weeks 39, 51, 63, 75, 87, 99, 111, 123, 135, 147,159, 171 and at ET Visit/SFU visit (i.e., up to Week 185)) | Part B: Mean Change From Baseline in Lactate Dehydrogenase (LDH) Level at Each Specified Time Points (Time: Baseline, Weeks 27,29,31,33,35,37,39,41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 83, 87, 91, 95, 99, 103, 107, 111, 115, 119, 123, 127, 131, 135, 139, 143, 147, 151, 155, 159, 163, 167, 171, 175, ET/SFU (up to Week 185)) | Part B: Number of Blood Transfusions Per Participant (Time: From Week 27 up to 149 weeks of treatment (i.e., up to Week 176)) | Part B: Number of Blood Units Transfused Per Participant (Time: From Week 27 up to 149 weeks of treatment (i.e., up to Week 176)) | Part B: Change From Baseline in Haptoglobin Values at Each Specified Time Points (Time: Baseline, Weeks 27,29,31,33,35,37,39,41,43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 83, 87, 91, 95, 99, 103, 107, 111, 115, 119, 123, 127, 131, 135, 139, 143, 147, 151, 155, 159, 163, 167, 171, 175, ET/SFU (up to Week 185)) | Part B: Number of Healthcare Visits by Type (Time: From Week 27 up to 149 weeks of treatment (i.e., up to Week 176))\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Incorporate a randomized-withdrawal period after an 8-week open-label run-in on sutimlimab: responders (e.g., hemoglobin increase \u22652 g/dL) are randomized 1:1 to continue sutimlimab versus matched placebo for 12 weeks, with relapse-free survival as the key efficacy readout and a protocol-mandated avoidance of transfusions during withdrawal unless hemoglobin falls below a life-threatening threshold.\nB. Convert Part A to a randomized-withdrawal design: treat all participants with open-label sutimlimab for 8 weeks, then randomize responders 1:1 to continue sutimlimab or undergo a 4\u20136 week treatment interruption (washout) to assess durability of response and rebound risk, with re-treatment permitted upon a >2 g/dL hemoglobin drop or need for transfusion.\nC. Prior to initiation, align doses and titration with known safe exposure ranges; exclude patients with labeled contraindications or high-risk DDIs based on metabolism/transport pathways; implement DDI screening and washouts; stratify by risk factors. Add sentinel cohort or adaptive safety stopping rules to detect emergent toxicity early.\nD. Predefine standard MedDRA coding, common AE preferred-term groupings, and identical ascertainment windows aligned with prior studies; specify identical grading criteria and solicited AE lists; include plans for indirect standardization to historical datasets to enable valid comparisons.\nE. Broaden eligibility to include secondary cold agglutinin syndrome (e.g., associated with lymphoproliferative disease or infection) and mixed warm/cold autoimmune hemolytic anemia, using etiology-based stratification to increase accrual and enhance generalizability of the efficacy and safety results.\nF. Screen for known high-risk genotypes affecting metabolism/transport/target; include genotype-based exclusions or stratification; prespecify subgroup safety analyses and dose adjustments; collect and analyze biomarker data prospectively.\nG. Introduce a double-blind, placebo run-in period of 8\u201312 weeks prior to open-label sutimlimab, with elevated transfusion thresholds (e.g., transfusions only if hemoglobin <6 g/dL or severe symptomatic anemia) to rigorously quantify the placebo effect and natural hemolysis trajectory before active treatment begins.\nH. Run feasibility using RWD incidence and site performance to set realistic enrollment and ensure adequate, uniform exposure time; broaden criteria where safe; staggered site activation plans; prespecify minimum on-treatment exposure per subject for inclusion in key safety analyses.\nI. Before launch, pre-specify in the SAP exposure-adjusted incidence rates (EAIRs), predefined handling of premature discontinuations (including reasons and competing risks), sensitivity analyses for missingness/dropouts, and require collection of person-time. Power the study considering expected discontinuation from historical trials and real-world adherence; include a comprehensive safety estimand that accounts for intercurrent events.\nJ. No optimization needed - the trial design is adequate", "answer": "C, D, F, H, I"} |
| {"_id": "trial_opt_adv_0094", "nctid": "NCT03417687", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection\n\nBrief Summary: This study compares the equivalence of hyperpolarized 129Xe MRI as compared to 133Xe scintigraphy for the evaluation of pulmonary function in patients being evaluated for lung resection.\n\nConditions: Pulmonary Surgical Procedures\n\nInterventions: DRUG: 129Xe MRI; DRUG: 133 Xe scintigraphy\n\nPhase: PHASE3\n\nEnrollment: 38.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: CROSSOVER\n\nMasking: NONE\n\nPrimary Purpose: DIAGNOSTIC\n\nEligibility Criteria: Inclusion Criteria:\n\n1. Male or female subjects \u226518 years of age.\n2. Subject is being evaluated for possible lung resection (e.g., segmentectomy, lobectomy, or pneumonectomy).\n3. Subject is able to undergo MRI imaging and able to fit in the MRI coil.\n4. Subject is willing and able to comply with all study procedures.\n5. Subject must understand and voluntarily sign an informed consent form (ICF) prior to any study specific assessments or procedures.\n\nExclusion Criteria:\n\n1. Baseline blood oxygen saturation (SpO2) \\<90% at rest. For patients requiring routine supplemental oxygen, SpO2 measurements should be taken with the patient's normal oxygen supplementation.\n2. Female subjects of childbearing potential with a positive serum pregnancy test at screening, or who are not taking (or not willing to take) acceptable birth control measures through the Follow-up Period. Adequate birth control methods include with a monogamous partner who was sterilized more than 6 months prior to screening, o... (truncated)\n\nArms and Interventions: Arm 1 (ACTIVE_COMPARATOR); Arm 2 (ACTIVE_COMPARATOR)\n\nPrimary Outcome Measures: Predicted Percentage of Remaining Pulmonary Function (Time: 48 hours)\n\nSecondary Outcome Measures: Predicted Versus Measured FEV1 (Time: 3 months) | Measured Percentage of Total Ventilation Contributed by the Lower Left Lung Zone. (Time: 48 hours) | Measured Percentage of Total Ventilation Contributed by the Upper Left Lung Zone. (Time: 48 hours) | Measured Percentage of Total Ventilation Contributed by the Middle Left Lung Zone. (Time: 48 hours) | Measured Percentage of Total Ventilation Contributed by the Upper Right Lung Zone. (Time: 48 hours) | Measured Percentage of Total Ventilation Contributed by the Middle Right Lung Zone. (Time: 48 hours) | Measured Percentage of Total Ventilation Contributed by the Lower Right Lung Zone. (Time: 48 hours)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Introduce a sham-controlled period within the crossover: require a non-polarized xenon inhalation session using identical equipment, setup, and duration as the active 129Xe MRI, with patients and site staff masked to the session type; compare adverse events and patient-reported tolerability between sham and active sessions to minimize expectation bias and assess placebo effects.\nB. Institute a design control and change management plan before trial launch: lock device and software versions; specify allowable configurations in Interventions field; prespecify verification/validation testing required before any device change during the trial; require harmonized labeling/training materials across sites. Exclude data from non-conforming configurations per SAP.\nC. Include prospectively in the protocol and ClinicalTrials.gov: (a) device reliability endpoints (uptime, failure rate, calibration drift), (b) drug production performance metrics (degree of polarization, yield, batch-to-batch variability), (c) acceptance criteria and statistical plans to analyze these as secondary/process endpoints. Pilot run with at least three batches to validate and lock process parameters before pivotal enrollment.\nD. Introduce a 28\u201342-day washout interval between crossover periods to eliminate any physiological carryover, mandating medication stability verification with two reproducible spirometry assessments one week apart, exclusion of participants who experience any respiratory exacerbation in the interval, and rescheduling of surgery if necessary to ensure both imaging modalities are performed under identical baseline conditions.\nE. Define polarization CQA target and acceptance range based on PK/PD and imaging performance literature; include lot-level polarization testing, real-time QC, and per-subject recorded polarization values as covariates in the SAP; restrict administration to lots within spec and include sensitivity analyses by polarization strata.\nF. Introduce a mandatory 30-day washout interval between 129Xe MRI and 133Xe scintigraphy to fully mitigate carryover effects, with exclusion of any subjects who require changes to inhaled therapies or supplemental oxygen during the washout period\nG. Elevate clinical relevance by adding 12\u201324 month postoperative endpoints (overall survival, time to respiratory failure, and rehospitalization rates) as co-primary outcomes, powered to detect a \u226510% difference between patients randomized to 129Xe MRI-first versus 133Xe scintigraphy-first sequences; amend the SAP to include Cox proportional hazards models stratified by surgical approach and baseline spirometry.\nH. No optimization needed - the trial design is adequate\nI. Before trial start, finalize the commercial-intent manufacturing process under cGMP, define release specs (including polarization degree) as protocol-specified lot release criteria, and prospectively require only compliant lots for dosing. Register on ClinicalTrials.gov the finalized intervention description, batch qualification criteria, and plan to exclude non-conforming lots.\nJ. Embed in protocol and registry: standardized AE collection windows, coding (MedDRA), prespecified tables for common AEs, discontinuation reasons, and death narratives; data standards (CDASH/SDTM) to enable direct NDA-ready outputs; plan for interim and final safety updates consistent with 21 CFR 314.50. Include these details in Statistical Analysis Plan and Outcome Measures fields.", "answer": "B, C, E, I, J"} |
| {"_id": "trial_opt_adv_0096", "nctid": "NCT00976911", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer\n\nBrief Summary: This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with disease progression within 6 months of platinum therapy. All patients will receive standard chemotherapy with either paclitaxel or topotecan or liposomal doxorubicin. Patients randomized to Arm 2 of the study will receive Avastin (10 mg/kg iv 2-weekly or 15 mg/kg iv 3-weekly) concomitantly. Anticipated time on study treatment is until disease progression. Patients will then receive standard of care, those in Arm 1 (chemotherapy only) may opt to receive Avastin (15 mg/kg iv 3-weekly). Target sample size is 100-500 individuals.\n\nConditions: Ovarian Cancer\n\nInterventions: DRUG: Bevacizumab; DRUG: liposomal doxorubicin; DRUG: paclitaxel; DRUG: topotecan\n\nPhase: PHASE3\n\nEnrollment: 361.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: NONE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria:\n\n* female patients, \\>/=18 years of age\n* epithelial ovarian, fallopian tube or primary peritoneal cancer\n* platinum-resistant disease (disease progression within \\<6 months of platinum therapy)\n* EOCG performance status of 0-2\n\nExclusion Criteria:\n\n* non-epithelial tumours\n* ovarian tumours with low malignant potential\n* previous treatment with \\>2 chemotherapy regimens\n* prior radiotherapy to the pelvis or abdomen\n\nArms and Interventions: Chemotherapy (ACTIVE_COMPARATOR); Chemotherapy + Bevacizumab (EXPERIMENTAL)\n\nPrimary Outcome Measures: Percentage of Participants With Disease Progression or Death (Data Cutoff 14 November 2011) (Time: Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011) | Progression Free Survival (PFS; Data Cutoff 14 November 2011) (Time: Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011)\n\nSecondary Outcome Measures: Percentage of Participants With Best Overall Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) Per Modified RECIST (Data Cutoff 14 November 2011) (Time: Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011) | Duration of Objective Response (Data Cutoff 14 November 2011) (Time: Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011) | Percentage of Participants Who Died (Data Cutoff 25 January 2013) (Time: Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 25 January 2013) | Overall Survival (Data Cutoff 25 January 2013) (Time: Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 25 January 2013) | European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Ovarian (OV) 28 Abdominal/Gastrointestinal (AB/GI) Symptom Scale - Percentage of Responders (Data Cutoff 14 November 2011) (Time: Baseline and Weeks 8, 9, 16, 18, 24 and 30 (Data Cutoff 14 November 2011))\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Introduce a patient-centric co-primary endpoint strategy replacing RECIST-PFS with a composite of time to next treatment (TTNT) and PRO-CTCAE symptom burden score; utilize hierarchical testing with TTNT first to minimize missing data impact and position RECIST-PFS as a key secondary endpoint.\nB. Implement a biomarker-adaptive cohort with mandatory serial core tumor biopsies at baseline, week 4, and progression for microvessel density (CD31) and VEGF-pathway transcriptomics; use week-4 biomarker change as an interim stratification factor to up-weight randomization toward bevacizumab in putative responders and down-weight in non-responders.\nC. Broaden eligibility to include patients with progression within 12 months of last platinum exposure (i.e., combine platinum-resistant and partially platinum-sensitive disease) and rely on stratification by platinum-free interval (<6, 6\u201312, >12 months) to adjust for heterogeneity, thereby accelerating accrual and enhancing generalizability.\nD. Qualify multiple reagent lots/sources during method development; include robustness studies stress-testing reagent/source variability and matrix conditions. Pre-specify system suitability criteria and backup methods in the protocol/lab manual. Do not initiate enrollment until robustness and suitability are consistently met across qualified reagent sources.\nE. Before trial start, plan and complete a formal three-way analytical and PK bridging package (US-Avastin vs EU-Avastin vs BAT1706), including assay cross-validation, side-by-side testing of lots, and a dedicated healthy-volunteer PK bridging study if needed. Update SAP to include predefined equivalence margins and success criteria for bridging; restrict clinical comparator to US-licensed product if bridging cannot be proven in advance.\nF. Embed explicit assay performance gates in SAP (e.g., predefined selectivity/suitability pass rates), criteria for data acceptability, and contingency pathways (e.g., switch to qualified backup assay, pause enrollment). Power the study with allowance for potential exclusions due to assay failure, and conduct a pilot PK run-in to confirm assay performance before full enrollment.\nG. No optimization needed - the trial design is adequate\nH. Complete full pre-study bioanalytical method validation per FDA/EMA guidance before first patient in: demonstrate selectivity in normal human serum, robustness (including different labeling reagent sources), system suitability, and cross-validation comparability across BAT1706, US-Avastin, and EU-Avastin. Lock an assay validation report and include contingency plans; if bridging to EU material is intended, pre-verify cross-reactivity and matrix effects and specify in SAP acceptance ranges for cross-validation.\nI. Adopt iRECIST as the primary tumor response framework and permit continued treatment beyond initial unconfirmed progression (iUPD) to capture delayed anti-angiogenic effects; revise the SAP to define iRECIST-based PFS as the primary endpoint and schedule confirmation scans at 8-week intervals to validate iUPD before declaring iCPD.\nJ. Prospectively design unified safety and immunogenicity endpoints, standardized AE coding, exposure metrics (person-time), and discontinuation reasons aligned with prior BLA and guidance. Power and plan pooled analyses across studies, with predefined tables comparing incidence rates to reference and historical data. Ensure CRFs capture narratives for deaths and AE-related discontinuations and predefine reporting formats.", "answer": "D, E, F, H, J"} |
| {"_id": "trial_opt_adv_0098", "nctid": "NCT04409262", "prompt": "Based on the following clinical trial information, identify the most appropriate optimization suggestions to improve the trial design:\n\nTitle: A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia\n\nBrief Summary: This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.\n\nConditions: COVID-19 Pneumonia\n\nInterventions: DRUG: Remdesivir; DRUG: Tocilizumab; DRUG: Placebo\n\nPhase: PHASE3\n\nEnrollment: 649.0\n\nDesign Allocation: RANDOMIZED\n\nIntervention Model: PARALLEL\n\nMasking: DOUBLE\n\nPrimary Purpose: TREATMENT\n\nEligibility Criteria: Inclusion Criteria\n\n* Hospitalized with COVID-19 pneumonia confirmed per a positive polymerase chain reaction (PCR) of any specimen (e.g., respiratory, blood, urine, stool, other bodily fluid) and evidenced by chest X-ray or CT scan\n* Requiring more than 6 L/min supplemental oxygen to maintain SpO2 \\> 93%\n* Agrees to not participate in another clinical trial for the treatment of COVID-19 while participating in this study\n\nExclusion Criteria\n\n* Known severe allergic reactions to tocilizumab or other monoclonal antibodies\n* Known hypersensitivity to remdesivir, the metabolites, or formulation excipients\n* Active tuberculosis (TB) infection\n* Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)\n* In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments\n* Treatment with immunosuppressive or immunomodulatory therapy (including tocilizumab) within the past 3 months\n* C... (truncated)\n\nArms and Interventions: Remdesivir + Tocilizumab (RDV+TCZ) (EXPERIMENTAL); Remdesivir + Placebo (RDV+Placebo) (ACTIVE_COMPARATOR)\n\nPrimary Outcome Measures: Time to Hospital Discharge or \"Ready for Discharge\" up to Day 28 (Time: Up to Day 28)\n\nSecondary Outcome Measures: Time to Mechanical Ventilation or Death up to Day 28 (Time: Up to Day 28) | Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 14 (Time: Day 14) | Time to Death up to Day 28 (Time: Up to Day 28) | Time to Death up to Day 60 (Time: Up to Day 60) | Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-category Ordinal Scale of Clinical Status up to Day 28 (Time: Up to Day 28) | Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 7 (Time: Day 7) | Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 21 (Time: Day 21) | Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 28 (Time: Day 28) | Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 60 (Time: Day 60) | Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline (Participants Who Did Not Require Mechanical Ventilation at Baseline) (Time: Day 28 and Day 60) | Proportion of Participants Who Are Alive and Free of Respiratory Failure at Day 28 and Day 60 (Participants Requiring Mechanical Ventilation at Baseline) (Time: Day 28 and Day 60) | Duration of Mechanical Ventilation (Participants Requiring Mechanical Ventilation at Baseline) up to Day 28 (Time: Up to Day 28) | Difference in Mortality at Days 14, 28, and 60 (Time: Days 14, 28, and 60) | Time to Recovery up to Day 28 (Time: Up to Day 28) | Proportion of Participants Who Are Discharged or \"Ready for Discharge\" up to Day 28 (Time: Up to Day 28) | Proportion of Participants Who Require Initiation of Mechanical Ventilation Post-baseline or Die up to Day 28 (Time: Up to Day 28)\n\nQuestion: Based on the trial design above, which of the following optimization suggestions would be MOST appropriate to improve this trial? (Select all that apply)\n\nPlease provide your answer as a comma-separated list of option IDs, ordered by priority from highest to lowest priority.\n\nOptions:\nA. Replace the concurrent randomized placebo-controlled comparator with a calibrated synthetic control arm derived from contemporaneous electronic health record cohorts treated with remdesivir alone, leveraging propensity score matching and inverse probability weighting to expedite enrollment and limit exposure to placebo.\nB. No optimization needed - the trial design is adequate\nC. Require validated bioavailability for the suspension versus reference product; include PK bridging or population PK substudy to confirm exposure; restrict enrollment to patients where administration route and gastric pH conditions allow reliable delivery; incorporate monitoring of preparation fidelity and exclude sites lacking compounding capability.\nD. Quantify and justify sodium bicarbonate exposure with stability-supported assays; include eligibility criteria to mitigate risk (e.g., exclude patients with severe electrolyte imbalance or fluid overload), and prespecify monitoring of acid-base status; confirm consistent deliverable volume and concentration prior to trial.\nE. Broaden eligibility to include non-hospitalized adults with mild-to-moderate COVID-19 and enable home or outpatient infusion administration of remdesivir and tocilizumab with telemedicine follow-up and patient-reported outcome collection, to enhance generalizability and accelerate accrual.\nF. Implement an adaptive, biomarker-guided tocilizumab dosing schema that permits protocolized dose escalation or de-escalation within the first 72 hours based on serial IL-6 and CRP thresholds, with interim unblinded safety reviews to tailor exposure and optimize inflammatory control at the patient level.\nG. Use validated, objective outcome definitions (e.g., clinically significant UGIB with hemoglobin drop and endoscopic confirmation) and power the study with accurate baseline event rates; tie dosing and administration to a proven-stable formulation to avoid misclassification and dilution of effect; pre-specify sensitivity analyses and monitoring for dose delivery fidelity.\nH. Redefine the primary endpoint to virologic efficacy: proportion of participants achieving a \u22652-log10 reduction in nasopharyngeal SARS-CoV-2 RNA by Day 7, supported by daily upper respiratory swabs and standardized Ct-normalized analyses, and include lower respiratory tract sampling via bronchoscopy at Day 3 for intubated patients; move clinical outcomes (mortality, ventilation-free days) to secondary endpoints.\nI. Before trial launch, lock a validated formulation with concordant analytical methods across development and stability studies; generate batch release data and \u22656 months long-term and accelerated stability for all fill configurations; confirm target fill weights/volumes to reliably achieve label claim concentrations; include particle size distribution monitoring and evidence of no particle size reduction; align assay procedures across studies; pre-specify in the protocol the preparation steps and in-use stability window supported by data.\nJ. Pre-specify comparator consistent with standard of care; stratify randomization by key co-interventions (anticoagulants, mechanical ventilation, renal failure); define exclusion criteria for conflicting therapies; prespecify covariate adjustment and sensitivity analyses.", "answer": "C, D, G, I, J"} |
|
|
